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 X
 FOXO proteins are evolutionarily conserved transcription factors implicated in several 
fundamental cellular processes, functioning as end-point for transcriptional programs 
involved in apoptosis, stress response and longevity. Abrogation of FOXO function is 
very frequent in human cancer, therefore the mechanisms of regulation of the FOXO 
proteins are receiving increasing attention in cancer research. The FOXO proteins 
integrate regulatory inputs from a variety of upstream signaling pathways, most 
importantly in response to growth factor and stress signaling. Recently, FOXO factors 
have been established as tumor suppressors, promoting the transcription of pro-
apoptotic molecules like FasL and Bim when the PI3K/Akt pathway is downregulated.  
In order to reveal novel modulators of FOXO activity we developed several 
technological platforms suitable for high throughput screenings that allow for the 
specific identification of repressors of FOXO proteins. 
The U2foxRELOC system is based on U2-OS Osteosarcoma cells stably expressing 
a GFP-FOXO3A fusion protein that translocates to the cell nucleus upon FOXO 
activation. This High Content Screening (HCS) system was shown to be accurate for 
the detection of small compounds able to induce the translocation of the fusion protein 
between both cell compartments. The U2nesRELOC system allows for the detection of 
unspecific FOXO nuclear trapping via the inhibition of CRM-1/exportin, members of the 
nuclear export machinery. The 293foxREP system can be used to detect FOXO 
activation by monitoring FOXO-dependent luciferase expression. The high transfection 
efficiency of those cells makes them ideal for RNAi-based screenings. Finally, the 
U2transLuc system constitutes a breakthrough in the screening field, combining both 
fluorescence-based translocation analysis and luciferase light emissions in a single 
multiplexed assay, offering the advantages of both U2foxRELOC and 293foxREP in a 
single cell-based system. 
In parallel, a pathway deconvolution system was also developed. The BaFiso system 
contains genetically engineered BaF/3 cells that can be used for pathway dissection, 
defining whether the effects triggered by a given agent occur via Akt-dependent 
signaling. 
The five technological platforms which have been developed in the scope of this 
thesis can be used either for primary screenings or deconvolution, offering a wide 
choice of complementary readouts either for compound or RNAi screenings for novel 
FOXO modulators. 
Finally, we developed a large-scale RNAi and a chemical genetics screen, from 
which several novel FOXO associations were found including Calmodulin and the 
Drosophila homolog tribbles. We further validated and characterized these novel FOXO 
modulators. 
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 XIV
 Las proteínas FOXO son una familia de factores de transcripción constituida por 
FOXO1, FOXO3A y FOXO6, que se encuentran conservados y están implicados en 
varios procesos celulares fundamentales. Funcionan como efectores de programas 
transcripcionales involucrados en apoptosis, respuesta a estrés y longevidad. La 
función de FOXO está frecuentemente desregulada en cáncer, con lo que la 
investigación de los mecanismos que regulan dichos factores de transcripción ha 
ganado relevancia. Las proteínas FOXO integran estímulos regulatorios de vías de 
señalización, sobre todo en respuesta a factores de crecimiento y estrés. 
Recientemente FOXO  se ha establecido como supresor tumoral, promoviendo la 
transcripción de genes pro-apoptoticos como FasL y Bim en respuesta a la inhibición 
de la vía de señalización PI3K/Akt. Esto es lo que ocurre durante privación de factores 
de crecimiento o de nutrientes. Con objetivo de identificar nuevos reguladores de la 
función de FOXO hemos desarrollado plataformas tecnológicas adaptadas para 
rastreos de alto rendimiento. El sistema U2foxRELOC se basa en células de 
osteosarcoma U2-OS que expresan establemente una proteína de fusión, GFP-
FOXO3A, que se transloca al núcleo de las células cuando se produce la activación de 
FOXO. Este sistema de rastreo de alto contenido (HCS) se ha demostrado fiable para 
la detección de moléculas pequeñas capaces de inducir la translocación de FOXO 
entre ambos compartimentos celulares. El sistema U2nesRELOC permite la detección 
de la localización inespecífica de FOXO en el núcleo de las células como 
consecuencia de la inhibición de la maquinaria de exporte nuclear CRM1/exportina.  El 
sistema 293foxREP puede ser utilizado para detectar la activación de FOXO a través 
de la monitorización de la expresión de luciferasa dependiente de transcripción 
inducida por FOXO. La alta eficiencia de transfección de estas células les hace ideal 
para rastreos basados en siRNA. Finalmente, el sistema U2transLuc combina el 
análisis de la translocación con luminiscencia dependiente de FOXO en un ensayo 
multiparamétrico, combinando las ventajas de cada uno de los sistemas U2foxRELOC 
y 293foxREP en un único sistema celular. Paralelamente hemos desarrollado un 
sistema de deconvolución, el sistema BaFiso,  que contiene células BaF/3 modificadas 
genéticamente que pueden ser usadas para el análisis de vías de señalización 
específicas, definiendo si el efecto de un determinado agente ocurre a través de la 
señalización dependiente de Akt. Los cinco sistemas desarrollados pueden ser usados 
tanto para rastreos primarios como para deconvolución, y con ese amplio espectro de 
análisis hemos podido realizar rastreos de de genética química y de interferencia de 
RNA en los cuales hemos encontrado dos nuevos moduladores de la actividad de 
FOXO: Calmodulina y el homólogo de Drosophila tribbles, que han sido validadas y 
caracterizadas en el presente trabajo. 
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Abbreviations 
Akt v-akt murine thymoma viral oncogene homolog  
Bad BCL2-associated agonist of cell death 
Bcl-2 B-cell lymphoma protein 2 
BCR-ABL Breakpoint cluster region (BCR) and Abelson tyrosine kinase (ABL) fusion 
protein 
BNIP3L BCL2/adenovirus E1B 19kDa interacting protein 3-like 
bp Base pairs 
BTG-1 B-cell translocation gene 1 
CaM Calmodulin 
CBP CREB binding protein 
CD3 Cluster of Differentiation 3 
cDNA Complementary DNA 
CG Chemical Genetics 
CK1 Casein kinase 1 
CRM1 Exportin-1 (required for chromosome region maintenance) 
DAF-16 Abnormal Dauer Formation 
DBE Daf-16 Binding Element 
DDB1 Damage-specific DNA binding protein 1 
DNA Deoxyribonucleic acid 
dsRNA Double-stranded RNA 
DYRK Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
eNOS Nitric oxide synthase 
Fas TNF superfamily, member 6 
FAT transcription factor acetyl-transferase 
FKH Forkhead 
FOXO Forkhead box O 
G6Pase Glucose 6 phosphatase 
GADD45 Growth arrest and DNA-damage-inducible 
HAT Histone Acetyl Transferase 
HCS High Content Screening 
HDAC Histone deacetylases  
HIF1 Hypoxia inducible factor 1 
HIF1A Hypoxia inducible factor 1, alpha subunit 
hTERT Telomerase reverse transcriptase 
HTS High Throughput Screening 
IGF-I Insulin-like growth factor 1 
IGFR1 Insulin-like growth factor 1 receptor 
IKKβ Inhibitor of nuclear factor kappa B kinase beta subunit 
IL2 Interleukin 2 
JNK JUN N-terminal kinase 
LKB1 Serine/threonine kinase 11 
MDM2 Transformed 3T3 cell double minute 2 
MDR1 Multidrug resistance protein 1 
MMP Matrix metalloproteinase 
MnSOD Mn superoxide dismutase 
MST1 Mammalian sterile 20-like 1 
MST2 Mammalian sterile 20-like 2 
MYC Avian myelocytomatosis viral oncogene homolog 
NAD Nicotinamide adenine dinucleotide 
NES Nuclear Export Signal 
NFκB Nuclear factor of kappa light polypeptide gene enhancer in B-cells 
NLS Nuclear Localization Signal 
p130 Retinoblastoma-like 2 
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Abbreviations 
p21 Cyclin-dependent kinase inhibitor 1A 
p27KIP Cyclin-dependent kinase inhibitor 1B 
p300 E1A binding protein p300 
p53 p53 transformation suppressor 
PA26 p53 regulated PA26 nuclear protein / sestrin 1 
PCAF p300/CBP-associated factor 
PCR Polymerase Chain Reaction 
PDGF Platelet-derived growth factor 
PDK1 3-phosphoinositide dependent protein kinase-1, 
PEPCK Phosphoenolpyruvate carboxykinase 
PH Pleckstrin homology domain 
PI3K Phosphoinositide 3-kinase 
PIK3CA Phosphoinositide-3-kinase, catalytic, alpha polypeptide 
PIP2 Phosphatidylinositol 4,5-bisphosphate 
PIP3 Phosphatidylinositol (3,4,5)-trisphosphate 
PMA Phorbol 12-myristate 13-Acetate 
Pml Promyelocytic leukaemia bodies 
PPH4.1 Protein phosphatase 4 
PTEN Phosphatase and tensin homolog 
qRT-PCR Quantitative Reverse Transcription Polymerase Chain Reaction 
Ran Ras-related nuclear protein 
RNA Ribonucleic acid 
RNAi RNA interference 
ROS Reactive Oxygen Species 
Ser Serine 
SGK Serum/glucocorticoid regulated kinase 
shRNA Short Hairpin RNA 
siRNA Small interfering RNA 
SIRT1 Sirtuin 1 
Skp2 S-phase kinase-associated protein 2 
SMAD Mothers against decapentaplegic homolog 4 
SMK-1 Suppressor of mek1 
TA Transactivation 
TCF Transcription factor-14 
TGFβ Transforming growth factor, beta 
Thr Threonine 
TRAIL Tumor necrosis factor (ligand) superfamily, member 10 
TRIB2 Tribbles homolog 2 
TSC1 Tuberous sclerosis 1 
TSC2 Tuberous sclerosis 2 
USP7 Ubiquitin specific peptidase 7, HAUSP 
UTR Unstranslated region 
VEGF Vascular endothelial growth factor 
WB Western Blot 
WIP1 Protein phosphatase 1D magnesium-dependent 
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Introduction 
1.1 Cancer 
Over the last decades immense amounts of information have been gathered, 
revealing cancer to be a genetic disease and leading to the discovery of many genes 
responsible for tumorigenesis. In spite of this breakthrough, cancer is still one of the 
diseases with the highest mortality rates in western societies. While an important 
reduction in the number of deaths caused by cardiac, cerebro-vascular and infectious 
diseases could be achieved over the last decade, cancer-related deaths did not follow 
the same pattern. Only particular types of cancer, namely testicular cancers and 
childhood leukemias show a satisfactory rate of remission and/or cure via classical 
chemotherapy, when detected at early stages. The reason for the slow translation of 
accumulated knowledge to the clinic is thought to be due to the inherent complexity of 
cancer. Nowadays cancer is considered as a set of diseases instead of a single one, 
originated from multi-step and progressive genetic alterations that confer diverse 
abilities to the malignant cells. Those enhanced features will allow them to survive and 
proliferate under adverse conditions, either through the activation of proto-oncogenes 
or via the silencing of tumor suppressor genes (55) . 
It has bee proposed that cancer cells harbor fundamental alterations that enable their 
success. Those enounced “hallmarks of cancer” consist in self-sufficiency in growth 
signals, insensitivity to growth-inhibitory (antigrowth) signals, evasion of programmed 
cell death (apoptosis), limitless replicative potential, sustained angiogenesis and tissue 
invasion and metastasis (55). 
 
1.2 The PI3K/Akt pathway 
The dysregulation of PI3K/Akt signaling has been shown to be implicated in the 
alteration of all the aspects of cell physiology that comprise these hallmark features 
that drive the formation and development of tumors (20, 55, 63, 155) (Figure 1).  
Physiological activation of PI3K is induced by growth factors and insulin targeting the 
catalytic subunit to the membrane where it is in close proximity with its substrate, 
mainly PIP2, which will be phosphorylated by PI3K and hence PIP3 is generated (153). 
The activity of PI3K is opposed by the action of the phosphatase and tensin homolog 
deleted on chromosome 10 (PTEN), which removes the 3' phosphate of PIP3, thus 
regenerating PIP2 and attenuating signaling downstream of activated PI3K.  PDK1 is 
activated by binding PIP3 through its C-terminal pleckstrin homology (PH) domain. 
Activated PDK1 phosphorylates Akt at Thr308 activating its Ser/Thr kinase activity. 
Once phosphorylated in Thr308, further activation occurs by PDK2 (the complex 
rictor/mTOR) by phosphorylation at Ser473. Akt amino terminus also contains a PH 
domain that binds phospholipids, therefore Akt activity is regulated through PIP3 
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binding, permitting its activation by PDK1. Akt activation and consequent 
phosphorylation of its many physiological substrates (25, 35, 71, 139, 155) stimulates 
cell cycle progression, survival, metabolism, resistance to hypoxia and migration, while 
apoptosis induced by growth factor withdrawal, detachment of extracellular matrix, UV 
irradiation, cell cycle discordance and activation of FAS signaling is inhibited (35, 71, 
120). Hence, the activation of the PI3K/Akt signaling cascade confers oncogenic 
properties to the neoplasic cells and is considered as one of the most frequently altered 
pathways in human cancer  (63). PTEN activity is lost by mutations, deletions or 
promoter methylation at high frequency in many primary and metastatic human 
cancers. Germline mutations of PTEN are found in Cowden, Bannayan-Riley-
Ruvalcaba and a Proteus –like syndromes, all of them familial cancer predisposition 
syndromes (92, 95, 111, 136). Many activating mutations have been described in the 
PI3KCA gene (coding for the p110α catalytic subunit of PI3K) to be present in human 
tumors (119, 133), which are able to constitutively activate Akt. These enhanced 
biochemical capabilities translate into enhanced oncogenic activity of the PI3K mutants 
(6, 167). Carpten et al. (21), reported a somatic mutation of Akt in human breast, 
colorectal and ovarian cancers, resulting in the activation of Akt by means of 
pathological localization to the plasma membrane, which stimulates downstream 
signaling, transforms cells and induces leukemia in mice. Hence, a direct role of Akt1 in 
human cancer is established, and adds to the known genetic alterations that promote 
oncogenesis through the PI3K/Akt pathway (21).  
Activation of PI3K and Akt without mutations in their coding genes is reported to 
occur in breast (5, 19, 79), ovarian (19, 110, 159) pancreatic (4), oesophageal (117), 
thyroid cancer (44) and other cancers (11, 119). 
Several other genes of the pathway act as tumor suppressors and are frequently 
inactivated in some cancers, which carrying germ line familial mutations. The frequent 
dysregulation of the PI3K/Akt pathway in human cancer has made components of this 
pathway attractive for therapeutic targeting. 
 
 
 
 
 - 8 -
Introduction 
 
Figure 1. PI3K/Akt is a fundamental pathway in cancer. Its activation induces 
oncogenicity while tumor suppressor features are diminished, covering nearly all the 
established Hallmarks of Cancer (Boxes). Bad: BCL2-associated agonist of cell death; 
NFkB: nuclear factor of kappa light polypeptide gene enhancer in B-cells 1; HIF-1: 
hypoxia inducible factor 1; eNOS: nitric oxide synthase; MMPs: metalloproteinases. 
Adapted from (34). 
 
1.3 FOXO proteins 
One of the major signaling branches downstream of PI3K/Akt couples growth factor 
signaling to diverse transcriptional networks via the inactivation of FOXO transcription 
factors. The molecular link between FOXO factors and PI3K/Akt signaling is highly 
conserved among vertebrates and invertebrates. The mammalian members of FoxO 
subclass of forkhead transcription factors FOXO1, FOXO3A, FOXO4 and FOXO6 
function as transcriptional regulators in the cell nucleus. They bind as monomers via 
the Forkhead box, a 110 amino acid region located in the central part of the molecule 
(Figure 2)(157) to their consensus DNA binding sequence TTGTTTAC, designated as 
DBE (DAF-16 binding element) (43).  
The ever-growing list of target genes for these factors contains many elements that 
function in metabolism, apoptosis, resistance to oxidative stress, and cell-cycle 
inhibition, and includes glucose-6- phosphatase (108, 135, 163), phosphoenolpyruvate 
carboxykinase (122) FasL (13), Bim (32), MnSOD (84, 113), catalase (113), p27KIP1 
(100), p130 (85), and cyclin G2 (42, 50). 
Moreover, bioinformatic evidence indicates that a large number of genes contain 
conserved FOXO-binding sites (DBEs) in their promoters (160). When present in the 
nucleus and bound to DNA, FOXO proteins typically act as potent transcriptional 
activators (13, 83). The transactivation domain of FOXO proteins is located in the c-
terminal region of the molecule. Gene array analyses have indicated that FOXO 
proteins can also act as transcriptional repressors (123). Thus, this family of 
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transcription factors may activate or repress transcription, depending on the promoter 
context and extracellular conditions (50). 
 
 
 
 
 
Figure 2. The general structure of FOXO transcription factors. FOXO proteins share a 
high structural similarity that comprises a forkhead domain (FKH), a nuclear localization 
signal (NLS), a nuclear export signal (NES) and a transactivation domain (TA). 
 
  
FOXO transcription factors are considered bona fide tumor suppressors that are 
inactivated in the great majority of human cancers, due to overactivation of the 
PI3K/Akt pathway (13, 27, 50, 105). Akt-mediated phosphorylation of FOXO proteins 
induces their nuclear export and interrupts the transcription of their target genes. 
Cellular stress or inhibition of the PI3K/Akt pathway promote the translocation of 
FOXO factors to the cell nucleus, where their transcriptional functions can be executed. 
Diverse cellular functions can be affected by the genes which are transcriptionally 
targeted by FOXO, ranging from metabolism to cell cycle, apoptosis and oxidative 
stress (50).  
 
 
1.3.1 Regulation of FOXO factors 
The activity of FOXO factors is regulated by a sophisticated signaling network that 
integrates information from PI3K/Akt and stress-induced signaling pathways resulting in 
a specific pattern of posttranscriptional modifications. The multiple post-transcriptional 
events include phosphorylation, acetylation and ubiquitylation at 3 different levels: 
subcellular localization, stability and transcriptional activity of FOXO proteins (Figure 3). 
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Figure 3 – The regulation of FOXO transcription factors occurs via phosphorylation, 
acetylation and ubiquitylation. The two phenomena that trigger FOXO translocation are 
growth factor signaling via the PI3K/Akt pathway and oxidative stress. Some of the 
main molecules known to influence the post-translational modifications of FOXO 
proteins are depicted in this figure. Akt: v-akt murine thymoma viral oncogene homolog; 
CBP: CREB binding protein; CK1: casein kinase 1; DYRK: dual tyrosine 
phosphorylated regulated kinase 1; IKKβ:  I kappaB kinase β; JNK: c-Jun N-terminal 
kinase 1; MST1: mammalian Ste20-like kinase 1; PI3K: phosphoinositide-3-kinase; 
SIRT1: sirtuin; Skp2: S-phase kinase-associated protein 2. 
 
1.3.1.1 Phosphorylation 
Activation of PI3K and subsequent activation of the downstream families of kinases 
Akt and the related SGK has been shown to culminate in the phosphorylation and 
inactivation of FOXO (13). Biochemical studies in mammalian cells have shown that 
Akt directly phosphorylate FOXO transcription factors (8, 13, 83, 109, 127, 143). 
Phosphorylation of FOXO factors by Akt triggers the rapid relocalization of FOXO 
proteins from the nucleus to the cytoplasm. Akt phosphorylates FOXO3A at three key 
regulatory sites (Thr32, Ser253 and Ser315) that are conserved from C. elegans to 
mammals and are part of a perfect consensus sequence for Akt phosphorylation (2). 
SGK also phosphorylates FOXO factors, at a different combination of sites.  While Akt 
preferentially phosphorylates Ser253, SGK favors the phosphorylation of Ser315. 
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Thr32 is phosphorylated by both kinases. The three regulatory sites are 
phosphorylated in response to a number of growth factors, including insulin growth 
factor I (IGF-I) (13), insulin (83), interleukin 3 (33), erythropoietin (72), epidermal 
growth factor (EGF) (68), and nerve growth factor (168). Hence, FOXO proteins 
integrate a broad range of external stimuli via phosphorylation of three conserved 
residues by Akt and SGK. The preferential phosphorylation of FOXO proteins by 
different protein kinases may allow FOXO to selectively respond to closely related but 
different stimuli, such as insulin and IGF-I (107). 
The major consequence of the phosphorylation of FOXO transcription factors by Akt 
and SGK is a change in their subcellular localization (8, 13, 142). In the absence of 
growth factors, when Akt and SGK are inactive, FOXO localizes within the nucleus. 
Upon exposure to growth factors, the PI3K/Akt cascade is activated and triggers the 
export of FOXO factors to the cytoplasm. Mutation analyses revealed that one or two 
leucine-rich domains in the C-terminal region of FOXO proteins function as a nuclear 
export signal (NES) (8, 14). In addition, phosphorylated FOXO factors have been 
shown to specifically interact with 14-3-3 proteins, which serve as chaperone 
molecules to escort FOXO proteins out of the nucleus (13, 14). 14-3-3 binding to FOXO 
may actively promote the nuclear export of FOXO factors, perhaps by inducing a 
conformational change in FOXO molecules that would expose the NES and allow 
interaction with Exportin/CRM1 (14). 14-3-3 binding to FOXO may also prevent he 
nuclear re-import of these transcriptional factors by masking the FOXO proteins 
nuclear localization signal (NLS) (12, 128). Mutational analysis of the three regulatory 
Akt/SGK sites revealed that the phosphorylation of each site contributes to the nuclear 
exclusion of FOXO factors (15). One attractive possibility is that each site participates 
in different aspects of the mechanisms that ensure the localization of FOXO proteins to 
the cytoplasm. Thus, phosphorylation of FOXO factors may represent a way of 
modulating the extent of the relocalization of these transcription factors to the 
cytoplasm in different cell types in response to different combination of signals. 
Insulin and growth factors also trigger the phosphorylation of several other sites of 
FOXO factors. Previous phosphorylation of Ser329 by the dual tyrosine phosphorylated 
regulated kinase 1 (DYRK1), a member of the MAP kinase family facilitates a further 
phosphorylation of Ser322 and Ser325 mediated by casein kinase 1 (CK1). The 
phosphorylation of FOXO factors at Ser322 and Ser325 appears to accelerate FOXO 
relocalization to the cytoplasm in response to growth factors by increasing the 
interaction between FOXO and the export machinery (Ran and exportin/CRM1) (129). 
These various mechanisms for regulating the translocation of FOXO transcription 
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factors from the nucleus to the cytoplasm may serve as a fail-safe mechanism to 
ensure a complete sequestration of FOXO factors away from their target genes. 
Another major input of FOXO regulation is cellular stress. In this context, JNK kinase 
is known to act upon FOXO, and contrarily to Akt JNK was shown to promote the 
activation of FOXO towards transcription. JNK has been shown to directly 
phosphorylate human FOXO1, FOXO3A and FOXO4 in vitro, as well as the worm 
homolog DAF-16, although the regulatory sites remain to be identified (50). Also, JNK 
has been shown to phosphorylate 14-3-3 proteins releasing FOXO into the cell nucleus 
(150). Therefore, stress-induced JNK will facilitate FOXO localization to the cell 
nucleus, either by direct phosphorylation or by lowering the ability of 14-3-3 to 
sequester FOXO proteins in the cell cytoplasm. 
 
Figure 4. The regulation of FOXO factors by growth factors and stress stimuli. In 
response to growth factors the PI3K/Akt pathway inhibits FOXO-dependent 
transcription through phosphorylation and subsequent sequestration in the cytoplasm. 
Stress stimuli are sufficient to overcome the cytoplasmic localization of FOXO factors. 
In response to stress stimuli, JNK phosphorylates FOXO proteins, which causes their 
nuclear translocation. Although phosphorylation by JNK does not directly inhibit the 
binding of 14-3-3 proteins it induces the release of its substrates. JNK activity is 
sufficient to overcome Akt inhibition of FOXO factors and causes the transcription of 
genes involved in stress resistance. It has been proposed that a specific subset of 
genes is transcribed under each condition and the specific transcriptional programs 
may dictate whether cells undergo cell cycle arrest, stress resistance or apoptosis 
(Adapted from (50)). 
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Stress-mediated FOXO activation via JNK constitutes a powerful input that induces 
FOXO transcriptional activity even when the PI3K/Akt pathway is activated, which 
reflects a marked hierarchy of the signals that will culminate in FOXO modulation. 
When both inputs are present stress signaling overrides PI3K/Akt impairment of FOXO 
function, and the gene expression pattern that occur in this context resembles more the 
pattern observed in stress conditions alone (50). 
The protein kinase Sterile 20 (Ste20) was reported to mediate hydrogen peroxide-
induced cell death in S. cerevisiae (1). The mammalian Ste20-like kinases (MSTs), of 
which MST1 and MST2 share the highest degree of homology, and the Drosophila 
ortholog Hippo have important functions in apoptotic cell death (23, 49, 59, 115, 158). 
MST1 was found to phosphorylate the FOXO transcription factors at a site that is 
conserved within the forkhead domain of these proteins from mammals to C. elegans 
(90). In mammalian neurons, oxidative stress activates MST1, which in turn 
phosphorylates FOXO3A at Ser207. The MST1-induced phosphorylation of FOXO3A 
disrupts its interaction with 14-3-3 proteins, promotes FOXO3A translocation to the 
nucleus, and thereby induces neuronal cell death (90).  
FOXO can also be phosphorylated by IKKβ,  which was reported to promote 
tumorigenesis (66). IKKβ induces the phosphorylation of FOXO3A at Ser644, in the 
extreme C-terminal position of the molecule (Figure 2). This phosphorylation results in 
the ubiquitylation and subsequent degradation of FOXO3A (66). 
Despite the abundant information concerning the phosphorylation events that regulate 
the subcellular localization of FOXO proteins very little is known about the 
phosphatases that dephosphorylate FOXO transcription factors. Protein phosphatase 
2A was identified as a possible FOXO3A binding partner in a purified FOXO3A-
containing protein complex, suggesting that protein phosphatase 2A may be one of the 
phosphatases that dephosphorylates FOXO  (130). The subcellular localization of the 
FOXO phosphatases could provide another layer of spatial control of FOXO activity. In 
addition, the rate at which the phosphatases remove the phosphate group from each 
phosphorylated site of FOXO proteins may affect the kinetics of localization of these 
transcription factors.  
Subcellular localization of FOXOs may also be deregulated independently of post-
translational modifications. The Kaposi sarcoma-associated herpes virus can promote 
tumorigenesis through interaction of latent protein LANA2 with FOXO3A and 14-3-3 
proteins, which are required for nuclear export of FOXO3A, resulting in a decrease in 
transcriptional activity.  
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1.3.1.2 Acetylation 
Phosphorylation of FOXO proteins is a fundamental mode of regulating their activity. 
Still, other post-translational modifications such as acetylation also influence the activity 
of FOXO factors, adding another layer to this complex regulation network. 
The nuclear proteins CBP and p300 and their associated proteins, such as p300- and 
CBP-associated factor (PCAF), possess intrinsic histone acetyl-transferase (HAT) 
activity. These proteins play essential roles promoting transcription by acetylating 
histones and integrating signaling from enhancer and promoter regions. They also 
directly acetylate transcription factors through FAT (transcription factor acetyl-
transferase) activity (Li et al., 2002). CBP appears to play a dual role in FOXO-
mediated gene transcription: it can facilitate FOXO-mediated transcription by 
acetylating chromosomal histones but also promotes acetylation and regulation of 
FoxO proteins themselves. Acetylation of FOXO proteins by acetylases such as CBP 
and p300 increases in response to oxidative stress (16, 41, 81). Acetyl-FOXO proteins 
accumulate in the nucleus and associate with Pml bodies, which hinders their activity 
(81). 
Increased levels of FOXO acetylation in the nucleus suggests an additional layer of 
regulation by other pathways, such as those involving SIRT1, a nicotinamide adenine 
dinucleotide (NAD)- dependent histone deacetylase. SIRT1 is localized in the nucleus 
in cells stimulated with growth factors (88, 154). Upon stress stimuli, SIRT1 forms a 
complex with and deacetylates FOXO proteins in the nucleus (16, 81). Interestingly, 
expression of SIRT1 augments FOXO3A-induced cell cycle arrest by increasing 
expression of p27KIP1 (16). This is consistent with the fact that acetylation of FoxO 
proteins by CBP inhibits their activity (26). By contrast, FOXO3A-induced expression of 
apoptotic genes such as Bim is further enhanced by inhibition of SIRT1 by the class III 
histone deacetylase (HDAC) inhibitor nicotinamide and the class I/II HDAC inhibitor 
trichostatin A (16). Moreover, expression of SIRT1 inhibits Bim promoter activity (104). 
Current evidence favors the hypothesis that association with SIRT1 differentially affects 
FOXO target genes, inducing cell cycle arrest, stress resistance and DNA repair rather 
than apoptosis (16, 86). 
 
1.3.1.3 Ubiquitylation 
FOXO proteins are also regulated by the ubiquitin-proteasome system. Steady-state 
levels of FOXO proteins are reduced in murine pro-B lymphocytes stably expressing 
Akt, and this effect is largely attenuated by treatment of cells with proteasome inhibitors 
(121). The levels of FOXO also decrease in HepG2 cells following insulin treatment 
(97). Similarly, treatment of chicken embryo fibroblasts with platelet-derived growth 
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factor (PDGF) decreases levels of FOXO. This effect is inhibited by the proteasome 
inhibitor lactacystin or the PI3K inhibitor LY294002 (3), which suggests that 
proteasome-mediated degradation of FOXO depends on Akt signaling. 
Moreover, phosphorylation by Akt is required for the polyubiquitylation of FOXO (97). 
Ubiquitin-dependent degradation of FOXO requires its interaction with the F-box 
protein Skp2, the substrate-binding component of the Skp1/culin 1/F-box protein 
(SCFSkp2) E3 ligase complex (67), which targets various proteins, including p27KIP1, 
for degradation in the nucleus (125). Skp2-dependent polyubiquitylation of FOXO 
requires phosphorylation by Akt (67). IKK-mediated phosphorylation of FOXO3A also 
leads to its ubiquitylation and degradation  by the MDM2 E3 ubiquitin ligase (66, 162). 
Whereas polyubiquitylation of FOXO proteins results in their degradation, 
monoubiquitylation leads to their nuclear localization and increases their transcriptional 
activity (152). Therefore, oxidative-stress-mediated monoubiquitylation provides 
another means for cells to regulate the subcellular localization and activity of FOXO. 
Deubiquitylation of FOXO is known to be catalyzed by the deubiquitylating enzyme 
herpes virus-associated ubiquitin-specific protease (HAUSP/USP7) (152). USP7-
mediated deubiquitylation of FOXO results in their relocalization from the nucleus to the 
cytoplasm. 
 
 
1.3.2 Functions of FOXO proteins 
FOXO factors are implicated in many fundamental cellular processes, through the 
transcriptional regulation of a wide array of target genes (Figure 5). The integration of 
diverse intracellular and extracellular stimuli translates in the post-translational 
modifications that occur on FOXO proteins generating a “FOXO code” that is read by 
protein partners and determines the level, intensity, duration and activity of FOXO 
transcription factors within cells (18).  
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Figure 5 A schematic representation of some FOXO target genes and cellular roles in 
which they are implicated. BTG-1: B-cell translocation gene 1; p21: cyclin-dependent 
kinase inhibitor 1A; p27: cyclin-dependent kinase inhibitor 1B; MnSOD: manganese 
superoxide dismutase; G6Pase: glucose-6-phosphatase; PEPCK: 
phosphoenolpyruvate carboxykinase; FasL: Fas ligand; GADD45: growth arrest and 
DNA damage-inducible protein 45; DDB1: damage-specific DNA-binding protein 1; 
FBE, FOXO binding element (Adapted from (50)).  
  
 
1.3.2.1 FOXO and apoptosis 
The expression of constitutively nuclear forms of FOXO proteins has been shown to 
trigger cell death, particularly in neurons and lymphocytes (13, 31, 46, 169). One way 
by which Akt promotes cell survival is by sequestering FOXO factors away from the 
promoters of apoptotic genes. FOXO target genes that mediate apoptosis include Bim, 
a proapoptotic Bcl-2 family member (33). Apoptosis induced by the inactivation of the 
PI3K/Akt pathway is reduced in lymphocytes from Bim-deficient mice, indicating that 
Bim is an important target gene of FOXO factors to induce cell death. FOXO-induced 
apoptosis also appears to be dependent on the induction of death cytokines, including 
Fas ligand and TRAIL (13, 102). Fas ligand, TRAIL and other death cytokines may 
amplify the ability of FOXO proteins to induce apoptosis by triggering death pathways 
in neighboring cells.  
 
 
 
 - 17 -
Introduction 
1.3.2.2 FOXO and cell cycle arrest 
The expression of active forms of FOXO proteins in dividing cells was shown to 
promote cell cycle arrest at the G1/S boundary (100). The target genes that mediate 
FOXO-induced cell cycle arrest are the Cdk inhibitor p27KIP1 (100), and the Rb family 
member p130 (85). The ability of FOXO factors to induce G1 arrest is diminished in 
p27/p130-deficient fibroblasts (85), suggesting that p27 and p130 are both critical to 
mediate FOXO-dependent G1 arrest. In the presence of TGFβ, FOXO proteins also 
bind to the promoter of the cell cycle inhibitor p21 and induce cell cycle arrest at G1/S 
transition (137). FOXO factors can also promote cell cycle arrest by repressing the 
expression of cyclin D1 and D2 (123, 134). Thus, FOXO proteins play a major role in 
G1 arrest by both upregulating cell cycle inhibitors (p21 and p27) and by repressing cell 
cycle activators (cyclins D1 and D2). 
FOXO factors are also involved in other cell cycle checkpoints. Cells in which 
FOXO3A is activated in the S phase display a delay in their progression through the G2 
phase of the cell cycle (148). Microarray analysis led to the identification of several 
FOXO3A target genes that may mediate the effect of FOXO proteins at the G2/M 
boundary, such as cyclin D2 and growth arrest and DNA damage-inducible protein 45 
(GADD45) (42, 148). Hence, FOXO factors mediate cell cycle arrest at the G1/S and 
G2/M transitions, two checkpoints that are critical in the cellular response to stress. 
FOXO-induced cell cycle arrest may allow time for repair of damaged DNA and for 
detoxification of cells (50). 
 
 
1.3.2.3 FOXO in stress resistance, DNA repair and detoxification 
Consistent with the role of FOXO factors in promoting cell cycle arrest at the G1/S 
and G2/M boundaries, the expression of active forms of FOXO proteins upregulates 
several genes involved in DNA repair such as DBB1 and GADD45. (123, 148). In 
addition, FOXO proteins have been reported to allow detoxification of reactive oxygen 
species (ROS) by upregulating free radical scavenging enzymes, including Mn 
superoxide dismutase (MnSOD) and catalase (85, 113, 123, 148). Thus, FOXO 
transcription factors control two aspects of cellular resistance to stress: repair of 
damages caused by ROS and detoxification of ROS (50). 
Recent work has shown that FOXO factors can stimulate the expression of multidrug 
transporter MDR1 (P- glycoprotein) that may promote increased resistance of tumor 
cells  to the toxicity generated as a consequence of chemotherapy (54). 
A recent cDNA microarray study identified IGFR1 and PIK3CA as target genes of 
FOXO3A in a colon carcinoma cell line (29). This negative feedback could be 
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considered as another stress resistance mechanism regulated by FOXO proteins, as 
the transcription of both genes will increase the activation of the PI3K/Akt pathway 
which is known to contribute in resistance to stress stimuli. 
 
1.3.2.4 FOXO in metabolism 
FOXO transcription factors also play an important role in upregulating genes that 
control glucose metabolism (50). FOXO factors elicit gluconeogenesis by upregulating 
glucose 6 phosphatase (G6Pase), which is responsible for converting glucose-6-
phosphate to glucose, and phosphoenolpyruvate carboxykinase (PEPCK), which 
converts oxaloacetate to phosphoenolpyruvate (108, 122, 135, 163). Thus, insulin 
effects on glucose metabolism are mediated in part through the repression of FOXO 
factors by the PI3K/Akt pathway.  
 
1.3.2.5  FOXO proteins in ageing and lifespan 
One of the most intriguing functions of FOXO transcription factors is their conserved 
ability to increase longevity (75). In worms, mutations in the insulin receptor or PI3K 
result in an extended longevity by up to threefold (69, 76, 78, 103). This lifespan 
extension is reverted when the worm FOXO ortholog (DAF-16) is mutated (93, 116). 
Thus, the FOXO ortholog DAF-16 plays a crucial role downstream of the insulin-
signaling pathway to regulate longevity. 
The target genes that mediate the ability of DAF-16 to increase longevity include 
MnSOD (SOD3 in worms) (65), MST1 (90), heat-shock proteins and antimicrobial 
agents (89, 99). DAF-16 appears to induce a program of genes that coordinately 
regulate longevity by promoting resistance to oxidative stress, protection of protein 
structure, and resistance to pathogens. Consistent with the notion that stress 
resistance is correlated with longevity, all the long-lived worm mutants that lead to the 
activation of DAF-16 also display resistance to oxidative stress, heat shock and UV 
radiations (62). Similarly, as for mammals, it has been shown that mice that are 
deficient for either the insulin or the IGF-1 receptor are long lived and resistant to 
oxidant stress stimuli (10, 64). In addition, FOXO proteins induce stress resistance in 
mammalian cells and some FOXO target genes involved in stress resistance, like 
MnSOD, are conserved between mammals and worms, raising the possibility that 
FOXO factors may also regulate the lifespan in mammals. 
 
1.3.3 FOXO and cancer 
In mammals, the antiproliferative and proapoptotic effects of FOXO proteins strongly 
suggested their functions as tumor suppressors (50). 
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Several lines of evidence indicate that FOXO factors are likely to play a significant 
role in cancer regulation. FOXO3A has been shown to be dysregulated in breast 
cancer. The presence of cytoplasmatic FOXO3A in breast cancer cells highly 
correlates with poor patient survival. A strong correlation has also been observed 
between the expression of IKKβ and the cytoplasmatic localization of FOXO3a in those 
tumors (27). 
 
 
 
Figure 6 – The tumor-suppressive functions of FOXO proteins could operate to block 
tumor development at multiple stages. FOXO-induced oxidative stress scavenging and 
DNA-damage repair prevents the induction and propagation of mutations required for 
oncogenic transformation. Because the progression from each stage of tumorigenesis 
to the next is probably driven by mutations, this FOXO function might be tumor 
suppressive at multiple stages. A tumor can only form if the balance of proliferation and 
apoptosis is shifted towards proliferation. FOXO proteins block the cell cycle and 
induce the expression of pro-apoptotic genes, which could re-balance tissue 
homeostasis. This function of FOXO proteins could also be tumor suppressive at 
different stages of tumorigenesis. Finally, for a malignant tumor to form angiogenesis 
has to occur. FOXOs repress HIF signaling, which is required for tumor angiogenesis. 
Taken together, the FOXO proteins function as tumor suppressors throughout the 
formation, expansion and spreading of the tumor (Adapted from (27)). 
 
FOXO proteins were shown to interact physically or functionally with tumor 
suppressors or oncogenes. In response to stress stimuli or to nutrient deprivation, 
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FOXO3A has been found to interact with the tumor suppressor p53 in the nucleus (16, 
112). The observation that FOXO and p53 interact, combined with reports that p53 and 
FOXO share similar target genes (p21, GADD45, WIP1, PA26), suggests that these 
two proteins may coordinate tumor suppression. Also, FOXO forms a complex with 
SMAD transcription factors (137), that act as tumor suppressor through the mediation 
of the cytostatic effect of transforming growth factor β (TGF-β). The interaction between 
FOXO factors and SMADs occurs at the p21 promoter in response to TGF-β 
stimulation. The FOXO/SMAD complex elicits the upregulation of p21 and subsequent 
G1 arrest (50). Finally, the proto-oncogene β-catenin has been shown to bind to FOXO 
proteins (39), enhancing their ability to inhibit cell-cycle progression. Since β-catenin 
has been implicated in cancer progression, in particular in colon cancer, it is possible 
that FOXO factors could counteract tumor progression by sequestering β-catenin 
thereby inhibiting cell cycle progression (50). 
The expression of altered forms of FOXO proteins reduces tumorigenicity in several 
models. Cell proliferation and tumorigenicity in mice induced by IKKβ expression can 
be overridden by the expression of an active form of FOXO3A (66). In Drosophila it 
was shown that FOXO affects MYC-induced protein translation by interfering with 
ribosome biogenesis (144). Others have shown that expression of triple mutant FOXO1 
or FOXO3A in which the three phosphorylation sites targeted by Akt have been altered 
to prevent FOXO inactivation efficiently induces apoptosis in melanoma cells (48). 
 
1.3.3.1 FOXO transcription factors are bona fide tumor suppressors 
The formal establishment of FOXO proteins as tumor suppressor came from a triple 
FOXO-knockout mouse model in which simultaneous loss of FoxO1, FoxO3a and 
FoxO4 induces spontaneous tumor formation, mainly aggressive lymphoblastic thymic 
lymphomas, with spread to spleen, liver, and lymph nodes. The knockdown of two 
FOXO genes does not produce such a marked phenotype, suggesting a strong 
redundancy of the three FOXO family members. The triple FOXO-knockout mice also 
displayed aberrant and widespread vasculature growth, indicating that FOXO has a 
major role in the regulation of vasculature homeostasis. All the mice developed a 
striking age-progressive hamartomatous phenotype in the endothelial cell lineage, and 
in a relative number of animals the condition progressed to lethal angiosarcomas.   
The thymocytes of the triple knockout mice exhibited enhanced response to growth 
stimulation and conversely a greater resistance to death stimuli (118). 
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1.3.4 Reactivation of FOXO as a therapeutic strategy. 
Due to mounting evidence of the inactivation of FOXO transcription factors in human 
tumors, the restoration of FOXO functions has been suggested as a promising strategy 
for anti-cancer therapy. 
Unlike other tumor suppressors whose functions are lost due to mutations, the 
abrogation of FOXO function occurs mainly via post-translational modifications induced 
by growth and survival pathways. Thus, although FOXO proteins are inactivated in 
tumors, the gene – and thus the protein – is still present and possibly reactivatable, 
whereas genetic loss as it is often the case for p53 is irreversible. Therefore, therapies 
aimed at reactivating FOXO could prove effective (27). 
Interestingly, several agents that are used in anti-cancer chemotherapy have been 
shown to reactivate FOXO proteins. FOXO3A was reported to be an indirect target of 
the chemotherapeutic drugs paclitaxel, a tubulin depolymerizing agent, and KP372-1, a 
multiple kinase inhibitor in breast carcinoma cells (140, 141) and in acute myeloid 
leukemia cells (166), respectively and both activate FOXO3A by reducing Akt activity. 
Paclitaxel also activates JNK, which has a double effect in the activating and stabilizing 
phosphorylation of FOXOs per se, and in the inhibition of 14-3-3 binding to FOXOs, 
preventing their nuclear exclusion. 
FOXO3A is also important for imatinib (Glivec)-induced apoptosis in chronic myeloid 
leukemia cell lines that express the BCR-ABL oncoprotein (38). FOXO3A is 
constituvely phosphorylated in BCR-ABL-positive cell lines and the inhibition of BCR-
ABL by imatinib induces FOXO3A transcriptional activity leading to Bim-dependent 
apoptosis (105). Blockade of epidermal growth factor receptors (EGFR) by antibodies 
(such as trustuzumab or cetuximab) or small molecules (such as lapatimib and 
gefitinib) represents a valuable therapeutic strategy against breast, prostate, kidney, 
ovarian, and NSCLC, and either single agent or combinational therapies have been put 
in clinical trials (126). The PI3K pathway is a major target of the EGFR pathway and 
EGFR blockade by the antibodies induces FOXO3A and transcriptional activation of 
the BNIP3L gene (124). Interestingly, FOXO3A is a crucial target of small molecule 
EGFR inhibitors, therefore the reintroduction of active FOXO3A may sensitize resistant 
cells to agents such as gefitinib (105).   
Activation of FOXO3A may also be effective in combination with other agents to 
overcome resistance or increase tumor killing. FOXO3A-induced upregulation of Bim 
has been reported in p53-null osteosarcoma cell lines following exposure to ionizing 
radiation (161), suggesting that FOXO3A may be an important effector of radiation-
inducing apoptosis, and chemotherapies targeting FOXO3A may also sensitize cells to 
radiotherapy. 
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However, the reactivation of FOXO has also been associated with resistance to 
chemotherapy, through the mechanisms that allows FOXO to protect the cells from 
stress.  
Therefore, it is fundamental to identify and characterize all the molecular components 
that influence FOXO activation comprehensively. A complete knowledge on how to 
program the FOXO code will enable the tailoring of more efficient anti-cancer therapies 
that will take advantage of the tumor suppressor features of FOXO proteins and at the 
same time avoid the development of resistance. 
 
1.4 The Search for Novel FOXO modulators 
Traditionally, systematic genetic screenings in mammalian cell systems were 
hampered by the lack of reliable tools (70, 138). 
However, recent technological advances have enriched the approaches available for 
the identification of components of complex signaling networks in cultured human cells.  
RNAi is an evolutionarily conserved, sequence-specific gene-silencing mechanism 
that is induced by double-stranded RNA (dsRNA) (22). Long dsRNAs are processed 
into 21–25 base pairs (bp) dsRNAs called small interfering RNAs (siRNAs) (51, 52, 
164) by Dicer, a ribonuclease III family (RNAse III). The resulting small RNAs enter the 
RNA-induced silencing complex (RISC), which uses a single-stranded version of the 
small RNA as a guide to substrate selection (52, 53, 151, 164). 
Perfect complementarity between the substrate and the small RNA leads to target-
RNA cleavage (22).  RNAi can result in the knockdown of single or multiple genes, 
providing a quick and convenient method of analyzing gene function (36). RNAi 
libraries have been developed as a useful screening tool for assessing functional 
consequences of inhibiting members of signaling pathways (30, 96). 
Chemical genetics is the study of gene-product function in a cellular or organismal 
context using exogenous ligands. In this approach, small molecules that bind directly to 
proteins are used to alter protein function, enabling a kinetic analysis of the in vivo 
consequences of these changes. Recent advances have strongly enhanced the power 
of exogenous ligands such that they can resemble genetic mutations in terms of their 
general applicability and target specificity. The growing sophistication of this approach 
raises the possibility of its application to any biological process (138). 
The adaptation of the RNAi technology to mammalian cells, together with the 
expansion of chemical genetics enabled systematic loss-of-function studies capable of 
revealing protein functions implicated in many human disease processes. However, the 
lack of powerful technologies capable of detecting the changes induced upon 
interference in a cell basis and in a high throughput fashion constituted a technological 
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gap that did not permit the implementation of large-scale RNAi and chemical genetic 
screenings. 
This technological gap was filled with the implementation of image acquisition using 
robotic fluorescent microscopy and automated image analysis, generally referred to as 
High Content Screening (HCS). This technology has become an essential tool in early 
drug discovery programs. High content cellular imaging has increasingly met the 
challenges of high throughput needs and facilitates the integration of disease-relevant 
screens at early stages of the drug discovery process (56, 87, 165). 
The combined use of RNAi, chemical genetics and HCS simultaneously constitutes a 
powerful methodology that allowed us to perform unbiased studies independent of 
preconceived notions on the network implicated in FOXO regulation. The identification 
and characterization of novel molecules implicated in FOXO modulation may provide 
new insights on how to re-activate FOXO, aiming for a better outcome of cancer 
treatment. 
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1.1 Cáncer 
En las últimas décadas se ha generado una gran cantidad de información revelando 
que el cáncer es una enfermedad genética. Esto ha llevado al descubrimiento de 
numerosos genes responsables del proceso de tumorigenesis. No obstante, el cáncer 
sigue siendo una de las enfermedades que presenta las tasas de mortalidad más 
elevadas en las sociedades occidentales. Mientras que se ha observado una 
importante reducción en el número de muertes causadas por enfermedades cardiacas, 
cerebro-vasculares e infecciosas en la última década, las muertes causadas por 
cáncer no han seguido ese patrón. Apenas algunos tipos particulares de cáncer, 
principalmente cánceres testiculares y leucemias infantiles, presentan una tasa 
satisfactoria de remisión y/o cura a través de la quimioterapia clásica, siempre y 
cuando sean detectados en estadios iniciales. La razón por la cual hay una transición 
lenta del conocimiento a la clínica se relaciona con la complejidad inherente del 
cáncer. Hoy en día el cáncer es considerado como un conjunto de enfermedades que 
se originan a partir de mutaciones progresivas a diversos niveles. Estas mutaciones  
confieren a las células neoplásicas las diversas capacidades que requieren para 
sobrevivir y proliferar en condiciones adversas, sea a través de la activación de proto-
oncogenes o a través del silenciamiento de genes supresores tumorales (55). 
Se ha propuesto que las células tumorales presentan alteraciones fundamentales 
que garantizan su éxito. Esas alteraciones, designadas “características fundamentales 
del cáncer” (55) consisten en autosuficiencia en factores de de crecimiento, 
insensibilidad a señales inhibidores del crecimiento, fuga a la muerte celular 
programada (apoptosis), capacidad de división ilimitada, mantenimiento de 
angiogénesis, y invasión tisular y metástasis (55). 
 
1.2 La vía de señalización PI3K/Akt 
Alteraciones de la vía de señalización PI3K/Akt modifican todos los aspectos de la 
fisiología celular que constituyen las características fundamentales del cáncer y que 
llevan a la formación y desarrollo de los tumores (20, 55, 63, 155) (Figura 1). 
La activación fisiológica de PI3K se induce por factores de crecimiento e insulina a 
través de la aproximación de su subunidad catalítica a la membrana, en donde se 
encuentra su sustrato, PIP2, que será fosforilado por la PI3K formando PIP3 (153). La 
actividad de la PI3K es contrarrestada por la actividad de la fosfatasa PTEN, que 
elimina el fosfato de la posición 3’ del PIP3, regenerando PIP2 y atenuando la 
señalización que ocurre gracias a PI3K. PDK1 se activa a través de la unión con PIP3 
a través de su dominio de homología con plecstrina (dominio PH). Cuando está 
activada, PDK1 fosforila a Akt en la Thr308, activando así su función de kinasa de 
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Ser/Thr. Una vez fosforilada en la Thr308, se da un incremento de la activación a 
través de PDK2 (el complejo rictor/mTOR), a través de la fosforilación de la Ser473. La 
activación de Akt y la consecuente fosforilación de sus diversos sustratos (25, 35, 71, 
139, 155) estimula la progresión del ciclo celular, la supervivencia, el metabolismo, la 
resistencia a hipoxia y la migración. Así mismo, inhibe la apoptosis inducida por la 
privación de factores de crecimiento, ausencia de contacto con la matriz extracelular, 
radiaciones ultravioleta, alteraciones en el ciclo celular y activación de la señalización 
mediada por Fas(35, 71, 120). Así, la activación de la cascada de señalización 
PI3K/Akt confiere características oncogénicas a las células y como tal es considerada 
una de las dianas que más frecuentemente se altera en el desarrollo del cáncer 
humano (63). La actividad de PTEN se pierde por mutaciones, deleciones o metilación 
del promotor. La inactivación de PTEN ocurre con una frecuencia elevada en muchos 
tumores primarios y metastáticos. Se encuentran mutaciones germinales de PTEN en 
los síndromes de Cowden, Bannayan-Riley-Ruvalcaba y en síndromes similares al 
síndrome de Proteus, siendo todos síndromes familiares con predisposición al cáncer 
(92, 95, 111, 136). Se han descrito varias mutaciones en el gen PIK3CA (que codifican 
p110α, la subunidad de PI3K) en tumores humanos (119, 133). Estas mutaciones son 
capaces de activar a Akt de forma constitutiva. La consecuente mejoría de las 
capacidades bioquímicas se traduce en un aumento de la actividad oncogénica de los 
mutantes de la PI3K (6, 167). 
Carpten y colaboradores (21) han descrito una mutación de Akt en cánceres 
humanos de mama, colo-rectales, y de ovario, cuya consecuencia es la activación de 
Akt a través de su localización constitutiva en la membrana plasmática, que estimula la 
señalización de la vía de Akt , lleva a la transformación de las células e induce 
leucemia en ratones. De esta forma se establece un papel fundamental de Akt en el 
cáncer, que se suma a las alteraciones genéticas ya conocidas y que promueven el 
proceso oncogénico a través de la diana de la PI3K/Akt (21). 
La activación de la PI3K y de Akt en ausencia de mutaciones en sus genes se ha 
descrito en cánceres de mama (5, 19, 79), de ovario (19, 110, 159), de páncreas (4), 
esófago (117), tiróide (44) y otros (11, 119). 
También se ha demostrado que otros genes de esa vía de señalización funcionan 
como supresores tumorales, tales como TSC1, TSC2 o LKB1 encontrándose 
frecuentemente inactivados en algunos cánceres. La alteración frecuente de la diana 
de la PI3K/Akt ha hecho que varios componentes de esa ruta de señalización se 
conviertan en objetivos atractivos para el desarrollo de nuevos fármacos contra el 
cáncer. 
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Figura 1. La diana PI3K/Akt es fundamental en cáncer. Su activación induce 
oncogenidad mientras disminuye la supresión tumoral, cubriendo casi todas las 
“características del cáncer” (cajas). Bad: BCL2-associated agonist of cell death ; NFkB: 
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1; HIF-1: hypoxia 
inducible factor 1; eNOS: nitric oxide synthase; MMPs: metalloproteinases. Adaptado 
de  (34). 
 
1.3 Proteínas FOXO 
Un importante nodo de señalización en la ruta de PI3K/Akt conecta la señalización 
desencadenada por factores de crecimiento con diversas redes transcripcionales a 
través de la inactivación de los factores de transcripción FOXO. La conexión molecular 
entre los factores FOXO y la señalización por PI3K/Akt está altamente conservada 
entre vertebrados e invertebrados. Los miembros de la subclase de factores de FOXO 
son FOXO1, FOXO3A, FOXO4 y FOXO6 actuando como reguladores de la 
transcripción en el núcleo. 
Las proteínas FOXO actúan como monómeros, y a través de su dominio forkhead, 
una región de 110 aminoácidos  situada en la zona central de la molécula (Figura 2) 
(157), se unen a su secuencia consenso de unión al DNA, TTGTTTAC, designada 
DBE (elemento de unión a DAF-16)  (43). 
La lista de genes cuyos promotores contienen sitios de unión para estos factores de 
transcripción está en expansión y contiene genes involucrados en apoptosis, 
resistencia a estrés oxidativo e inhibición del ciclo celular. Incluye genes como la 
glucosa-6-fosfatasa (108, 135, 163), la fosfoenolpiruvato carboxilasa (122), FasL (13), 
Bim (32), MnSOD (84, 113), catalasa (113), p27KIP1 (100), p130 (85), y ciclina G2 (42, 
50). 
Cuando se localizan en el núcleo y ligados al DNA, las proteínas FOXO actúan 
típicamente como potentes activadores transcripcionales (13, 83). El dominio de 
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transactivación de FOXO se localiza en el extremo carboxilo de la molécula. Análisis 
hechos en matrices de genes indican que las proteínas FOXO pueden también actuar 
como represores transcripcionales (123).  De este modo, esta familia de factores de 
transcripción puede activar o reprimir la transcripción, dependiendo del contexto del 
promotor y de las condiciones extracelulares (50). 
 
 
 
Figura 2. Estructura general de los factores de transcripción FOXO. Las proteínas 
FOXO comparten una gran similiaridad estructural, que incluye un dominio forkhead 
(FKH), una señal de localización nuclear (nuclear localization signal - NLS), una señal 
de exporte nuclear (nuclear export signal - NES) y un dominio de transactivación 
(transactivation domain - TA). 
  
Los factores de transcripción FOXO son considerados supresores tumorales bona 
fide que son inactivados en la mayoría de cánceres humanos, debido a la sobre-
activación de la diana PI3K/Akt (13, 27, 50, 105). La fosforilación de las proteínas 
FOXO mediada por Akt induce su exporte nuclear y así interrumpe la transcripción de 
sus genes diana. El estrés celular, o bien, la inactivación de la vía PI3K/Akt, 
promueven la translocación de los FOXO al núcleo en donde pueden ejecutar su 
función transcripcional. Varias funciones celulares pueden ser afectadas por genes 
que son activados transcripcionalmente por FOXO, implicados en funciones que van 
desde metabolismo hasta ciclo celular, apoptosis y estrés oxidativo (50). 
 
 
1.3.1 Regulación de los FOXO 
La actividad de los factores FOXO es regulada por una sofisticada red de 
señalización que integra la información proveniente de la vía PI3K/Akt y dianas de 
señalización de estrés, lo que resulta en un patrón específico de modificaciones post-
traducionales. Las modificaciones post-traducionales que los FOXO pueden sufrir 
incluyen fosforilación, acetilación y ubiquitinación, que afectan a las proteínas FOXO a 
tres diferentes niveles: localización subcelular, estabilidad y actividad transcripcional 
(Figura 3). 
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Figura 3 – La regulación de las proteínas FOXO ocurre a través de fosforilación, 
acetilación, y ubiquitinación. Los dos estímulos que desencadenan cambios en la 
localización subcelular de las proteínas FOXO son la señalización desencadenada por 
factores de crecimiento a través de PI3K/Akt y estrés oxidativo. Algunas de las 
principales moléculas capaces de inducir modificaciones post-traducionales en los 
FOXO se encuentran representadas en esta figura. Akt: v-akt murine thymoma viral 
oncogene homolog; CBP: CREB binding protein; CK1: casein kinase 1; DYRK: dual 
tyrosine phosphorylated regulated kinase 1; IKKβ:  I kappaB kinase β; JNK: c-Jun N-
terminal kinase 1; MST1: mammalian Ste20-like kinase 1; PI3K: phosphoinositide-3-
kinase; SIRT1: sirtuin; Skp2: S-phase kinase-associated protein 2. 
 
1.3.1.1 Fosforilación 
La activación de PI3K y subsecuente activación de las familias de kinasas Akt y SGK 
culmina en la fosforilación e inactivación de los FOXO (13). Estudios bioquímicos 
realizados en células de mamíferos han demostrado que Akt fosforila a FOXO 
directamente (8, 13, 83, 109, 127, 143), llevando a la rápida relocalización de las 
proteínas FOXO desde el núcleo hasta el citoplasma. Akt fosforila FOXO3A en tres 
sitos regulatorios clave (Thr32, Ser253 y Ser315). SGK también fosforila los factores 
FOXO, pero en una combinación de sitios ligeramente distinta. Mientras Akt fosforila 
preferiblemente la Ser253, SGK favorece la fosforilación de la Ser315. La Thr32 es 
fosforilada por las dos kinasas. Los tres sitios regulatorios son fosforilados como 
respuesta a determinados factores de crecimiento, incluyendo IGF-I (13), insulina (83), 
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interleukina 3 (33), eritropoyetina (72), factor de crecimiento epidermal (EGF) (68) y 
factor de crecimiento neuronal (NGF) (168). Así, las proteínas FOXO integran un largo 
rango de estímulos a través de la fosforilación por Akt y SGK de tres residuos 
conservados. La fosforilación preferencial de las proteínas FOXO por diferentes 
kinasas de proteínas puede permitir que los FOXO respondan de manera selectiva a 
estímulos muy similares, tales como insulina e IGF-I (107). 
La consecuencia más evidente de la fosforilación de FOXO por Akt y SGK es el 
cambio en su localización subcelular (8, 13, 142). En ausencia de factores de 
crecimiento, contexto en el que Akt y SGK están inactivas, FOXO se localiza en el 
núcleo. Cuando las células son expuestas a factores de crecimiento, la cascada  
PI3K/Akt se activa y lleva a la exportación de FOXO al citoplasma. Estudios de análisis 
mutacional revelaron que uno o dos dominios ricos en leucina en la zona carboxílica 
de FOXO funcionan como señal de exporte nuclear (NES) (8, 14). Además, se ha 
demostrado que cuando las proteínas FOXO están fosforiladas interaccionan 
específicamente con las proteínas 14-3-3, que sirven de chaperones para escoltar las 
proteínas FOXO hacia fuera del núcleo (13, 14). La unión de 14-3-3 a FOXO puede 
activar el exporte nuclear de los factores FOXO, quizás induciendo un cambio 
conformacional en las moléculas FOXO que exponga su dominio NES y permita la 
interacción con la Exportina/CRM1 (14). Al unirse a FOXO, las proteínas 14-3-3 
pueden también prevenir la re-importación de esos factores de transcripción, a través 
de la ocultación de su señal de localización nuclear (NLS) (12, 128). Análisis 
mutacionales de los tres sitios regulatorios de Akt y SGK han revelado que la 
fosforilación de cada sitio contribuye para la exclusión nuclear de los factores FOXO 
(15). Una posibilidad atractiva es que cada sitio participa en diferentes aspectos de los 
mecanismos que aseguran la localización de los FOXO en el citoplasma. Así, la 
fosforilación de los factores FOXO puede representar una manera de modular la 
extensión de la relocalización de esos factores de transcripción en diferentes tipos 
celulares en respuesta a diferentes combinaciones de señales. 
Insulina y factores de crecimiento también desencadenan la fosforilación de otros 
residuos de FOXO. Una fosforilación previa por la kinasa DYRK1 (dual tyrosine 
phosphorylated regulated kinase 1), miembro de la familia de las MAP kinasas, facilita 
la fosforilación posterior de la Ser322 y la Ser325 mediadas por CK1 (casein kinase 1). 
La fosforilación de los FOXO en esos dos residuos parece acelerar la localización de 
FOXO en el citoplasma como respuesta a factores de crecimiento presumiblemente a 
través del aumento de la interacción entre los FOXO y la maquinaría de exporte (Ran y 
exportina/CRM1) (129). Puede que los diversos mecanismos de regulación de los 
factores de transcripción FOXO del  núcleo hacia el citoplasma funcionen como un 
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sistema de seguridad para asegurar el distanciamiento de los FOXO de los promotores 
de sus genes diana. 
El otro elemento fundamental de la regulación de FOXO es el estrés celular. En ese 
contexto, se sabe que la kinasa JNK también actúa sobre FOXO y, al contrario de Akt, 
se ha demostrado que JNK promueve la activación de FOXO hacia su actividad 
transcripcional. Se ha demostrado que JNK fosforila directamente a FOXO1, FOXO3A 
y FOXO4 in vitro  (50). Se ha demostrado también que JNK fosforila a las proteínas 
14-3-3, liberando FOXO hacia el núcleo (150). Así, la inducción de JNK por estrés 
facilita la localización nuclear de FOXO, bien por la fosforilación directa de los FOXO o 
bien por reducir la capacidad de 14-3-3 para mantener a las proteínas FOXO en el 
citoplasma.  
La activación de FOXO por JNK constituye un potente inductor de la actividad 
transcripcional de FOXO aunque la vía PI3K/Akt se encuentre activada, lo que refleja 
una jerarquía bien marcada de los señales que modulan a FOXO (Figura 4).  Cuando 
ambos elementos están presentes, la señalización de estrés se solapa a la 
interrupción de la función de FOXO mediada por PI3K/Akt y el patrón de genes que se 
expresa en ese contexto se asemeja más al patrón de genes que se expresa cuando 
sólo se verifica estrés (50). 
Se ha descrito que la kinasa de proteínas Ste20 participa en la muerte celular 
inducida por peróxido de hidrógeno en S. cerevisae (1). Las kinasas homólogas a 
Ste20 en mamíferos (MSTs), de entre las cuales MST1 y MST2 comparten el grado de 
homología más elevado, tienen funciones importantes en la muerte celular por 
apoptosis  (23, 49, 59, 115, 158). Se ha descubierto que MST1 fosforila los factores de 
transcripción FOXO en un sitio conservado del dominio forkhead  (90). En neuronas de 
mamíferos, el estrés oxidativo activa a MST1, que a su vez fosforila FOXO3A en 
Ser207. La fosforilación de FOXO3A inducida por MST1 rompe la interacción con 14-
3-3, promueve la translocación de FOXO hacia el núcleo induciendo la muerte celular 
en neuronas.  
FOXO también puede ser fosforilado por IKKβ, promoviendo tumorigenesis (66). 
IKKβ induce la fosforilación de FOXO3A en Ser644, en el extremo carboxílico de la 
molécula (Figura 2). Esa fosforilación lleva a la poli-ubiquitinación y posterior 
degradación de FOXO3A (66). 
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Figura 4. Regulación de FOXO por factores de crecimiento y estrés. La activación de 
PI3K/Akt inhibe a FOXO como respuesta a factores de crecimiento, a través de 
fosforilación y retención en el citoplasma. El estrés celular es suficiente para solapar la 
localización citoplasmática de los FOXO. JNK fosforila las proteínas FOXO como 
respuesta al estrés, lo que conlleva a su translocación nuclear. Aunque la fosforilación 
mediada por JNK no inhiba directamente la unión de 14-3-3 a las proteínas FOXO, 
induce la liberación de sus sustratos. La actividad de JNK es suficiente para solapar la 
inhibición de FOXO mediada por Akt y causa la transcripción de genes involucrados en 
resistencia a estrés. Se ha propuesto que en cada una de las condiciones se 
transcribe un conjunto específico de genes y los programas transcripcionales pueden 
determinar si se induce parada del ciclo celular, resistencia al estrés o apoptosis. 
(Adaptada de (50)). 
 
A pesar de haber mucha información respecto a los eventos que regulan la 
localización subcelular de las proteínas FOXO, hay relativamente poco conocimiento 
en cuanto a las fosfatasas responsables de su desfosforilación. La proteína fosfatasa 
2A ha sido identificada como un compañero de unión a FOXO en un complejo de 
proteínas purificadas que contenía FOXO3A, lo que sugiere que la proteína fosfatasa 2 
puede ser una de las fosfatasas que defosforila a FOXO (130). La localización 
subcelular de las fosfatasas de FOXO podría aportar otro nivel de control de la 
actividad de FOXO. Además, la rapidez con que esas fosfatasas eliminan el grupo 
fosfato de cada sitio fosforilado de las proteínas FOXO puede afectar la cinética de la 
localización de estos factores de transcripción. 
La localización subcelular de las proteínas FOXO puede también ser regulada 
independientemente de modificaciones post-traducionales. El virus de herpes asociado 
al sarcoma de Kaposi puede promover tumorigenesis a través de la proteína latente 
LANA2 con FOXO3A y 14-3-3, resultando en una disminución de la actividad 
transcripcional. 
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1.3.1.2 Acetilación 
La fosforilación de las proteínas FOXO es un modo esencial de regular su actividad 
transcripcional. No obstante, otras modificaciones post-traducionales, tales como 
acetilación también influencian la actividad transcripcional de FOXO, añadiendo otra 
capa a esta compleja red de regulación. 
Las proteínas nucleares CBP y p300 y sus proteínas asociadas, tales como el factor 
PCAF presentan una actividad intrínseca de acetil-transferasas de histonas (HAT). 
Esas proteínas tienen un papel esencial en la indución de transcripción a través de la 
acetilación de histonas y de la integración de señales de elementos de las regiones de 
enhancers y promotores. Esas proteínas también presentan actividad directa de acetil 
transferasas de factores de transcripción (FAT) (91). Se cree que CBP tiene un doble 
papel en la transcripción de genes mediada por FOXO: por un lado puede facilitar la 
transcripción a través de la acetilación de las histonas de los cromosomas, y por otro 
promueve la acetilación de las mismas proteínas FOXO. La acetilación de las 
proteínas FOXO por acetilasas como CBP y p300 aumenta en respuesta a estrés 
oxidativo (16, 41, 81). Las proteínas FOXO acetiladas se acumulan en el núcleo y se 
asocian con cuerpos Pml, lo que disminuye la actividad de FOXO (81). 
Los niveles elevados de acetilación de FOXO en el núcleo sugieren otra capa 
regulatoria formada por otras dianas como SIRT1, una deacetilasa dependiente de 
nicotinamida adenina (NAD),  que se localiza en el núcleo de células estimuladas con 
factores de crecimiento (88, 154). En condiciones de estrés SIRT1 forma un complejo 
con las proteínas FOXO promoviendo su deacetilación en el núcleo (16, 81). La 
expression de SIRT1 aumenta la parada del ciclo celular inducida por FOXO3A a 
través del aumento de la expresión de p27KIP1 (16), lo que es consistente con el hecho 
de que la acetilación de las proteínas FOXO por CBP inhibe su actividad (26). En 
contraste, la expresión inducida por FOXO de genes implicados en apoptosis tales 
como Bim se ve aumentada con la inhibición de SIRT1 por los inhibidores de  
deacetilasas de histonas (HDAC) de clase III como nicotinamida y de los inhibidores 
de HDAC de la clase I y II como tricostatina A (16). Además, la expresión de SIRT1 
inhibe a la actividad del promotor de Bim (104). Actualmente se favorece la hipótesis 
de que la asociación con SIRT1 afecta a la transcripción de los genes diana de FOXO 
de manera diferencial, induciendo parada de ciclo celular, resistencia a estrés y 
reparación del DNA (16, 86). 
 
1.3.1.3 Ubiquitinación 
Las proteínas FOXO también están reguladas por el sistema ubiquitina-proteasoma. 
Los niveles basales de proteínas FOXO en linfocitos pre-B murinos que expresan Akt 
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establemente son bajos, aumentando significativamente con el tratamiento con 
inhibidores del proteasoma (121). Los niveles de FOXO también disminuyen en células 
HepG2 tras tratamiento con insulina (97). De igual manera, el tratamiento de 
fibroblastos embrionarios de pollo con el factor de crecimiento derivado de plaquetas 
(PDGF) disminuye los niveles de FOXO. Ese efecto se bloquea con inhibidores de 
proteasoma o de PI3K (3), lo que sugiere que la degradación de FOXO mediada por el 
proteasoma depende de la señalización por Akt. Además, la fosforilación causada por 
Akt es un requisito para la poliubiquitinación de FOXO (97). La degradación de FOXO 
dependiente de ubiquitina  requiere la interacción con la proteína F-box Skp2, el 
componente de unión al sustrato del complejo  Skp1/culin 1/proteína F-box  
(SCFSkp2) E3 ligase (67). La fosforilación de FOXO mediada por IKK también lleva a 
su poliubiquitinación y degradación, mediada por la ubiquitina ligasa E3 MDM2 (66, 
162). Mientras que la poliubiquitinación de FOXO lleva a su degradación, la 
monubiquitinación, también mediada por MDM2, aumenta en respuesta a estrés 
oxidativo, llevando a translocación nuclear y aumento en actividad transcripcional 
(152). Por ultimo, se ha descrito que la desubiqutinación de FOXO es catalizada por 
HAUSP/USP7 (152). La desubiquitinación de FOXO mediada por USP-7 lleva a su 
relocalización celular en el citoplasma. Por tanto, la monoubiquitinación mediada por 
estrés oxidativo constituye un medio adicional de regulación de la localización 
subcelular y actividad de FOXO. 
 
1.3.2 Funciones de las proteínas FOXO 
Los factores de transcripción FOXO están implicados en muchos procesos celulares 
fundamentales, a través de la regulación de  un amplio conjunto de genes diana 
(Figura 5). La integración de diversos estímulos extracelulares e intracelulares se 
refleja en modificaciones post-traducionales que ocurren en las proteínas FOXO, 
dando origen a un “código FOXO” que puede ser interpretado por otras proteínas, 
determinando el nivel, intensidad, duración y actividad de los factores de transcripción 
FOXO en las células (18). 
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Figura 5 Una representación esquemática de algunos de los genes diana de FOXO y 
los procesos celulares en los que están implicados. BTG-1: B-cell translocation gene 1; 
p21: cyclin-dependent kinase inhibitor 1A; p27KIP1: cyclin-dependent kinase inhibitor 
1B; MnSOD: manganese superoxide dismutase; G6Pase: glucose-6-phosphatase; 
PEPCK: phosphoenolpyruvate carboxykinase; FasL: Fas ligand; GADD45: growth 
arrest and DNA damage-inducible protein 45; DDB1: damage-specific DNA-binding 
protein 1; FBE, FOXO binding element (Adaptada de (50)).  
  
1.3.2.1 FOXO y apoptosis 
Se ha demostrado que la expresión de mutantes nucleares de FOXO activan la 
muerte celular, particularmente en neuronas y linfocitos (13, 31, 46, 169). Una de las 
maneras por las cuales Akt promueve la supervivencia celular es a través del 
alejamiento de FOXO de los promotores de genes involucrados en apoptosis, como 
Bim (33). La apoptosis inducida por FOXO también parece ser dependiente de la 
inducción de citokinas relacionadas con muerte celular, en las que se incluyen el 
ligando de Fas y TRAIL (13, 102), que juntamente con otras citokinas pueden 
amplificar la capacidad de los factores FOXO en inducir apoptosis a través de la 
activación de dianas de muerte celular en células vecinas. 
 
1.3.2.2 FOXO y ciclo celular  
La expresión de formas constitutivamente activas de FOXO induce la parada del 
ciclo celular en el umbral G1/S (100). Los genes diana que median la parada del ciclo 
celular inducida por FOXO parecen ser el inhibidor de Cdk’s p27KIP1 (100) y p130,  
miembro de la familia Rb (85). La capacidad de FOXO en inducir parada en G1 se ve 
reducida en fibroblastos deficientes en p27KIP1 y p130 (85), lo que sugiere que p27KIP1 y 
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p130 son ambos fundamentales para mediar la parada en G1 inducida por FOXO. En 
presencia de TGFβ, los factores FOXO se unen al promotor de p21, que a su vez 
induce parada del ciclo celular en la transición G1/S(137). FOXO puede también 
promover la parada del ciclo celular a través de la represión de la expresión de las 
ciclinas D1 y D2(123, 134).  Por tanto, las proteínas FOXO desempeñan un papel 
fundamental en la parada en G1 tanto por la sobre-expresión de inhibidores (p21 y 
p27KIP1) como por la represión de activadores del ciclo celular (ciclinas D1 y D2). 
Los factores FOXO también tienen un papel fundamental en otros puntos de control 
del ciclo celular. Las células en las que FOXO3A se encuentra inactivado en la fase S 
presentan un retraso en la progresión a la fase G2 del ciclo celular (148). A través de 
análisis genómico  se identificaron diversos genes diana de FOXO que pueden mediar 
el efecto de FOXO en la transición G2/M, tales como la proteína GADD45  (42, 148). 
Por tanto, los factores FOXO median la parada del ciclo celular en las transiciones 
G1/S y G2/M, ambos puntos de control cruciales en la respuesta celular a estrés. La 
parada de ciclo celular inducida por FOXO podría permitir más tiempo para reparar el 
DNA dañado y para promover la desintoxicación de las células (50). 
 
1.3.2.3 FOXO en resistencia a estrés, reparación del DNA y desintoxicación 
Consistentemente con el papel de FOXO en la parada del ciclo celular en las 
transiciones G1/S y G2/M, la expresión de formas activas de FOXO lleva a la sobre-
expresión de diversos genes involucrados en reparación del DNA tales como DBB1 y 
GADD45 (123, 148). Además, se ha descrito que las proteínas FOXO promueven la 
desintoxicación de especies reactivas de oxígeno (ROS) a través de la sobre-
expresión de enzimas captadoras de radicales libres, tales como la súper-óxido 
dismutasa de Mn (MnSOD) y catalasa (85, 113, 123, 148). Así, los factores de 
transcripción FOXO controlan dos aspectos fundamentales de la resistencia celular al 
estrés: reparación de los daños al DNA causados por ROS y desintoxicación de ROS 
(50). 
Se ha demostrado recientemente que los factores FOXO pueden estimular la 
expresión del transportador de drogas MDR1 (glicoproteína P), que puede inducir un 
aumento de la tolerancia de las células tumorales a la toxicidad generada por la 
quimioterapia (54). 
A través de un estudios genómicos de expresión de mRNA se han identificado 
IGFR1 y PIK3CA como genes diana de FOXO3A en una línea de carcinoma del colon 
(29). Este mecanismo de retroalimentación negativa puede ser considerado un 
mecanismo añadido de tolerancia al estrés mediado por las proteínas FOXO, una vez 
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que la transcripción de ambos genes contribuye a la activación de la diana PI3K/Akt, 
que está implicada en la resistencia al estrés. 
 
1.3.2.4 FOXO en metabolismo 
Los factores de transcripción FOXO también desempeñan un papel importante en la 
sobre-expresión de genes que controlan el metabolismo de glucosa (50). Los factores 
FOXO desencadenan la gluconeogénesis a través de la sobre-expresión de la glucosa 
6 fosfatasa (G6Pase), que es responsable de la conversión de glucosa-6-fosfato en 
glucosa; y de la fosfoenolpiruvato carboxilasa (PEPCK), que convierte oxaloacetato en 
fosfoenolpiruvato  (108, 122, 135, 163). De este modo, los efectos de la insulina en el 
metabolismo de glucosa son mediados parcialmente a través de la represión de FOXO 
por la diana PI3K/Akt. 
 
1.3.2.5  FOXO en envejecimiento y longevidad 
Una de las funciones más interesantes de FOXO es su capacidad de aumentar la 
longevidad (75). En nemátodos se ha demostrado que mutaciones inactivantes en el 
receptor de insulina o en PI3K llevan a un aumento de longevidad de hasta tres veces 
(69, 76, 78, 103). Esa extensión de la longevidad se revierte cuando se produce la 
mutación del ortólogo de FOXO en nemátodos DAF-16, demostrando que DAF-16 
tiene un papel crucial en la señalización por debajo de la diana de insulina en la 
regulación de la longevidad. 
Los genes que median la capacidad de DAF-16 de aumentar la longevidad incluyen 
la MnSOD (SOD3 en nemátodos) (65), MST1 (90), proteínas de choque térmico y 
agentes antimicrobianos (89, 99). DAF-16 parece inducir un programa de genes que 
coordinadamente regulan la longevidad promoviendo la resistencia a estrés oxidativo, 
protección de la estructura de las proteínas y resistencia a patógenos. Así, la 
resistencia a estrés se correlaciona con la longevidad, ya que todos los nematodos 
mutantes que presentan una activación de DAF-16 también presentan resistencia a 
estrés oxidativo, choque térmico y radiaciones UV (62). En mamíferos se ha 
demostrado que ratones que son deficientes para los receptores de insulina o de IGF-
1 tienen una mayor esperanza de vida y son resistentes a estímulos desencadenados 
por estrés oxidativo (10, 64). Además, se sabe que las proteínas FOXO son capaces 
de inducir resistencia a estrés en células de mamíferos y algunos de los genes diana 
de FOXO involucrados en resistencia a estrés, como la MnSOD, están conservados 
entre mamíferos y nematodos, lo que sugiere que FOXO podría también regular la 
longevidad en mamíferos. 
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1.3.3 FOXO y cáncer 
Los efectos anti-proliferativos y pro-apoptóticos de las proteínas FOXO en 
mamíferos han sugerido que estas podrían funcionar como supresores tumorales. En 
ausencia de FOXO, las células anormales que normalmente morirían pueden llegar a 
sobrevivir, lo que puede contribuir a la formación de tumores  (Figura 6)  (50). 
 
 
 
Figura 6 – Las funciones de supresor tumoral de FOXO pueden bloquear el desarrollo 
de tumores en diversos estadios. La reducción de estrés oxidativo y reparación del 
DNA inducidas por FOXO previenen la inducción y propagación de mutaciones 
requeridas a la transformación oncogénica. Como la progresión entre estadios de 
tumorigenesis probablemente ocurre a través de mutaciones, los FOXO pueden ser 
supresores en diversos estadios. Un tumor puede formarse si el balance entre 
proliferación y apoptosis se altera hacia la proliferación. Las proteínas FOXO bloquean 
el ciclo celular e inducen la expresión de genes pro-apoptóticos, que pueden re-
balancear la homeostasis tisular. Finalmente, para que se pueda formar un tumor 
maligno, es necesario que ocurra angiogénesis. FOXO reprime la señalización de HIF, 
que es necesaria para la angiogénesis en los tumores. En suma, los FOXO funcionan 
como supresores tumorales al largo de todo el proceso de formación, expansión y 
diseminación del tumor  (Adaptado de (27)). 
 
Numerosas evidencias, por tanto, indican que los factores FOXO pueden tener un 
papel importante en cáncer. FOXO3A se encuentra desregulado en cáncer de mama. 
La localización citoplasmática de FOXO3A en células de cáncer de mama muestra una 
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importante correlación con la reducción de la supervivencia. Se ha observado también 
una correlación entre la expresión de IKKβ y la localización citoplasmática de FOXO 
en esos tumores (27). 
Las proteínas FOXO interaccionan física o funcionalmente con supresores tumorales 
y oncogenes. En respuesta a estrés o deprivación de nutrientes se ha visto que FOXO 
interacciona en el núcleo con el supresor tumoral p53 (16, 112). Esta observación 
junto con el hecho de que p53 y FOXO comparten genes dianas similares (p21, 
GADD45, WIP1, PA26), sugiere que esas dos proteínas pueden coordinar la supresión 
tumoral. Además, las proteínas FOXO forman complejos con los factores de 
transcripción SMAD (137), que funcionan como supresores tumorales mediando el 
efecto citoestático de TGF-β. La interacción entre FOXO y SMAD ocurre en el 
promotor de p21 como respuesta a la estimulación por TGF-β. El complejo 
FOXO/SMAD provocaría la sobre-expresión de p21 y la consecuente parada de ciclo 
celular (50). Finalmente, se ha demostrado que el proto-oncogen β-catenina se une a 
proteínas FOXO (39) aumentando su capacidad para forzar la progresión en el ciclo 
celular. Una vez que la β-catenina ha sido implicada en la progresión del cáncer, en 
particular en cáncer de colon, es posible que los factores FOXO puedan contrarrestar 
la progresión de los tumores inhibiendo a la β-catenina (50).  
La expresión de mutantes activos de FOXO reduce la tumorigenesis en varios 
modelos. La proliferación celular y tumorigenicidad inducidas por IKKβ puede ser 
inhibida en ratones por la expresión de una forma activa de FOXO3A (66). Se ha 
demostrado en Drosophila que FOXO afecta a la traducción proteica de MYC, 
interfiriendo con la biogénesis de los ribosomas (144). Otros autores han demostrado 
que la expresión de mutantes de FOXO no fosforilables por Akt previne la inactivación 
de FOXO e induce apoptosis eficientemente en células de melanoma (48). 
 
1.3.3.1 Los factores de transcripción FOXO son “bona fide” supresores 
tumorales.  
En modelos de ratones genéticamente modificados, la eliminación simultanea de 
FoxO1, FoxO3a y FoxO4, produce la formación espontánea de tumores, 
principalmente linfomas tímicos linfoblásticos, diseminados por el bazo, hígado y 
nódulos linfáticos. La eliminación de 2 de ellos no produce un fenotipo tan evidente, 
sugiriendo una fuerte redundancia de los 3 factores FOXO (118). 
El triple knockout también presenta un crecimiento aberrante y diseminado de la 
vasculatura, confirmando que FOXO tiene un papel fundamental en la homeostasis de 
la vasculatura (118). Todos los ratones desarrollan un fenotipo harmatomatoso 
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progresivo con la edad en el tejido endotelial, con amplia diseminación de 
hemangiomas, resultando en muerte prematura. En un número relativo de animales la 
condición progresa a angiosarcomas letales. 
Los timócitos de los triple knockout presentan una respuesta aumentada a estímulos 
de crecimiento y concordantemente una disminución de la muerte inducida por 
estímulos pró-apoptóticos. 
 
1.3.4 La reactivación de FOXO como estrategia terapéutica. 
Debido a la gran cantidad de evidencias de que los factores de transcripción FOXO 
son inactivados en los tumores humanos, se ha propuesto que la re-activación de 
FOXO puede ser una estrategia prometedora en la terapia contra el cáncer. 
A diferencia de otros supresores tumorales cuyas funciones se pierden a través de 
mutaciones, la perdida de las funciones de FOXO ocurre sobre todo por alteraciones 
post-traducionales inducidas por dianas moleculares implicadas en crecimiento y 
supervivencia. De este modo, a pesar de que las proteínas FOXO están inactivadas en 
tumores, el gen y por tanto la proteína se encuentran todavía presentes y son 
fácilmente re-activables. Por tanto, puede que las terapias que buscan a la 
reactivación de FOXO sean efectivas (27). Además, se ha demostrado que la 
reactivación indirecta de FOXO es beneficiosa para el tratamiento del cáncer. Se ha 
descrito que FOXO3A es una indiana indirecta de taxol y del pan-inhibidor de kinasas 
KP372-1 (140, 141) en células de cáncer de mama y de leucemia mieloide aguda 
(166) respectivamente, y ambos  activan a  FOXO3A a través de la reducción de la 
actividad de Akt. Taxol también activa a JNK, lo que tiene un efecto doble en la 
fosforilación de FOXO per se y en la inhibición de la unión de 14-3-3 a FOXO, evitando 
su exclusión del núcleo. 
FOXO3A también es importante en la apoptosis inducida por imatinib (Glivec) en 
líneas celulares de leucemia mieloide crónica que expresan la oncoproteína BCR-ABL 
(38). En las células que son positivas para BCR-ABL, FOXO3A está constitutivamente 
fosforilado y la inhibición de BCR-ABL causada por imatinib induce la actividad 
transcripcional de FOXO3A, lo que lleva a la apoptosis mediada por Bim (105). El 
bloqueo de los receptores de factores de crecimiento epidermales (EGFR) por 
anticuerpos (como trastuzumab o cetuximab) o moléculas pequeñas (como lapatinib y 
gefitinib) representa una valiosa estrategia terapéutica contra cánceres de mama, 
próstata, riñón, ovario y carcinomas pulmonares no microcíticos, y se han puesto en 
ensayos clínicos estos agentes individualmente o en combinaciones entre ellos (126). 
La cascada de señalización de PI3K es diana de la cascada de EGFR y el bloqueo 
de EGFR con anticuerpos induce la activación transcripcional de FOXO, llevando a la 
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activación del gen pro-apoptótico BNIP3L (124). FOXO es una diana crucial de 
pequeñas moléculas inhibidoras de EGFR, por tanto es posible que la re-introducción 
de FOXO3A activo sensibilice las células resistentes a agentes como gefitinib (105).  
La activación de FOXO3A puede también ser efectiva en combinación con otros 
agentes, para inhibir la resistencia o aumentar la muerte celular en el tumor. Se ha 
descrito una sobre-expresión de Bim inducida por FOXO3A como consecuencia de la 
exposición de de células de osteosarcoma mutantes para p53 a radiaciones ionizantes 
(161), lo que sugiere que FOXO3A es un importante efector de la apoptosis inducida 
por radiaciones. De este modo, puede que las quimioterapias que activan a FOXO3A 
también sensibilicen las células a radioterapia. 
La reactivación de FOXO también ha sido asociada a resistencia a la quimioterapia, 
a través de los mecanismos que permiten que FOXO proteja las células de estrés. Por 
tanto, es fundamental identificar y caracterizar todas las moléculas que tienen 
influencia sobre la activación de FOXO, así como las modificaciones post-
traducionales inducidas. El conocimiento completo de cómo programar el código 
FOXO permitirá el desarrollo de terapias más eficientes contra el cáncer, que 
aprovecharán las características supresoras de tumores de FOXO y al mismo tiempo 
evitarán el desarrollo de resistencia. 
 
1.4 Búsqueda de nuevos moduladores de FOXO. 
Tradicionalmente los estudios de perdida de función genética apenas podían ser 
llevados a cabo en sistemas biológicos simples, tales como S. cerevisae (58), C. 
elegans (101), y Drosophila (114). Se consideraba imposible la aplicación de este tipo 
de abordaje a mamíferos por su lenta tasa de reproducción, gran tamaño físico y 
genoma diploide (70, 138).  No obstante, algunos avances tecnológicos recientes han 
enriquecido los abordajes disponibles para la identificación de componentes de redes 
de señalización complejas en células humanas en cultivo. 
La interferencia de RNA (RNAi) es un mecanismo de silenciamiento de genes 
dependiente de la especificidad de las secuencias y que se induce por RNAs de doble 
cadena (dsRNA)  (22). Cada dsRNA silenciador es procesado en elementos de 21-25 
pares de bases (bp) designados “RNAs de interferencia pequeños” (siRNAs) (51, 52, 
164) por Dicer, una ribonucleasa de la familia III (RNAse III). Los siRNAs resultantes 
entran en el complejo RISC, que utiliza una versión de cadena simples del siRNA 
como guía para la selección de sustrato (52, 53, 151, 164). Una perfecta 
complementariedad entre el sustrato y el siRNA lleva a la rotura del RNA diana  (22). 
siRNA puede resultar en el knockdown de uno o varios genes, propiciando un método 
rápido y conveniente para el análisis de la función génica (36). Las librerías de siRNA 
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se han desarrollado como un método útil para la identificación funcional de la inhibición 
de distintos miembros de cascadas de señalización (30, 96). 
La genética química (chemical genetics – CG) consiste en el estudio del producto de 
un gen en un contexto celular o en un organismo utilizando moléculas químicas de 
bajo peso molecular. En este abordaje se utilizan moléculas pequeñas que se unen 
directamente a proteínas para alterar su función, lo que permite un análisis cinético de 
la consecuencia de esos cambios in vivo. Avances recientes han aumentado 
considerablemente el poder de estas moléculas, de forma que estas se asemejen a 
mutaciones genéticas, en cuanto a su aplicabilidad y especificidad para una diana. La 
sofisticación creciente de este abordaje lanza la posibilidad de que pueda ser aplicado 
a cualquier proceso biológico (138). 
La adaptación de iRNA a células de mamíferos, junto con la expansión de la CG ha 
hecho posible los estudios sistemáticos de perdida de función capaces de revelar 
interacciones entre proteínas implicadas en muchas enfermedades humanas. No 
obstante, la falta de tecnología robusta, capaz de detectar los cambios producidos a 
consecuencia de las interferencias con un alto rendimiento constituía una laguna 
tecnológica que no permitía la implementación de rastreos por iRNA y CG a gran 
escala. 
Esa laguna ha sido rellenada con la implementación de la adquisición de imágenes 
utilizando microscopía de fluorescencia robotizada y análisis de imágenes 
automatizado, a la que normalmente se refiere como rastreo de alto contenido (High 
Content Screening – HCS). Esa tecnología se ha convertido en una herramienta 
esencial en fases iniciales de programas de desarrollo de nuevos fármacos (56, 87, 
165). La obtención de imágenes con alto contenido (de información) ha podido dar 
respuesta progresivamente a los retos crecientes que suponen la implementación  de 
ensayos a larga escala y facilita la integración de rastreos dirigidos al tratamiento de  
enfermedades en estadios iniciales del desarrollo de fármacos. 
El uso combinado de iRNA, CM y HCS simultáneamente constituye una metodología 
poderosa que nos ha permitido realizar estudios imparciales independientes de 
nociones pré-existentes a cerca de la red de señalización implicada en la regulación 
de FOXO. La identificación y caracterización de nuevas moléculas implicadas en la 
regulación de FOXO puede aportar información a cerca de cómo re-activar FOXO, con 
el objetivo de mejorar el tratamiento del cáncer. 
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Given the importance of FOXO in many fundamental processes and its relevance in 
cancer, the aims of this work are: 
 
1. Generation, validation and characterization of cellular systems suitable to perform 
large scale screenings to identify molecules implicated in FOXO regulation: 
- Generation of an image-based cellular system suitable to measure FOXO 
nuclear translocation. 
- Generation of a luciferase-based assay to measure FOXO transcriptional 
activity. 
- Generation of a multiplex cellular system in which FOXO nuclear 
translocation and transcriptional activity can be measured in a single assay. 
- Generation of an image-based cellular system able to measure unspecific 
nuclear trapping via CRM-1. 
- Generation of an image-based cellular system to identify Akt-mediated 
survival. 
 
2. Realization of large-scale screenings to identify novel targets that can be exploited 
pharmacologically for the reactivation of FOXO: 
 - Realization of a Chemical Genetic screening. 
 - Realization of a large-scale loss-of-function RNAi screening. 
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3 Results 
 
 
 
Following the objectives that have been proposed in the scope of this thesis we 
developed five technological platforms that allowed us to perform a chemical genetics 
screening and a large-scale RNAi screening. Undescribed interactions with FOXO 
were identified and a further characterization was carried out. 
The following projects resulted in the publications that reflect the results obtained in 
each part of this work. 
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3.1 Development of technological platforms for the identification of new targets 
implicated in FOXO activity. 
 
3.1.1 First Project: The U2nesRELOC system 
Summary 
FOXO transcription factors are excluded from the cell nucleus in a 14-3-3 and 
CRM1/exportin-dependent fashion. Therefore, the need for a complementary screening 
system in which the inhibition of this nuclear export machinery could be detected was 
evident. Based on a GFP fusion protein that contains a NES which is not regulated by 
Akt, but that relies on 14-3-3 and CRM1/exportin for nuclear exclusion, the 
U2nesRELOC system was generated by transfecting U2-OS cells stably with a plasmid 
containing the HIV virus Rev protein fused with a GFP reporter. This assay was 
upscaled to a high throughput format and a high content analysis of compounds known 
to influence CRM-1 -dependent nuclear export showed that this system can be used for 
the detection of nuclear trapping induced by those compounds. Thus, this system is a 
valuable tool for the deconvolution of the hits obtained in FOXO-based systems as the 
unspecific nuclear sequestration of FOXO can be distinguished from real activation that 
triggers nuclear translocation and consequent transcriptional activity. The specificity of 
the U2nesRELOC system was tested comparing the behavior of hose cells with U2-OS 
cells stably transfected with a FOXO-GFP fusion protein, generating the U2foxRELOC 
system. The U2foxRELOC cells were shown to accurately respond to PI3K/Akt 
inhibition, as seen by the shift in the localization of the fusion protein upon treatment 
with LY294002. Importantly, treatment with nuclear export inhibitor leptomycin B 
induced nuclear trapping of the reporter in both systems, while LY294002 only 
triggered nuclear accumulation of the reporter in the U2foxRELOC cells. Thus, the 
combined use of the U2nesRELOC with the U2foxRELOC system allows for the 
distinction between PI3K/Akt inhibitors and nuclear export inhibitors. Furthermore, the 
U2nesRELOC assay has also been shown to be suitable as a primary screening 
system for the identification of novel, nuclear export inhibitors which have been 
suggested to have therapeutic potential for several human diseases, including cancer. 
Therefore, the U2nesRELOC system represents a versatile technology platform well 
suited for primary high throughput screening and as a counter-screening system for 
deconvolution procedures. 
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Personal Contribution 
I generated the cell-based system and performed the experiments required for its 
validation and adaptation to the high-throughput format. Once established, I performed 
the experiments carried with the compounds mentioned with the assistance of 
Aránzazu Rosado and helped in the data analysis and interpretation. 
 
Publication: 
Zanella F, Rosado A, Blanco F, Henderson BR, Carnero A, and Link W, A HTS 
approach to screen for antagonists of the nuclear export machinery using high 
content cell based assays. ASSAY and Drug Development Technologies. 2007 Jun; 
5(3): 333-41.  
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An HTS Approach to Screen for Antagonists of the Nuclear
Export Machinery Using High Content Cell-Based Assays
Fabian Zanella,1 Aranzazú Rosado,1 Fernando Blanco,1 Beric R. Henderson,2
Amancio Carnero,1 and Wolfgang Link1
Abstract: Intracellular localization is essential for the regulated activity of many signaling molecules
associated with disease-relevant pathways. High content screening is a powerful technology to
monitor the impact of small molecules or interfering RNAs on translocation of proteins within intact
cells. Several assays have been developed to measure the nucleocytoplasmic shuttling of proteins like
nuclear factor B, FoxO, or nuclear factor of activated T-cells involved in distinct signaling
networks. However, since all these proteins bear a leucine-rich nuclear export signal (NES),
modulators of the NES-dependent export machinery can lead to misinterpretation of the assay
readout. Here we report the generation of U2nesRELOC, a cell-based system for the identification of
nuclear export inhibitors and specific silencers of the nuclear export machinery, and its adaptation to
high throughput screening. The assay is based on mammalian cells stably expressing green
fluorescent protein (GFP)-labeled Rev protein, which contains a strong heterologous NES. The
fluorescent signal of untreated U2nesRELOC cells localizes exclusively to the cytoplasm. Upon
treatment with the nuclear export inhibitor leptomycin B the GFP-labeled reporter protein
accumulates rapidly in the cell nucleus. The assay has been adapted to 96-multiwell format and fully
automated. Pilot experiments with a panel of 50 test compounds using three different concentrations
per compound resulted in very consistent data sets with excellent reproducibility and an average Z
value of 0.76. In summary, U2nesRELOC is a cell-based nuclear export assay suitable for high
throughput screening, providing counterscreens for pathway deconvolution.
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Introduction
IMAGE ACQUISITION using robotic fluorescent mi-croscopy and automated image analysis, generally re-
ferred to as HCS, has become an essential tool in early
drug discovery programs. High content cellular imaging
has increasingly met the challenges of high throughput
needs and facilitates the integration of disease-relevant
screens at early stages of the drug discovery process.1,2
This effort aims to produce high-quality leads and de-
crease the current drug attrition rate by means of large-
scale analysis of biologically relevant cellular events.
Aberrant localization of proteins is known to be associ-
ated with many diseases, including cancer, inflammation,
and cardiovascular diseases.3–5 Consequently, monitor-
ing the subcellular localization of proteins can yield im-
portant information about the impact of compounds on
disease-relevant pathways in a cellular context. Several
high content translocation assays using genetically tagged
proteins or fluorescent-labeled antibodies to detect pro-
teins that shuttle between cell nucleus and the cytoplasm
have been published. Reporter proteins including nuclear
1Experimental Therapeutics Program, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain.
2Westmead Millennium Institute, University of Sydney at Westmead Hospital, Sydney, NSW, Australia.
ABBREVIATIONS: DAPI, 4,6-diamidino-2-phenylindole; DMSO, dimethyl sulfoxide; EGFP, enhanced green fluorescent protein; FACS,
fluorescence-activated cell sorting; GFP, green fluorescent protein; IC50, 50% inhibitory concentration; MAPK, mitogen-activated protein kinase;
MAPKK (or MEK), mitogen-activated protein kinase kinase; NES, nuclear export signal; NF-B, nuclear factor B; PBS, phosphate-buffered
saline; PI3K, phosphoinositide 3-kinase.
factor B (NF-B), FoxO, mitogen-activated protein ki-
nase (MAPK)-activated protein kinase 2, and ERF1 were
used to monitor the activity of the corresponding signal-
ing pathways.6–9 These proteins contain a leucine-rich
nuclear export signal (NES) known to bind to the nuclear
exportin receptor CRM-1, which mediates nucleocyto-
plasmic translocation through the nuclear pore.10,11
CRM1 has a conserved Ran binding domain, and it binds
Ran-GTP in the nucleus together with the NES cargo to
form a tripartite complex.12 Several compounds have
been described that specifically inhibit CRM1-mediated
nuclear export. The best-studied nuclear export inhibitor
is leptomycin B, a fungal metabolite that binds covalently
to a cysteine residue in the active center of CRM-1, pre-
venting the efflux of NES-containing proteins.13 Conse-
quently, compounds that interfere with the general export
machinery and in turn accumulate NES-containing pro-
teins in the cell nucleus are likely to score in translocation
assays for pathway analysis using NES-reporter proteins.
In order to deselect hit wells treated with pathway-unre-
lated nuclear export inhibitors several counterscreens
have been developed.6,9 The basic strategy is to monitor
a different NES-containing reporter protein whose cellu-
lar localization is regulated by a pathway-independent
signaling pathway. In the present work we established an
NES-dependent nuclear export assay in HTS format. As-
say robustness and reproducibility are reflected in excel-
lent Z-factor values. Specificity of the system has been
confirmed using test compounds with known mechanism
of action.
Materials and Methods
Compounds and recombinant proteins
All chemicals were purchased from commercial sources
except UCN01, which was kindly provided by the National
Cancer Institute (Bethesda, MD), cisplatin, which was pro-
vided by C. Navarro (U.A.M., Madrid, Spain), minerval,
which was generously provided by P. Escriba (University
of the Balearic Islands, Palma de Mallorca, Spain), and
gemcitabine, which was a gift from Eli Lilly Pharmaceu-
ticals (Indianapolis, IN). Akt inhibitor, Akt inhibitor VIII,
Akt inhibitor X, Bay11-7082, cisplatin, ionomycin,
LY294002, NL71-101, PD98059, PP1, Raf1 kinase in-
hibitor, ratjadone A, SB203580, W-13 HCl, W-7 HCl, and
wortmannin were purchased from Calbiochem (San Diego,
CA). Brefeldin, cyclosporin A, forskolin, genistein, H-89,
leptomycin B, rapamycin, roscovitine, thapsigargin, tyr-
phostatin AG 1478, tyrphostatin SU1498, and U0126 were
purchased from LC Laboratories (Woburn, MA). D609,
LY83583, manumycin A, pifithrin- cyclic, rifampicin,
tyrphostin AG 82, and tyrphostin AG 1433 were purchased
from Alexis Biochemicals (San Diego). Caffeine, calmi-
dazolium chloride, etoposide, staurosporine, and 12-O-
tetradecanoylphorbol 13-acetate were purchased from
Sigma-Aldrich (St. Louis, MO). Lithium chloride was pur-
chased from Merck (Darmstadt, Germany). D000 was pur-
chased from Labotest (Niederschoena, Germany). Epider-
mal growth factor and platelet-derived growth factor were
purchased from RELIATech A.S. (Braunschweig, Ger-
many). Human insulin-like growth factor-I and human in-
sulin were purchased from Roche Diagnostics (Mannheim,
Germany). Stock solutions of the test compounds were de-
posited in three different concentrations onto 96-well
mother plates, transferred to multiple replicate plates, and
frozen at 80°C.
Plasmids
The U2nesRELOC assay uses the reporter construct
pRevMAPKKnesGFP, which has been described earlier.14
pRevMAPKKnesGFP carries the NES from MAPK kinase
(MAPKK) (or MEK) cloned between the BamHI and AgeI
sites of pRev(1.4)-GFP, sandwiched between the Rev and
the green fluorescent protein (GFP) coding sequences.14
The GFP-Foxo3a fusion protein was kindly provided by T.
Finkel (National Institutes of Health, Bethesda, MD).
Cell culture and stable transfections
The human osteosarcoma cell line U2OS was obtained
from the American Type Culture Collection (Manassas,
VA) and cultured in Dulbecco’s modified Eagle’s
medium, supplemented with 10% fetal bovine serum
(Sigma) and antibiotics-antimycotics. Cell cultures were
maintained in a humified incubator at 37°C with 5% CO2
and passaged when confluent using trypsin/EDTA.
Transfection of plasmids was performed using jetPEI™
transfection reagent (Polyplus Transfection, Ilkirch,
France) according to the manufacturer’s instructions.
Forty-eight hours after transfection, cells were selected
with 800 l/ml G418 for 10 days. Stable transfectants
were fluorescence-activated cell sorting (FACS)-sorted
to ensure that they expressed similar levels of fluores-
cent reporter protein. Clonal U2OS cells expressing 
pRevMAPKKnesGFP reporter protein and U2OS cells ex-
pressing GFP-Foxo3a reporter protein were seeded in six-
well plates and incubated at 37°C with 5% CO2 for 12
h. Then, cells were treated with 4 nM leptomycin B or
20 M LY294002 for 1 h and photographed with a flu-
orescent microscope.
U2nesRELOC assay
Cells of the clonal U2OS cell line expressing 
pRevMAPKKnesGFP reporter protein (U2nesRELOC cells)
were seeded at a density of 1.0  105 cells/ml into black-
wall clear-bottom 96-well microplates (BD Biosciences,
Franklin Lakes, NJ) using a Multidrop automatic dis-
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penser (Titertek, Huntsville, AL). The final volume of
the cell suspension was 200 l in each well. After incu-
bation at 37°C with 5% CO2 for 12 h, 2 l of each test
compound was transferred from the mother plates to the
assay plates using a robotic workstation (Biomek® FX,
Beckman Coulter, Fullerton, CA). Cells were incubated
in the presence of the compounds for 1 h. All additional
pipetting steps were performed by the robotic worksta-
tion. The culture medium was removed by aspiration, and
then the plates were washed with 1 phosphate-buffered
saline (PBS) twice and fixed in 100 l of 6% parafor-
maldehyde for 30 min at room temperature. After aspi-
ration of the paraformaldehyde, fixed cells were washed
twice with 1 PBS and, in order visualize the cell 
nucleus, stained with 4,6-diamidino-2-phenylindole
(DAPI) (Invitrogen, Carlsbad, CA) for 20 min at room
temperature. The DAPI solution was removed by aspira-
tion. Finally the plates were washed with 1 PBS twice
and stored at 4°C before analysis.
Image acquisition and processing
Assay plates were read on the BD Biosciences Path-
way™ 855 Bioimager equipped with a 488/10 nm en-
hanced GFP (EGFP) excitation filter, a 380/10 nm DAPI
excitation filter, a 515LP nm EGFP emission filter, and
a 435LP nm DAPI emission filter. Images were acquired
in the DAPI and GFP channels of each well using a 10
dry objective. The plates were exposed 0.066 ms (Gain
31) to acquire DAPI images and 0.55 ms (Gain 30) for
GFP images.
Data analysis
The BD Pathway Bioimager outputs its data in stan-
dard text files. Data were imported into the data analy-
sis software BD Image Data Explorer. The nuclear/cyto-
plasmic ratios of fluorescence intensity were determined
by dividing the fluorescence intensity of the nucleus by
the cytoplasmic fluorescence intensity. A threshold ratio
of greater than 1.8 was employed to define nuclear ac-
cumulation of fluorescent signal for each cell. Based on
this procedure we calculated the percentage of cells per
well displaying nuclear translocation or inhibition of nu-
clear export. Compounds that induced a nuclear accu-
mulation of the fluorescent signal greater than 60% of
that obtained from wells treated with 4 nM leptomycin B
were considered as hits.
In order to estimate the quality of the HCS assay, the
Z factor was calculated by the equation: Z  1  [(3 
standard deviation of positive controls)  (3  standard
deviation of negative controls)/(mean of positive con-
trols)  (mean of negative controls)] as previously de-
scribed by Zhang et al.15
Results
Generation of the U2nesRELOC reporter cells
In order to generate a system suitable to monitor CRM-
1-dependent nuclear export in a HTS format we used a
reporter protein previously described as extremely active
in an in vivo nuclear transport assay. Henderson and
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FIG. 1. Different behavior of U2nesRELOC and U2foxRELOC assay cell lines. Cells stably expressing REVMAPKKnesGFP
(U2nesRELOC; A–C) or a FoxO-GFP fusion protein (U2foxRELOC; D–F) were seeded in six-well plates, incubated for 12 h,
and treated with DMSO (Control, A and D), 4 nM leptomycin B (B and E), or 20 M LY294002 (C and F) for 1 h and pho-
tographed using a fluorescence microscope.
Eleftheriou14 restored nuclear export activity in an ex-
port-defective mutant of a human immunodeficiency
virus type-1 Rev-GFP fusion protein by inserting several
different heterologous NES sequences between Rev 
and the GFP coding sequence. The strongest export 
signals were mediated by the NES from MAPKK or 
protein kinase inhibitor-. We stably transfected a GFP
reporter plasmid that carries the NES from MAPKK
(RevMAPKKnesGFP) into U2OS cells and prepared cell
clones. In order to obtain the homogeneously GFP-
expressing assay cell line U2nesRELOC, we performed
several rounds of FACS. As a proof of principle we
treated U2nesRELOC cells and cells stably expressing a
FoxO-GFP fusion protein (U2foxRELOC) with one of
the two pathway reference compounds, leptomycin B or
LY294002. Leptomycin B is an inhibitor of the CMR-1-
dependent nuclear export that covalently binds to a sin-
gle cysteine residue of the CRM1 protein.16 LY294002
is a broad-spectrum phosphoinositide 3-kinase (PI3K) in-
hibitor widely used to suppress activation of PI3K/Akt
signaling.17 In unstimulated U2nesREOC cells, GFP fu-
sion protein was exclusively cytoplasmic. FoxO-GFP
was present in both cytoplasm and nucleus, with a sig-
nificantly higher level in the cytoplasm than in the nu-
cleus of unstimulated U2foxRELOC cells. Leptomycin
B inhibited the nuclear export of RevMAPKKnesGFP and
FoxO-GFP, leading to localization of the fluorescent sig-
nal in the cell nucleus of both cell lines. In contrast,
LY294002 only induced nuclear translocation of FoxO-GFP
(Fig. 1). PI3K inhibition had no effect on RevMAPKKnes
GFP localization, indicating the capacity of U2nesRELOC
to deconvolute signaling pathways. Drug washout ex-
periments, replacing the drug solution with fresh
medium, showed that the nuclear accumulation of
REVMAPKKnesGFP upon leptomycin B treatment was re-
versible. Removal of the drug restored the cytoplasmic
localization of the fluorescent reporter protein almost
completely 24 h after washout (data not shown).
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FIG. 2. The automated workflow for the U2nesRELOC assay allows standardization of the process. Cells were seeded auto-
matically and incubated overnight. The test compounds were transferred from mother plates to assay plates using a robotic work-
station. After a 1-h incubation at 37°C in medium containing the compounds cells were washed, fixed, and stained in a fully au-
tomated manner using a robotic workstation. For automated microscopy we used the BD Biosciences Pathway HT cell imaging
platform.
Up-scaling and automation
The U2nesRELOC-based assay was formatted in 96-
well plates, and workflow has been automated (Fig. 2).
Cells were seeded at a density of 20,000 cells per well
using a Multidrop dispenser. All liquid handling for com-
pound treatment, washing, fixing, and staining steps was
performed by a robotic workstation. The BD Pathway HT
cell imaging platform was used for automated image ac-
quisition. Cells were stained with DAPI to facilitate aut-
ofocus of the microscope and to aid the image segmen-
tation. An image algorithm was applied to allow the cell
nucleus segmentation based on a local thresholding. Our
segmentation strategy assumes that the cell’s cytoplasm
surrounds the nucleus. Consequently, cytoplasmic fluo-
rescence intensity is calculated from all the pixels within
a circumferential ring surrounding the nuclear ring mask.
The width of the ring was defined to be small enough to
avoid ambiguities due to irregular cell shape. Based on
the definition of cell compartments, the nuclear and cy-
toplasmic levels of GFP fluorescence were quantified.
The nuclear/cytoplasmic ratios of fluorescence intensity
were determined by dividing the fluorescence intensity
of the nucleus by that of the cytoplasm. A threshold ra-
tio of greater than 1.8 was employed to define nuclear
accumulation of fluorescent signal for each cell. Based
on this procedure we calculated the percentage of cells
per well displaying nuclear translocation or inhibition of
nuclear export.
Kinetics of leptomycin B-induced nuclear GFP
accumulation in U2nesRELOC cells
In order to define the optimal time period of compound
treatment for the U2nesRELOC-based end-point assay,
we investigated the kinetics of leptomycin B-induced nu-
clear GFP accumulation using the above-described auto-
mated procedure. We performed leptomycin B treatment
at 4 nM, a concentration widely used to study nuclear ex-
port. Nuclear accumulation of REVMAPKKnesGFP re-
porter protein in U2nesRELOC cells was detectable as
early as 10 min after blocking nuclear export by lepto-
mycin B treatment and further increased during a period
of 1 h (Fig. 3).
Leptomycin B dose–response analysis using
U2nesRELOC cells
We next determined the 50% inhibitory concentration
(IC50) value of the reference compound leptomycin B in
the U2nesRELOC assay. Cells were cultured as indicated
in Materials and Methods and treated with different 
doses of leptomycin B for 1 h. Figure 4 shows that 
U2nesRELOC is very sensitive in detecting the presence
of leptomycin B at concentrations as low as 50 pM. The
IC50 value was calculated as being the inhibitor concen-
tration that increases nuclear accumulation of the reporter
protein by 50%. The IC50 of leptomycin B was 0.91 nM
in the U2nesRELOC assay. IC50 values for leptomycin
B-mediated inhibition of nuclear export in the low
nanomolar range have been reported in several earlier re-
ports for other cell types.18,19
Screening a panel of test compounds using the
U2nesRELOC-based assay
To assess specificity of the assay we screened a panel
of commercially available compounds of known mech-
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FIG. 3. Kinetics of leptomycin B-induced nuclear GFP ac-
cumulation using the U2nesRELOC assay system in HTS for-
mat. Cells were seeded automatically at appropriate density in
96-well (200 l per well) black-wall clear-bottom tissue cul-
ture plates and allowed to attach overnight. Cells were then
treated with 4 nM leptomycin B. All liquid handling for com-
pound treatment, washing, fixing, and staining steps was per-
formed by a robotic workstation. Nuclear accumulation of GFP
reporter was assessed after 2 min, 5 min, 10 min, 15 min, 20
min, 25 min, 30 min, and 60 min. Data shown here represent
three independent experiments.
FIG. 4. Dose–response of the leptomycin B inhibition of nu-
clear export measured using the U2nesRELOC assay system in
HTS format. Cells were seeded automatically at appropriate
density in 96-well (200 l per well) black-wall clear-bottom
tissue culture plates and allowed to attach overnight. Cells were
then treated with different concentrations of leptomycin B for
1 h. All liquid handling for compound treatment, washing, fix-
ing, and staining steps was performed by a robotic workstation.
Graphs represent the growth of the cells relative to cells treated
only with carrier. Each curve is the average of two independent
experiments performed in triplicate samples.
anism of action (Table 1), using the U2nesRELOC cell
system. The panel of compounds consisted of inhibitors
of different kinases, including PI3K, Akt, MAPK,
MAPKK, Raf1, MEK-1, MEK-2, mammalian target of
rapamycin, Src, protein kinase A, protein kinase C,
platelet-derived growth factor -receptor kinase, inhib-
itors of phospholipase C, guanylate cyclase, Ras farne-
syltransferase, RNA polymerase, p34cdc2, p53, NF-B,
Flk-1, epidermal growth factor, calcineurin, activators
of adenylate cyclase, intracellular calcium release,
Zanella et al.338
TABLE 1. PANEL OF COMPOUNDS OF KNOWN MECHANISM OF ACTION TESTED IN THE U2NESRELOC CELL SYSTEM
Concentration
Compound Source Low Medium High Description
Akt inhibitor Calbiochem 1 M 10 M 30 M Akt inhibitor
Akt inhibitor VIII Calbiochem 50 nM 500 nM 5 M Akt inhibitor
Akt inhibitor X Calbiochem 50 nM 500 nM 5 M Akt inhibitor
Bay11-7082 Calbiochem 1 M 10 M 30 M NF-B inhibitor
Brefeldin LC Laboratories 200 nM 1 M 20 M Membrane transport blocker
Caffeine Sigma 500 nM 4 nM 10 nM (Cyclic AMP) phosphodiesterase inhibitor
Calmidazolium chloride Sigma 1 M 10 M 30 M Inhibitor of calmodulin-regulated enzymes
Cisplatin C. Navarro 3 M 30 M 300 M DNA-damaging antitumor compound
Cyclosporin A LC Laboratories 40 nM 400 nM 4 M Calcineurin inhibitor
D000 Labotest/ICOS 100 nM 500 nM 2 M PI3K inhibitor
D609 Alexis 1 M 10 M 30 M Phospholipase C inhibitor
EGF ReliaTech 0.5 ng/ml 5 ng/ml 25 ng/ml Growth factor
Etoposide Sigma 100 nM 10 M 100 M Topoisomerase II inhibitor
Forskolin LC Laboratories 200 nM 1 M 20 M Activator of adenylate cyclase
Gencitabine Eli Lilly 100 nM 500 nM 1 M Nucleoside analogue with antitumor activity
Genistein Sigma 200 nM 20 M 50 M Protein tyrosine kinase inhibitor
H-89 LC Laboratories 50 nM 500 nM 5 M Inhibitor of protein kinase A
IGF-I, human Roche 1 ng/ml 20 ng/ml 50 ng/ml Growth factor
Insulin, human Roche 0.5 g/ml 2 g/ml 10 g/ml Growth factor
Ionomycin Calbiochem 5 nM 50 nM 200 nM Inducer of calcium influx
Kenpaullone Calbiochem 100 nM 500 nM 20 M Protein kinase inhibitor
Leptomycin B LC Laboratories 0.5 nM 1 nM 4 nM Inhibitor of nuclear export
LY294002 Calbiochem 1 M 20 M 50 M PI3K inhibitor
LY83583 Alexis 1 M 10 M 20 M Guanylate cyclase inhibitor
Manumycin A Alexis 500 nM 5 M 25 M Ras farnesyltransferase inhibitor
Minerval P. Escriba 25 M 100 M 200 M Modulator of membrane lipid structure
NL71-101 Calbiochem 200 nM 2 M 10 M Akt inhibitor
PD98059 Calbiochem 1 M 10 M 30 M Inhibitor of MEK
PDGF ReliaTech 0.2 ng/ml 1 ng/ml 10 ng/ml Growth factor
Pifithrin- cyclic Alexis 10 nM 200 nM 20 M p53 inhibitor
PP1 Calbiochem 10 nM 100 nM 10 M Src inhibitor
Raf1 kinase inhibitor Calbiochem 5 nM 20 nM 200 nM Raf1 kinase inhibitor
Rapamycin LC Laboratories 50 pM 0.5 nM 5 nM mTOR inhibitor
Ratjadone A Calbiochem 4 pM 4 nM 40 nM Inhibitor of nuclear export
Roscovitine LC Laboratories 200 nM 2 M 30 M Inhibitor of p34cdc2
Rifampicin Alexis 3 nM 300 nM 3 M RNA polymerase inhibitor
SB203580 Calbiochem 5 nM 40 nM 400 nM MAP kinase inhibitor
Sataurosporine Sigma 2 nM 20 nM 10 M Protein kinase inhibitor
Thapsigargin LC Laboratories 5 nM 20 nM 200 nM Intracellular calcium releaser
Tyrphostin AG 82 Alexis 1 M 10 M 20 M Protein tyrosine kinase inhibitor
Tyrphostin AG 1433 Alexis 1 M 10 M 20 M Inhibitor of the PDGF b-receptor kinase
Tyrphostatin AG 1478 LC Laboratories 5 nM 20 nM 200 nM Inhibitor of the EGF-receptor kinase
Tyrphostatin SU1498 LC Laboratories 700 nM 10 M 30 M Inhibitor of the VEGF-receptor kinase
Tetradecanoyl phorbol Sigma 10 nM 150 nM 10 M Activator of PKC
acetate
U0126 LC Laboratories 1 M 20 M 50 M MEK-1 and MEK-2
UCN01 NCI 200 nM 1 M 10 M
W-7 HCl Calbiochem 1 M 20 M 50 M Calmodulin antagonist
W-13 HCl Calbiochem 400 nM 4 M 40 M Calmodulin antagonist
Wortmannin Calbiochem 50 nM 150 nM 500 nM PI3K inhibitor
We exposed U2nesRELOC cells to three different concentrations (low, medium, and high) of test compounds. EGF, epider-
mal growth factor; IGF-I, insulin-like growth factor-I.
translocation of proteins from the endoplasmic reticu-
lum, etc. We also included the antifungal metabolite rat-
jadone A, a well-described, potent inhibitor of CRM1-
mediated nuclear export.20 A robotic workstation was
used to prepare mother plates containing three different
concentrations of these compounds. We exposed U2nes-
RELOC cells to equal volumes of test compounds re-
sulting in a range of final concentrations of greater than
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FIG. 5. Nuclear accumulation of REVMAPKKnesGFP reporter protein achieved upon treatment with test compounds. We exposed
U2nesRELOC cells to three different concentrations. Low, medium, and high concentrations are indicated by (1), (2), and (3),
respectively. Control wells containing phosphate-buffered saline (PBS), DMSO, ethanol, and leptomycin B are indicated by PBS,
DMSO, control, and LMB, respectively. TPA, 12-O-tetradecanoylphorbol 13-acetate. The bar graph and the corresponding left
y-axis show the percentage of cells in each well exhibiting nuclear/cytoplasmic ratios of fluorescence intensity greater than 1.8.
Black dots represent the average number of nuclear vertices in each well. The right y-axis indicates measurement of the average
number of nuclear vertices. Data shown here represent three independent experiments.
FIG. 6. Representative images of the compound-treated assay cell line using the high throughput format of the U2nesRELOC sys-
tem: (A) vehicle control (1% DMSO); (B) vehicle control (1% ethanol); (C) positive control (4 nM leptomycin B); (D) 1 M forskolin;
(E) 30 M Bay11-7082; (F) 40 nM SB203580; (G) 4 pM ratjadone A; (H) 4 nM ratjadone A; and (I) 40 nM ratjadone A.
two orders of magnitude around the IC50 value for each
compound. The final concentration of dimethyl sulfox-
ide (DMSO) was kept at 1% after addition of the com-
pounds. Each plate contained several internal controls,
including wells without treatment and wells treated with
different concentrations of DMSO or ethanol. As a ref-
erence compound we used leptomycin B at 4 nM in trip-
licate. To determine the cutoff threshold for primary
hits, the accumulation of fluorescent signal triggered by
leptomycin B in the U2nesRELOC-based assay was de-
fined as 100% activity. The primary hits were defined
as those samples that had an activity of greater than
60%. Ratjadone A at concentrations of 4 nM and 40 nM
fulfilled these criteria (Fig. 5). In contrast, treatment of
U2nesRELOC cells with 4 pM ratjadone A did not trig-
ger significant nuclear accumulation of the GFP reporter
protein. None of the other compounds tested scored as
hits, not even at the highest concentration more likely
to produce unspecific effects (Fig. 5 and data not
shown). These data indicate that nuclear accumulation
of the reporter protein REVMAPKKnesGFP is a very spe-
cific event and is suitable to monitor inhibition of the
general nuclear export machinery.
In addition, we used auxiliary algorithms to monitor
information related to cell viability. Analyzing the num-
ber of nuclear vertices we could not detect compound-
related toxicity probably because of the short incubation
period. Furthermore, visual inspection of images gener-
ated by the BD Pathway Bioimager was used to qualita-
tively confirm quantitative data from the data analysis
process (Fig. 6). The quality of the U2nesRELOC-based
assay has been assessed by calculating the Z values. The
U2nesRELOC-based assay has great performance with
an average Z higher than 0.76.
Discussion
Cell-based screens analyzing multiple intervention
points within signaling pathways to identify small mole-
cule inhibitors are increasingly gaining importance in
drug discovery. Nucleocytoplasmic translocation of GFP-
based reporter molecules has been used as a reliable read-
out of pathway activity. However, most of the reporter
proteins used in translocation assays have been found to
be subject to complex regulation, demanding the incor-
poration of a series of counterscreens to deconvolute the
effects of compound treatment.
In the present study we established U2nesRELOC, a
highly sensitive and selective cell-based assay for nucleo-
cytoplasmic shuttling suitable for HTS. The assay strategy
is based on a fluorescent reporter protein containing a het-
erologous NES that is efficiently exported from the nu-
cleus into the cytoplasm. The reporter protein used in our
screen was preselected with respect to the strength of the
export signal based on the systematic comparison of Rev-
type NES established by Henderson and Eleftheriou.14 In
fact, in untreated U2nesRELOC cells, the fluorescent sig-
nal is exclusively cytoplasmic. Conversely, in U2fox-
RELOC cells stably expressing a Foxo3a-GFP fusion 
protein that also carries a functional NES, subcellular lo-
calization of the fluorescent reporter was both cytoplasmic
and nuclear. Consistently, compounds that interfere with
the NES-mediated export lead to the nuclear accumulation
of fluorescent reporter proteins in both cell lines. In con-
trast, inhibition of PI3K/Akt signaling known to induce
nuclear translocation of Foxo transcription factors resulted
in accumulation of fluorescent signal in U2foxRELOC but
not in U2nesRELOC cells. These data demonstrate the util-
ity and potential of the U2nesRELOC system for pathway
deconvolution in a whole-cell environment.
We implemented U2nesRELOC as a fixed-cell assay
and automated the workflow using a Multidrop dispenser,
robotic workstation, and robotic cell imaging platform. We
assessed the properties of this HTS translocation assay us-
ing leptomycin B as a reference compound. Using the full
automated procedure, we monitored the kinetics of nuclear
accumulation of the fluorescent reporter protein, confirm-
ing earlier studies that revealed leptomycin B-mediated in-
hibition of nuclear export as a fast event.18,19 The fast ki-
netics of the assay allowed us to reduce the incubation time
necessary to attain unambiguous responses to compound
treatment, which is an important factor to minimize pos-
sible toxic effects interfering with data analysis procedures.
Dose–response studies underscored the sensitivity of the
U2nesRELOC system in HTS format, allowing the detec-
tion of leptomycin B at the picomolar level. Taken to-
gether, these data demonstrate that U2nesRELOC provides
a fast and sensitive method to monitor inhibition of nu-
clear export in a high throughput manner. However, the
usefulness of U2nesRELOC as a counterscreen for path-
way deconvolution depends greatly on its ability to pro-
vide a tool to deselect hit compounds from other translo-
cation screens that specifically inhibit nuclear export. We
assessed the specificity of U2nesRELOC using a panel of
test compounds of known mechanism of action aimed to
interfere with the major known signaling pathways. In or-
der to mimic characteristics of a real single-point concen-
tration screening scenario where biologically active con-
centrations can fluctuate widely, we performed the test
screening with three different concentrations for each com-
pound. The fact that only the reference compound lepto-
mycin B and the cytotoxic metabolite ratjadone A, known
as a potent nuclear export inhibitor,20 induced the nuclear
accumulation of REVMAPKKnesGFP reporter suggests that
the major known signaling pathways targeted by the panel
of test compounds do not significantly interfere with NES-
mediated nuclear export and demonstrates the ability of
the U2nesRELOC assay in high throughput format to iden-
tify specifically inhibitors of nuclear export. Since the
U2nesRELOC assay is performed in intact cells in the pres-
ence of serum, insoluble, membrane-impermeable, or un-
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stable compounds or compounds with strong serum bind-
ing affinities are excluded by default. The single-cell imag-
ing approach of the U2nesRELOC system provides the
possibility of automatically deselecting false-positives in
the primary screening using auxiliary algorithms like num-
ber of nuclear vertices relating to cellular morphology. In
addition, visual inspection of the hit wells allows the iden-
tification of fluorescent compounds and compounds 
with toxic effects. In summary, we have developed 
U2nesRELOC, a cell-based, high throughput, high content
assay suitable for primary screening of antagonists of nu-
clear export or counterscreening aimed at the deselection
of nuclear export inhibitors from pathway-specific high
content protein translocation assays. U2nesRELOC is fast,
robust, and reproducible, providing the intrinsic benefits
of image-based HCS and delivering excellent Z values.
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Results 
3.1.2 Second Project: The U2transLUC system 
 
Summary 
The activity of FOXO transcription factors is mainly regulated via post-translational 
modifications. Phosphorylation is the best characterized mode of regulation of FOXO 
and it influences both FOXO subcellular relocalization and transcriptional activity. 
FOXO transcriptional activity can be further influenced once FOXO proteins are 
localized in the cell nucleus. It has been reported that other post-translational 
modifications, namely monoubiquitylation and acetylation also contribute to change 
FOXO affinity to DNA and may direct FOXO-dependent transcription to different 
programs, suggesting that nuclear translocation constitutes a starting point for the 
modulation of FOXO activity. Hence, to fully understand the mechanisms underlying 
FOXO modulation it is fundamental to distinguish the stimuli that can induce different 
levels of regulation of nuclear FOXO. Classically, FOXO-GFP translocation has been 
applied in High Content Assays and FOXO-induced luciferase activity has been used in 
High Throughput Assays for the readout of either subcellular relocalization or 
transcriptional activity underlying FOXO activation separately. The combination of both 
assays constitutes an interesting approach for the further dissection of the impact a 
given stimuli can have upon FOXO. We developed U2transLUC, an assay system in 
which luciferase and fluorescent read-outs can be multiplexed to provide a powerful 
cell-based high content screening method. Nuclear-cytoplasmic FOXO shuttling and 
FOXO-driven transcription can be measured simultaneously for the analysis of these 
two key features of FOXO regulation in a single assay, increasing the amount of 
information obtained from each experiment.  The combination of different biological 
read-outs in a single cell line offers significant advantages over conventional cell-based 
assays. U2transLUC is suitable for high throughput screening and can identify small 
molecules that interfere with FOXO signaling at different levels. 
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Abstract 
Background: Independent luciferase reporter assays and fluorescent translocation 
assays have been successfully used in drug discovery for several molecular targets. We 
developed U2transLUC, an assay system in which luciferase and fluorescent read-outs 
can be multiplexed to provide a powerful cell-based high content screening method.  
 
Results: The U2transLUC system is based on a stable cell line expressing a GFP tagged 
FOXO transcription factor and a luciferase reporter gene under the control of human 
FOXO-responsive enhancers. The U2transLUC assay measures nuclear-cytoplasmic 
FOXO shuttling and FOXO-driven transcription, providing a means to analyze these 
two key features of FOXO regulation in the same experiment. We challenged the 
U2transLUC system with chemical probes with known biological activities and we were 
able to identify compounds with translocation and/or transactivation capacity. 
 
Conclusions: Combining different biological read-outs in a single cell line offers 
significant advantages over conventional cell-based assays. The U2transLUC assay 
facilitates the maintenance and monitoring of homogeneous FOXO transcription factor 
expression and allows the reporter gene activity measured to be normalized with respect 
to cell viability. U2transLUC is suitable for high throughput screening and can identify 
small molecules that interfere with FOXO signaling at different levels. 
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Background 
Forkhead box O (FOXO) proteins are emerging as transcriptional integrators of 
pathways that regulate a variety of cellular processes, including differentiation, 
metabolism, stress response, cell cycle and apoptosis (1-3). FOXO transcription factors 
have been proposed to act as bona fide tumor suppressors due to their inhibitory effects 
on cell cycle and survival (4), properties mediated by their binding as monomers to 
consensus DNA binding sites. Their transcriptional activity is governed by a network of 
signaling events, the best recognized of which is the phosphorylation of FOXO proteins 
at three highly conserved serine and threonine residues by Akt that provokes its 
association with 14-3-3 protein and in turn, the nuclear exclusion of phospho-FOXO. 
However, the relocation of FOXO from the nucleus to the cytoplasm alone cannot 
account for the inhibitory effect of PI3K/Akt signaling on FOXO activity since a 
nuclear form of FOXO1 in which the nuclear export sequence is disrupted is still 
inhibited by the PI3K/Akt pathway (5). Indeed, the introduction of a negative charge in 
the positively charged DNA binding domain by means of FOXO phosphorylation at the 
second of the three Akt consensus sites inhibits DNA binding of FOXO (6, 7). The 
FOXO DNA interaction is also regulated by the transfer of acetyl groups to lysine 
residues in FOXO proteins by the histone acetyltransferases (HATs) CBP and p300 (2), 
which alters the DNA binding capacity of FOXO1 and FOXO3a (8). Conversely, Sirt1 
deacetylases deacetylate FOXO factors and regulate their DNA binding at specific 
target genes. Taken together, these observations suggest that translocation and 
transactivation are different and separate means to regulate FOXO. However, large 
scale tools are not available to assess the different levels of FOXO regulation. Therefore 
systematic chemical genetic or loss of function studies to investigate the complex 
regulation of FOXO factors have been limited only to certain aspects (9).  
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In anticancer drug discovery, much effort is directed towards identifying small molecule 
inhibitors of PI3K/Akt signaling using cell based high content screening. In particular, 
monitoring the intracellular localization of FOXO transcription factors has been used to 
screen large numbers of small molecules (10, 11). Despite being commonly used as a 
reporter-gene system in drug discovery, luciferase-based transcriptional assays have not 
been applied to massive compound screens for PI3K/Akt inhibitors. Inhibiting the 
PI3K/Akt pathway causes FOXO3a to remain in the cell nucleus and subsequently, it 
induces the transcription of downstream genes. To take advantage of these regulatory 
features we generated the stable U2transLUC dual assay cell line that expresses FOXO 
responsive luciferase activity and GFP labelled FOXO. Thus, U2transLUC can be used 
to simultaneously monitor the intracellular translocation and the transcriptional activity 
of FOXO proteins. We have used this cell line in an attempt to identify small molecules 
that interfere with FOXO signaling. 
 
Results 
Generation and testing of luciferase reporter gene constructs 
FOXO proteins drive the transcription of downstream genes by binding to the 
TTGTTTAC FOXO responsive enhancer element, generally referred to as a daf-16 
family protein-binding element (DBE) (12). To take advantage of these regulatory 
features, we engineered several luciferase reporter constructs that contained one to six 
copies of the DBE consensus cassette in front of a SV40 minimal viral promoter that 
was linked to a luciferase reporter gene. The resulting reporter gene construct were 
designated as pGL-1xDBE, pGL-2xDBE, pGL-3xDBE, pGL-4xDBE, pGL-5xDBE and 
pGL-6xDBE (Fig.1A), and the luciferase activity driven by FOXO from these 
constructs was evaluated after they were transiently transfected into U2OS 
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osteosarcoma cells. Since endogenous FOXO3a is only weakly expressed in these cells, 
ectopic FOXO3a also had to be expressed to achieve acceptable basal levels of 
luciferase activity (data not shown). In transient co-transfection assays, all the luciferase 
reporter constructs that carried FOXO responsive DBE elements produced a significant 
increase in luciferase activity when compared to the empty pGL3-Promoter vector. 
Constructs that contained three or six copies of the DBE element conferred significantly 
stronger FOXO-dependent transcriptional activity than those with one, two, four or five 
copies (Fig. 1B). A reporter plasmid that carried three copies of a mutated DBE (pGL-
3xDBEmut) element did not promote significant luciferase activity, confirming the 
specificity of the original constructs for FOXO-mediated transcriptional activity.  
In order to evaluate the responsiveness of the reporter constructs to the inhibition of the 
PI3K/Akt pathway, we transiently co-transfected the pGL-3xDBE or pGL-6xDBE 
construct with FOXO3a into U2OS cells and then treated them with the PI3K inhibitor, 
LY294002 (20μM). Inhibition of the PI3K pathway increased FOXO-dependent 
transcription from both the pGL-3xDBE and pGL-6xDBE constructs approximately 3-
fold (Figure 1B). By contrast, activation of the PI3K/Akt signaling pathway following 
exposure to insulin decreased this luciferase activity. However, the differences between 
the transcriptional activity of FOXO3a in untreated and insulin treated U2OS cells were 
small, indicating that steady-state level of PI3K/Akt activity was already quite high. In 
addition, to confirm the specificity of our system we examined the effect of constitutive 
FOXO activation by co-expressing the pGL-3xDBE or pGL-6xDBE reporter construct 
with FOXO3a-A3, a constitutively active form of FOXO3a in which the three PI3K-
dependent phosphorylation sites have been mutated to alanine. The expression of 
FOXO3a-A3 induced a strong increase in pGL-3xDBE or pGL-6xDBE driven 
luciferase activity. Together, these data indicate that the firefly luciferase-based read-out 
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of FOXO activity is very specific, and that it provides a large window to measure any 
upregulation in the response (e.g. upon the inhibition of the PI3K/Akt pathway). Since 
the responsiveness of the triple tandem repeat of DBE (pGL-3xDBE) to PI3K inhibition 
was slightly higher than that of pGL-6xDBE, the p3xDBE-luc construct was used to 
generate the stable cell assay line, U2transLUC.  
 
Generation of the assay cell line, U2transLUC 
We recently reported the use of a high-throughput cellular imaging assay to monitor the 
nucleo-cytoplasmic translocation of a GFP-FOXO3a fusion protein in U2OS cells 
(U2foxRELOC) for a chemical genetic study (9). In order to generate an assay system 
that combines the benefits of large-scale image-based analysis and luciferase-based end 
point measurements, we examined the compatibility of transcriptional and 
translocational reporters expressed in a single cell line. We first explored whether the 
GFP-tagged FOXO protein is still capable of driving luciferase expression from FOXO 
responsive reporters. We compared the reporter activity of the pGL-3xDBE construct or 
the mutated version (pGL-3xDBEmut) co-expressed with either untagged FOXO3a wt 
protein or EGFP-tagged FOXO3a. Hence, we transiently transfected untagged FOXO3a 
and EGFP-FOXO3a into U2OS cells and measured the luciferase activities 4 hours after 
exposure to LY294002 or DMSO. The N-terminal EGFP tag did not significantly affect 
transcriptional function of FOXO3a in U2OS cells (Fig. 2) indicating the compatibility 
of luminescent and fluorescent read-outs in a single cell line. In addition, we compared 
the level of luciferase activity driven by the pGL-3xDBE construct in the context of 
stable EGFP-FOXO3a expression in U2foxRELOC cells (9) and with the transient co-
expression of the fluorescent fusion protein. The luciferase expression in the presence of 
stable EGFP-FOXO3a expression was only slightly lower than that in U2OS cells 
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transiently overexpressing EGFP-FOXO3a. To stably integrate the pGL-3xDBE 
construct into the genome of U2foxRELOC cells, we modified the pGL3-promoter 
construct by inserting a puromycin-resistance cassette to obtain pGLpuro-3xDBE. 
Puromycin-resistant stable clones were generated (U2transLUC) and one was chosen 
for further use based on FOXO-induced luciferase activity. 
 
The use of GFP fusion protein for normalization 
We examined whether the expression of the GFP fusion protein could be used to 
normalize the transcriptional reporter gene to the changes in cell viability. U2transLUC 
cells were seeded and allowed to attach to the wells overnight. Subsequently, they were 
incubated with increasing doses of sodium azide, a known inhibitor of the respiratory 
chain that provokes necrosis in many cell types (13, 14). Cell viability was estimated 
through a crystal violet assay or through the intensity of the fluorescence measured in 
each well. Both methods take advantage of the fact that when epithelial cells undergo 
apoptosis or necrosis, they detach from plates and are no longer detectable by these 
assays. After a 6 hour exposure to 0.05% sodium azide the viability of U2transLUC 
cells was slightly reduced with no significant differences between crystal violet or 
fluorescent intensity read-outs. Higher doses of sodium azide dramatically 
compromised U2transLUC viability, as reflected by both measures of viability. A 
normalization procedure using crystal violet staining or the GFP-FOXO mediated 
fluorescent signal resulted in similar indices of viability (Fig. 3), indicating that the 
fluorescent reporter protein can be used to monitor the viability of U2transLUC cells. 
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Multiplexed U2transLUC assay 
The U2transLUC-based assay was formatted for 96-well plates and the workflow has 
been automated. To assess the specificity of the transcriptional and the translocational 
read-out, we challenged the U2transLUC system with small molecule inhibitors under 
living cell conditions in order to observe the translocation of the fluorescent reporter 
protein and luciferase activity as the transcriptional end point. We exposed U2transLUC 
cells to a panel of test compounds with known biological activity. Three different doses 
were used that resulted in a range of final concentrations greater than two orders of 
magnitude around the IC50 value for each individual compound. The live cells were 
stained with the fluorescent nuclear dye DRAQ5 and images were obtained on an 
automatic microscope. The nuclear/cytoplasmic (Nuc/Cyt) fluorescence intensity ratios 
were determined and the percentage of cells per well displaying nuclear translocation or 
the inhibition of nuclear export was calculated. Compounds that induced the nuclear 
accumulation of the fluorescent signal above 60% of that obtained from wells treated 
with LY294002 were considered as hits. Several compounds known to inhibit PI3K 
activity or the nuclear export machinery fulfilled these criteria (Fig 4A). As expected 
from the results of a previous study in U2foxRELOC cells (9, 15), the PI3K inhibitors 
PI-103 and LY294002 were capable of inducing FOXO translocation into the nucleus of 
U2transLUC cells. By contrast, known activators of the PI3K/Akt pathway produced 
little nuclear localization of GFP-FOXO, including EGF, IGF and PDGF. The exposure 
of U2transLUC cells to the nuclear export inhibitors leptomycin B or ratjadone A 
provoked the nuclear accumulation of fluorescent signal, as shown previously for 
U2foxRELOC cells (9, 15). Conversely, through the measurement of the FOXO-
dependent production of firefly luciferase, leptomycin B and ratjadone A exerted no 
significant effect on the transcriptional activity of FOXO (Fig 4B). Finally, exposure to 
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PI-103 and LY294002 triggered a dramatic increase in FOXO-dependent luciferase 
activity. Together, these data show that the U2transLUC assay serves as an automated 
high throughput assay that can identify inhibitors of PI3K/Akt signaling through the 
high content analysis of protein translocation in conjunction with an independent 
analysis of the transcriptional activity of FOXO transcriptions factors.  
 
Discussion and conclusion 
FOXO transcription factors are tightly regulated at different levels, including their 
intracellular translocation and transcriptional activity (1, 3). Here we report the 
generation of a multiplexed assay system that is capable of simultaneously monitoring 
these signaling events. The assay system is based on U2transLUC cells that stably 
express two different reporter constructs. The intracellular translocation of FOXO 
factors is followed using a fluorescent tagged FOXO reporter protein, whereas 
transcriptional activity is monitored via FOXO-dependent luciferase production. We 
show here that the fluorescent and luminescent read-outs are compatible in the same 
cell.  
The design of the U2transLUC screen presented here offers some major advantages 
over more classical cellular assays. Primary and secondary screens of small molecule 
compounds are usually performed in different cell systems. By contrast, the 
U2transLUC provides the possibility of using two different read-outs within the same 
experiment, enabling a direct comparison of the hits from each of these. These hits 
might be divided into translocation, transactivation and dual hits, and they may in turn 
be analyzed according to a corresponding hit ranking. The U2transLUC assay does not 
need the introduction of additional plasmids and hence, it avoids the limitations 
associated with transfection procedures.  
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The use of the GFP-FOXO fusion protein provides a multifunctional tool that allows for 
versatile assay read outs, measurement of cell viability/number and sorting and 
maintaining a homogeneous cell assay population. We show that the fluorescent signal 
from the GFP-FOXO fusion protein is suitable to monitor viability and it can be used to 
normalize the values obtained by measuring firefly luciferase activity. Furthermore, the 
fluorescent FOXO functions as a reporter protein for FOXO translocation and as an 
effector protein that drives DBE-dependent luiferase production. On the other hand the 
GFP-FOXO fusion protein offers the possibility to control the level of expression of the 
transcriptional effector in the luciferase assay, and at the same time it serves as a sorting 
tool to maintain a homogenous cell population. Thus, the multifunctional use of GFP-
FOXO allows also to reduce the variability of the assay. The U2transLUC is an image 
based high throughput assay that enables compounds that produce artifacts and 
cytotoxicity to be identified on a single cell basis. Finally, the U2transLUC assay design 
might be adaptable to any transcription factor that undergoes nucleo-cytoplasmic 
shuttling. We challenged the U2transLUC system with chemical agents with known 
biological activity and were able to identify known PI3K inhibitors as double-hits that 
score in the translocation and the transactivation read-out. By contrast, chemical probes 
that inhibit the general nuclear export machinery failed to produce an increase in 
luciferase activity although GFP–FOXO was trapped in the cell nucleus.  
In summary, our data demonstrate that U2transLUC is a sensitive and robust assay to 
identify small-molecule inhibitors of signaling events that regulate the subcellular 
localization and/or the transcriptional activity of FOXO proteins. The signaling events 
identified here include PI3K/Akt signaling and nuclear export. Our data raise the 
expectation that a more extensive chemical interrogation of the U2transLUC read-outs 
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could lead to the identification of new molecular targets and small molecules that might 
contribute to the development of more potent therapeutic agents to treat tumors. 
 
Methods 
Compound supply and recombinant proteins 
All chemicals were purchased from commercial sources except for the PI3K inhibitor 
PI-103, which was synthesized following published patent specifications. Cisplatin was 
provided by C. Navarro, Minerval was generously provided by P. Escriba, and all other 
chemicals were purchased from commercial sources: LY294002, Ratjadone A, were 
purchased from Calbiochem (San Diego, CA); Forskolin, Leptomycin B and 
Rapamycin, were purchased from LC Laboratories (Woburn, MA, U.S .A.); DMSO was 
purchased from Sigma-Aldrich (St. Louis, USA); Epidermal growth factor (EGF), 
platelet-derived growth factor (PDGF) were purchased from RELIATech A.S. 
(Braunschweig, Germany); and human Insulin-Like Growth Factor-I (IGF-I) and human 
insulin were purchased from (Roche Diagnostics, Mannheim, Germany). Stock 
solutions of the test compounds were deposited in three different concentrations in 96-
well master plates, transferred to multiple replica plates and frozen at -80ºC. 
 
Plasmids 
The luciferase reporter constructs pGL-1xDBE, pGL-2xDBE, pGL-3xDBE, pGL-
4xDBE, pGL-5xDBE and pGL-6xDBE were generated by inserting one to six copies of 
the DBE consensus sequence (12) in front of a SV40 minimal viral promoter of the 
pGL3-Promoter vector (Promega). The annealed and phosphorylated oligonucleotides 
5´-CTAGAAGTAAACAA-3´ (1xDBE-forward) and 5´-GATCTT-GTTTAC-3´ 
(1xDBE-reverse) or 5´-CTAGAAGTAAACAACTATGTAAACAA-3´ (2xDBE-
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forward) and 5´-GATCTTGTTTACATAGTTGTTTACTT-3´ (2xDBE-reverse) were 
ligated as single copy or concatemerized into NheI and BglII digested pGL3 promoter 
vector. In order to generate the negative control plasmid pGL-3xDBEmut, three copies 
of a DBE sequence that contains a point mutation that prevents FOXO binding 
(annealed and phosphorylated oligonucleotides (3xmDBE-forward) 5´-CTAGAAGTA-
AGCAACTATGTAAG-CAACTATGTAAGCAA-3´ and (3xmDBE-reverse) 5´-GAT-
CTTGCTTACATAGTTGCTTACATAGTTGCT-TACATAG-3´) were inserted into 
pGL3-Promoter vector. The constitutively active construct FOXO3a-A3, in which three 
PI3K-dependent phosphorylation sites have been mutated to alanine was kindly 
provided by Dr. M. Hu (University of Texas M. D. Anderson Cancer Center, Houston). 
In order to generate stable cell lines for the assay, we inserted a puromycin-resistance 
cassette into the pGL-3xDBE construct. This was achieved by PCR amplifying the 
puromycin resistance gene from pBABEpuro vector and cloning it into the SalI and 
BamHI sites of the pGL3-Promoter vector derived pGL-3xDBE construct, thereby 
obtaining pGLpuro-3xDBE. 
Cell culture  
U2-OS cells obtained from the ATCC were cultivated in Dulbecco's modified Eagle's 
medium (DMEM), supplemented with 10% fetal bovine serum (FBS, Sigma), 
antibiotics and antimycotics in a humidified incubator at 37°C with 5% CO2. 
U2foxRELOC cells have been described previously (9). 
 
Transfection and Luciferase assays 
U2OS cells were cultured in a 96-well plate (100 μl final volume per well) and 
transfected at 70% confluence with the plasmids indicated using the effectene 
transfection reagent (Qiagen). LY294002 or insulin were added individually to wells 42 
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hours later, at a final concentration of 20 μM or 5mg/ml, respectively, and the cells were 
incubated for an additional 6 h. Luciferase assays were carried out using the Dual-
Luciferase Reporter Assay System (Promega), according the manufacturer's instructions 
on a multilabel plate reader (Wallac Victor, Perkin-Elmer), and the ratio of firefly- to 
Renilla-luciferase activities was calculated. All values were presented as means ± SEM. 
The unpaired t-test (two-tailed) was performed for statistical analysis using the 
GraphPad PRISM® Version 4.0 program. Differences with a p value < 0.05 were 
considered statistically significant. 
 
 
Generation and maintenance of U2transLUC cells 
U2foxRELOC cells were transfected at 75% confluence with pGLpuro-3xDBE using 
the effectene transfection reagent (Qiagen). Cells were selected with puromycin 
(Calbiochem) for five days and the resistant colonies that best expressed the reporter 
constructs were then recovered and cultured, as was the most homogeneous population. 
Fluorescence-activated cell sorting (FACS) of GFP-FOXO expressing cells was 
performed on a FACSAria (BD Biosciences, San Jose, CA, USA). U2transLUC cell 
clones were maintained in DMEM, supplemented with 10% FBS (Sigma), antibiotics 
and antimycotics, 0.1 mg/ml Neomycin and 1 µg/ml puromycin. Cell cultures were 
maintained in a humidified incubator at 37°C with 5% CO2, and they were passaged 
when confluent using trypsin/EDTA.  
 
Crystal violet assay 
Triplicate samples of 104 cells were seeded in 2.5 cm dishes and allowed to attach. After 
24 hours, the medium was removed and replaced with culture medium with sodium 
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azide at the concentrations indicated, while the controls remained untreated. After the 
appropriate time period the cells were fixed with 0.5% glutaraldehyde and stained with 
1% crystal violet. After extensive washing, crystal violet was resolubilized in 10% 
acetic acid and quantified at 595 nm as a relative measure of cell number. 
 
Viability assay measuring fluorescent intensity 
Samples of 104 cells per well were allowed to attach overnight in 96-well Greiner plates 
and the following day the culture medium was replaced with fresh medium containing 
the concentrations of sodium azide indicated. After a three hour treatment, the cells 
were washed with PBS and the fluorescent intensity was measured in a multilabel plate 
reader (Wallac Victor 2, Perkin-Elmer) using UV light as the excitation source, as well 
as a F485 CW lamp Filter and a F535 CW emission filter for 0.5 seconds per well. The 
values are the averages obtained from experiments carried out in triplicate. 
 
U2transLUC assay 
U2transLUC cells were seeded at a density of 1.0×105 cells/ml in black-wall clear-
bottom 96-well microplates (BD Biosciences) using a Titan Multidrop 384 automatic 
dispenser (Titertek Instruments, Inc., Huntsville, AL). The final volume of the cell 
suspension was 200 μl in each well. After incubation at 37°C in 5% CO2 for 12 hours, 
2μl of each test compound was transferred from the master plate to the assay plate. Cells 
were incubated in the presence of the compounds for 1 hour and the far-red fluorescent 
cell-permeable DNA probe, DRAQ5TM (Biostatus Ltd,Leicestershire, UK), was then 
added to all wells at a final concentration of 5 mM 15 minutes prior to obtaining the 
images. The images were acquired as described previously (16) using a BD Pathway™ 
855 Bioimager equipped with a incubation chamber that provided a constant 
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temperature of 37°C in 5% CO2. Images were acquired in the GFP and DRAQ5 
channels using 488/10 nm EGFP excitation filter, a 515LP nm EGFP emission filter and 
635/20 nm/695/55 nm DRAQ5 excitation/emission filter with a 10x dry objective. The 
plates were exposed for 0.066 ms (Gain 31) to acquire DAPI images and 0.55 ms (Gain 
30) for GFP images. Image and data analysis was performed as described previously 
(15). After image acquisition, the plates were incubated for another 5 hours at 37°C and 
then the average GFP intensity per well was measured as described above. Finally, 
U2transLUC cells were processed to measure the firefly luciferase activity using the 
Luciferase Assay System (Promega) on a multilabel plate reader (Wallac Victor, Perkin-
Elmer) according to the manufacturer's instructions. The relative luciferase activity, as a 
measurement of FOXO3a’s transcriptional activity was calculated dividing the value 
obtained for Firefly luciferase activity for each well by the the average GFP intensity 
from the same well. 
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Figure 1. 
FOXO-driven transcriptional activity measured by Luciferase production from 
different reporter gene constructs  
A. Schematic diagram of the luciferase reporter constructs used in this study. One to six 
copies of the DBE binding cassettes were cloned upstream of the luciferase reporter 
gene in the pGL3-Promoter vector to create the plasmids pGL-1xDBE, pGL-2xDBE, 
pGL-3xDBE, pGL-4xDBE, pGL-5xDBE and pGL-6xDBE. The empty pGL3-Promoter 
vector and a reporter plasmid that carries three copies of a mutated DBE (mDBE) region 
were used as control plasmids. B. Each construct was transiently co-transfected with 
plasmids encoding FOXO3a and Renilla luciferase into U2OS cells, and the luciferase 
activities were determined as described in the “Methods” section. The data were 
normalized to the Renilla luciferase (phRG-TK vector) reporter construct and expressed 
relative to the normalized activity of the pGL3-Promoter vector. The results are given as 
the mean ± SEM of three independent experiments performed in triplicate. C. Basal and 
induced FOXO-dependent transcriptional activity conferred by three or six copies of the 
DBE binding cassette (grey and black bars, respectively). The plasmids pGL-3xDBE or 
pGL-6xDBE were transiently co-transfected into U2OS cells with plasmids encoding 
wild type FOXO3a or the constitutively active FOXO3a-A3 and Renilla luciferase. 
Where indicated cells were treated with 20µM LY294002 or insulin for 6 hours. 
 
Figure 2. 
FOXO3a and GFP-FOXO trigger a similar induction of luciferase activities. pGL-
3xDBE or pGL-3xDBEmut were transiently co-transfected with plasmids encoding 
FOXO3a or GFP-FOXO3a into U2OS cells. U2foxRELOC cells that stably express the 
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GFP-FOXO3a protein (9) were transiently transfected with pGL-3xDBE. LY294002 
(20μM, hatched bars) or DMSO (black bars) were added to the transfected cells six 
hours before processing the cells to assay the luciferase assay. The values are the means 
± SEM of relative luciferase activities from three independent experiments performed in 
triplicates. 
 
Figure 3. 
Viability of U2transLUC cells using crystal violet assay or by monitoring the GFP-
intensity per well. U2transLUC cells were exposed to 0.05%, 0.10%, 0.25%, 0.50% or 
1% sodium azide for three hours and processed as described in the “Methods” section. 
The values are the means (± SD) of GFP intensity per well or the absorbance at 595nm 
from three independent experiments. 
 
Figure 4. 
Validation of U2transLUC assay using a panel of test compounds. A. The nuclear 
accumulation of the GFP-FOXO reporter protein and FOXO driven luciferase activity 
induced by the test compounds. We exposed U2transLUC cells to three different 
concentrations of the test compounds. The results shown here are the values obtained 
from the treatment of U2transLUC cells with 4nM Ratjadone A, 20μM LY294002, 
1ng/ml PDGF, 100μM Minerval, 1μM Forskolin, 4nM Leptomycin B, 30μM Cisplatin, 
100nM PI-103, 0.5nM Rapamycin, 20ng/ml IGF, 5ng/ml EGF and Dimethyl sulfoxide 
(DMSO) as a negative control. The grey bar graphs and the corresponding left hand y-
axis depict the values in relation to the control values normalized to the corresponding 
measure of viability values. The relative luciferase activity was calculated dividing the 
value obtained for Firefly luciferase activity for each well by the average GFP intensity 
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from the same well. The right hand y-axis and the hatched bars indicate the percentage 
of cells in each well exhibiting nuclear/cytoplasmic (Nuc/Cyt) ratios of fluorescence 
intensity greater than 1.8 normalized to the percentage in DMSO-treated wells. 
B. Representative images of treated cells using high throughput format of the 
U2transLUC system. Images of cells expressing GFP-FOXO and stained with DRAQ5 
were obtained by automated microscopy 2 hour after drug exposure. The images 
correspond to U2transLUC cells exposed to 4nM Ratjadone A, 4nM Leptomycin B, 
20μM LY294002, 100nM PI-103 and DMSO. The images are shown from the GFP and 
DRAQ5 channels, as well as the corresponding merged image in the case of the DMSO 
treated control cells. 
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Figure 1. FOXO-driven transcriptional activity measured by Luciferase
 
production from 
different reporter gene constructs.
A. Schematic diagram of the luciferase
 
reporter constructs used in this study. One to six copies of 
the DBE binding cassettes were cloned upstream of the luciferase
 
reporter gene in the pGL3-
 
Promoter vector to create the plasmids pGL-1xDBE, pGL-2xDBE, pGL-3xDBE, pGL-4xDBE, pGL-
 
5xDBE and pGL-6xDBE. The empty pGL3-Promoter vector and a reporter plasmid that carries 
three copies of a mutated DBE (mDBE) region were used as control plasmids. B. Each construct 
was transiently co-transfected
 
with plasmids encoding FOXO3a and Renilla
 
luciferase
 
into U2OS 
cells, and the luciferase
 
activities were determined as described in the “Methods”
 
section. The data 
were normalized to the Renilla
 
luciferase
 
(phRG-TK vector) reporter construct and expressed 
relative to the normalized activity of the pGL3-Promoter vector. The results are given as the mean 
±
 
SEM of three independent experiments performed in triplicate. C. Basal and induced FOXO-
 
dependent transcriptional activity conferred by three or six copies of the DBE binding cassette 
(grey and black bars, respectively). The plasmids pGL-3xDBE or pGL-6xDBE were transiently co-
 
transfected
 
into U2OS cells with plasmids encoding wild type FOXO3a or the constitutively active 
FOXO3a-A3 and Renilla
 
luciferase. Where indicated cells were treated with 20µM LY294002 or 
insulin for 6 hours.
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Figure 2. FOXO3a and GFP-FOXO trigger a similar induction of luciferase
 
activities.
pGL-3xDBE or pGL-3xDBEmut were transiently co-transfected
 
with plasmids encoding FOXO3a or 
GFP-FOXO3a into U2OS cells. U2foxRELOC cells that stably express the
 
GFP-FOXO3a protein (9) 
were transiently transfected
 
with pGL-3xDBE. LY294002 (20μM, hatched bars) or DMSO (black bars) 
were added to the transfected
 
cells six hours before processing the cells
 
to assay the luciferase
 
assay. 
The values are the means ±
 
SEM of relative luciferase
 
activities from three independent experiments 
performed
 
in triplicates.
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Figure 3. Viability of U2transLUC cells using
 
crystal violet assay or by monitoring the
 
GFP-intensity per 
well. U2transLUC cells were exposed to 0.05%, 0.10%, 0.25%, 0.50% or 1% sodium azide
 
for three hours and 
processed as described in the “Methods”
 
section. The values are the means
 
(±
 
SD)
 
of GFP intensity per well or the 
absorbance at 595nm from three independent experiments.
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Figure 4. Validation of U2transLUC assay using a panel of test compounds.
A. The nuclear accumulation of the GFP-FOXO reporter protein and FOXO driven luciferase
 
activity induced by the test compounds. We exposed U2transLUC cells to three different 
concentrations of the test compounds. The results shown here are
 
the values
 
obtained from the 
treatment of U2transLUC cells with 4nM Ratjadone
 
A, 20μM LY294002, 1ng/ml PDGF, 100μM 
Minerval, 1μM Forskolin, 4nM Leptomycin
 
B, 30μM Cisplatin, 100nM PI-103, 0.5nM 
Rapamycin, 20ng/ml IGF, 5ng/ml EGF and Dimethyl
 
sulfoxide
 
(DMSO) as a negative control. 
The grey bar graphs and the corresponding left hand y-axis depict the values in relation to the 
control values normalized to the corresponding measure of viability values. The relative 
luciferase
 
activity was calculated dividing the value obtained for Firefly
 
luciferase
 
activity for 
each well by the average GFP intensity from the same well. The right hand y-axis and the 
hatched bars indicate the percentage of cells in each well exhibiting nuclear/cytoplasmic
 
(Nuc/Cyt) ratios of fluorescence intensity greater than 1.8 normalized to the percentage in 
DMSO-treated wells.
Figure 4. Validation of U2transLUC assay using a panel of test compounds.
B. Representative images of treated cells using high throughput format of the U2transLUC system. Images of cells 
expressing GFP-FOXO and stained with DRAQ5 were obtained by automated microscopy 2 hour after drug exposure. The 
images correspond to U2transLUC cells exposed to 4nM Ratjadone A, 4nM Leptomycin B, 20μM LY294002, 100nM PI-
103 and DMSO. The images are shown from the GFP and DRAQ5 channels, as well as the corresponding merged image 
in the case of the DMSO treated control cells.
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3.1.3 Third Project: The BaFiso system 
 
Summary 
The activation of the PI3K/Akt is an essential feature of virtually all types of cancer 
and constitutes the primary mechanism by which FOXO is inactivated in human 
cancers. Therefore, it is important to identify compounds or RNAi that will specifically 
target this pathway, as inhibition of this pathway induces FOXO activation. In order to 
determine if the activation of FOXO promoted by a given a stimuli occurs via the 
inhibition of the Akt we generated a live-cells assay based on Ba/F3 cells that depend 
on the cytokine IL-3 for their survival and growth. Taking advantage of that specific 
feature, genetic modifications were carried out in the parental cells in order to express 
different fluorescent reporters according to the signaling pathway they will rely on for 
survival. This system has shown to accurately distinguish Akt dependent survival upon 
treatment with compounds previously described to interfere with this pathway from 
other interferences. Therefore, this system can be used as a primary screening system 
for the discovery of new anti- Akt therapies or targets as well as a deconvolution 
system for FOXO activators. 
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The generation of the cell lines described in this work as well as the execution of the 
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Abstract
Background: Inhibition of Akt signaling is considered one of the most promising therapeutic strategies for many cancers.
However, rational target-orientated approaches to cell based drug screens for anti-cancer agents have historically been
compromised by the notorious absence of suitable control cells.
Methodology/Principal Findings: In order to address this fundamental problem, we have developed BaFiso, a live-cell
screening platform to identify specific inhibitors of this pathway. BaFiso relies on the co-culture of isogenic cell lines that
have been engineered to sustain interleukin-3 independent survival of the parental Ba/F3 cells, and that are individually
tagged with different fluorescent proteins. Whilst in the first of these two lines cell survival in the absence of IL-3 is
dependent on the expression of activated Akt, the cells expressing constitutively-activated Stat5 signaling display IL-3
independent growth and survival in an Akt-independent manner. Small molecules can then be screened in these lines to
identify inhibitors that rescue IL-3 dependence.
Conclusions/Significance: BaFiso measures differential cell survival using multiparametric live cell imaging and permits
selective inhibitors of Akt signaling to be identified. BaFiso is a platform technology suitable for the identification of small
molecule inhibitors of IL-3 mediated survival signaling.
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Introduction
Cell-based screens have been widely used in drug discovery
although historically, these assays are conducted using genetically
diverse cell lines derived from human tumors [1,2]. Since the
complex intracellular signaling networks that drive cancer cell
growth and survival have begun to be elucidated, a more rational
approach to drug discovery has become feasible [3]. However, the
implementation of target-orientated cell-based screens for anti-
cancer drugs remains a challenge, both because of their reliance on
defined genetic changes and because of the lack of proper control
cells. To overcome this fundamental problem, we have developed a
rational strategy for cell-based drug discovery that is based on the
convenience and flexibility of the Ba/F3 cell system, an immortalized
IL-3-dependent pro-B lymphoblastic cell line [4]. IL-3 supports the
growth and survival of Ba/F3 cells through the activation of distinct
signaling pathways. Upon binding to its cognate receptor IL-3
activates the Janus kinase signal transduction and transcriptional
activation pathways (JAK/STAT) to induce Bcl-xL [5]. Similarly,
IL-3 activation of the PI3K/Akt pathway is involved in inhibiting the
intrinsic apoptotic machinery in Ba/F3 cells [6–8].
Overexpression of several constitutively active signaling mole-
cules abrogates the dependence of these cells on IL-3 [9]. Hence,
we generated isogenic cell lines derived from Ba/F3 (BaFiso) in
which IL-3 independent survival is sustained by independent
signaling events. Each of these isogenic lines was genetically
labeled with a fluorescent reporter and thus, the ratio of two
spectrally distinct cell populations could be used as primary
endpoint of the system to monitor pathway-specific cytotoxicity.
Accordingly compounds can be screened in co-cultures of these
lines and the change in the relative cell number of the two lines
readily and rapidly measured to identify those molecules that
specifically interact with one of the signaling pathways. In this
instance, BaFiso has been designed as a live-cell system suitable to
identify specific inhibitors of Akt signaling.
Results
Tagging isogenic Ba/F3 cells individually with two
different chromophores
The BaFiso system is a dual fluorescence cell-based screening
system in which compounds can be readily monitored thanks to
the stable expression of yellow or cyan fluorescent proteins that
individually tag each of the isogenic cell lines (Fig. 1). To introduce
the genes encoding the different fluorescent proteins into Ba/F3
cells, retroviral supernatants were generated by transfection of
PLoS ONE | www.plosone.org 1 March 2008 | Volume 3 | Issue 3 | e1823
LinX packaging cells. Through clonal propagation, we were able
to establish Ba/F3 cell lines that robustly and homogeneously
expressed ECFP (Fig. 2A and B) or EYFP (Fig. 2C and D). Stable
transfectants of these proteins were FACS-sorted to ensure that
they expressed similar levels of the fluorescent reporter protein.
Generation of double stable Ba/F3 cell lines
The strategy described here is based on paired isogenic cell lines
whose survival in the absence of IL-3 is sustained by the activation
of independent signaling pathways. Several signaling pathways
have been implicated in IL-3-mediated survival, including those
involving Akt and Stat5 [10,11]. In order to introduce constitu-
tively active forms of these genes into our dual fluorescence cell-
based system, we used retroviral constructs carrying a myristoy-
lated derivate of Akt and STAT5A1*6, which contains two
activating amino acid substitutions [11]. The yellow labeled Ba/F3
cells were used to generate Akt-dependent reporter cells whereas
the cyan tagged cells were used to establish PI3K/Akt independent
reporter cells. The retroviral supernatants of LinX packaging cells
were employed to transduce Ba/F3/EYFP cells (BY) with myr-Akt
and Ba/F3/ECFP cells (BC) with STAT5A1*6 (Fig. 2E). Stably
expressing cell clones were selected and the expression of the
transgenes was confirmed by western blot analysis (Fig. 2F). The
level of Akt expression was monitored using an antibody that
recognizes Akt irrespective of its phosphorylation state. Akt
migrates as a single band with an apparent molecular weight of
60 kDa, although a larger protein was also identified in
immunoblots of Akt from lysates of BYA cells. This additional
form can be explained by the difference in size produced by the
myristoylation signal present in the constitutive active form of Akt
used to generate the BYA cell line. Despite the Stat5a protein
present in the parental BC cells, ectopic expression of the
constitutively active form of Stat5a in BCS cells could be
unequivocally demonstrated in western blots probed with an
antibody directed against the Flag-tag. Indeed, STAT5A1*6
expression also increased the total Stat5a protein level in BCS
cells as shown by immunoblotting using an antibody recognizing
Stat5.
Figure 1. Schematic overview of the BaFiso assay system. BaFiso consists of paired isogenic cell lines that have been engineered to acquire IL-
3 autonomous growth through constitutive activation of Akt or Stat5 signaling. The two cell lines to be compared are individually tagged with either
yellow or cyan fluorescent proteins. Equal numbers of yellow and cyan cells were co-cultured, treated with compounds and the change in the relative
cell number was calculated on the basis of the distinct fluorescent proteins measured. Our strategy aims to identify lead compounds that specifically
kill test cells with activated Akt signaling (yellow cells) and that spare the otherwise isogenic control cells (cyan cells).
doi:10.1371/journal.pone.0001823.g001
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To examine whether PI3K/Akt or Stat5 signaling is indeed
activated in the stable BYA or BCS cells respectively, we analyzed
downstream elements in these two pathways. Phosphorylation of
Akt (Ser473) has been widely used as a read out of activation of the
PI3K pathway. When we compared the level of Akt phosphor-
ylation in lysates of BY and BYA cells cultured in the presence of
IL-3, there was dramatic increase in Ser473 phosphorylation of
Akt in BYA cells, reflecting the activity of this pathway. To
investigate whether the activation of Akt in BYA cells had an
impact on downstream events, we analyzed the Thr389 phos-
phorylation of the linker domain of the p70 S6 kinase that is
constitutively activated upon overexpression of a gag fusion of Akt
[12]. There was a significant increase in the intensity of the band
corresponding to p70 S6 kinase (Thr389) in BYA cells when
compared to BY control cells. On the other hand, the expression
of the known STAT5 target gene, pim-1, was upregulated upon
expression of constitutive activated Stat5a, consistent with previous
studies [13].
Ectopic expression of activated Akt and Stat5a confers IL-
3 independence
Consistent with previous reports, expression of constitutively
active mutants of Akt and Stat5a provide signals for cytokine-
independent survival of Ba/F3 cells [9,11]. The increased
resistance to IL-3 withdrawal of the BYA and BCS cell lines
when compared to the parental BY and BC cell lines was
Figure 2. The generation of BaFiso cell lines. Ba/F3 cells were transduced with retroviral supernatant carrying pBabePuro-EYFP or pBabePuro-
ECFP. Cell clones were established and sorted in a fluorescence activated cell sorter (FACS) to generate lines homogeneously expressing the
corresponding fluorescent tags. (A) and (C), viable Ba/F3 cells show robust and homogeneous expression of the respective fluorescent protein. (B)
and (D), corresponding light field views. (E), Generation of stable BaFiso cell lines. Clonal Ba/F3 cells stably expressing EYFP (BY) or ECFP (BC) were
used to generate stable BaFiso cell lines that co-express yellow fluorescence and myr-Akt (BYA), or cyan fluorescence and STAT5A1*6 (BCS). Cell
clones were established and analyzed. (F), Analysis of transgene expression and downstream activation of the corresponding signaling pathways by
western blotting. Antibodies against total Akt, Stat5a, Flag phospho-Akt (Ser473), phospho-p70 S6 (Thr389) and Pim-1 were used and the signals
normalized to the respective a-tubulin levels.
doi:10.1371/journal.pone.0001823.g002
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confirmed by morphological assessment. Parental BY and BC cells
were cultured in the presence or absence of IL-3 and the degree of
cell death was assessed after 24 hours by microscopic examination
(Fig. 3A). The number of cells with an apoptotic phenotype
increased significantly after IL-3 withdrawal in the cultures. The
effect of the constitutive activation of Akt or Stat5 signaling was
examined when IL-3 was withdrawn from representative BYA and
BCS cell clones. As such, the capacity of the constitutively active
forms of the signaling molecules Akt and Stat5a to impede
apoptosis was evident and accordingly, cell death was dramatically
reduced in Ba/F3 cells ectopically expressing myr-Akt or
STAT5A1*6, even in the absence of IL-3 (Fig. 3A). We also
determined the metabolic activity as a measure of cell viability
using the alamar blue assay, in which a redox indicator changes
color from blue to pink depending on metabolic status of the cells
(Fig. 3B). The activity of myr-Akt in BYA cells was significantly
higher in the absence of IL-3 than that of the parental cells.
Similarly, STAT5A1*6 also maintained the activity of BCS cells
albeit to slightly lesser degree (Fig. 3C). We examined the time
course of cell viability following IL-3 withdrawal (Fig. 3D) and
24 hours after IL-3 deprivation, approximately 60% of the BYA
or BCS cells remained viable compared to approximately 25% of
the parental BY and BC cell lines. The viability of BY and BC cells
further diminished after 60 hours of IL-3 starvation to 13% and
9%, respectively. In contrast, the viability of BYA and BCS cells
remained around 50% after 60 hours in the absence of IL-3.
Figure 3. The viability of BaFiso cell lines in the absence of IL-3. (A) Parental Ba/F3 derived BY and BC cells, and the BaFiso cell lines BYA and
BCS were maintained in the presence or absence of IL-3 (+IL3 and2IL3). Photos were taken 24 h after transferring the cells to medium without IL-3 or
in the presence of 3 ng/ml of the recombinant cytokine. (B) Measurement of cell viability using the Alamar blue assay. Alamar blue fluoresces and
changes color in response to chemical reduction, and the extent of the conversion is a reflection of cell viability. Metabolic conversion of Alamar blue
to its reduced, pink derivative upon cytokine-deprivation (2IL-3) or in its presence (+IL-3). (C), Bar graph showing the results of Alamar Blue cell
viability assay. Maximal absorbance of the reduced and oxidized forms of AlamarBlueTM, 570 and 600 nm was measured using Victor 1420 multilabel
counter 24 h after IL-3 withdrawal. The percentage of cell survival was calculated compared with control cells in the presence of 3 ng/ml of IL3. The
data represents three independent experiments performed in triplicate samples. (D) Time course of cell viability upon IL-3 withdrawal. Cells were
washed twice in PBS and seeded in media lacking IL-3. Viability was assessed at 12 hour intervals by trypan blue exclusions followed by cell
countings. Black rhombs and open squares represent percentage viability of BY and BC cells, respectively. Open triangles and black circles represent
percentage viability of BYA and BCS cells, respectively. Data are presented as mean6SD from three independent experiments.
doi:10.1371/journal.pone.0001823.g003
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The protection from IL-3 withdrawal afforded by
enhanced Stat5 signaling is independent of Akt activity
The capacity to monitor pathway-specific cytotoxicity in our
assay is based on the use of isogenic control cells that confer
survival in the absence of IL-3 in an Akt-independent manner.
Since Akt is one of the major downstream targets of PI3K
signaling, its phosphorylation status is commonly used to monitor
the activity of the PI3K/Akt pathway. We analyzed the impact of
ectopic expression of myr-Akt and STAT5A1*6 on Akt activation
using an antibody that specifically recognizes Ser473 phosphor-
ylated Akt (Fig. 4). The intensity of Akt phosphorylation was
compared to the overall expression of Akt and a-tubulin using
specific antibodies. Parental BY and BC cells possess relatively low
basal levels of Akt phosphorylation which further decreased upon
withdrawal of IL-3. Ectopic constitutively active Stat5a expression
had no significant impact on the phosphorylation of Akt in the
presence or absence of IL-3, indicating that the enhanced survival
of BCS cells triggered by STAT5A1*6 upon IL-3 starvation is
independent of Akt signaling. Consistent with previous studies,
overexpression of myr-Akt dramatically augmented Ser473
phosphorylation [14] and high levels of Akt phosphorylation were
still detected in the complete absence of IL-3 (Fig. 4).
In conclusion, these results show that we have generated stable
Ba/F3-derived cell lines in which the inhibition of the intrinsic
apoptotic machinery is mediated by ectopic expression of constitu-
tively active mutants of Akt or Stat5a. Since the abrogation of IL-3
dependence occurred through the activation of independent
signaling pathways, these cell lines can be used together as paired
isogenic test and control cells to identify pathway specific inhibitors.
Detection of selective toxicity associated with activated
Akt signaling
The BaFiso assay was set up in 96-well plates and with an
automated workflow [15]. Equal numbers of BYA and BCS cells
were mixed and seeded at a density of 20,000 cells per well using
multidrop dispenser. All liquid handling for treatment and staining
was carried out by a robotic workstation and the BD Pathway 855
cell imaging platform was used for automated image acquisition.
In order to test the sensitivity and the capacity to detect EYFP and
ECFP separately using BD Pathway 855 bioimager, the co-
cultured cells were photographed for the two fluorochromes
sequentially and the images superimposed. In order to avoid
ECFP bleeding into the EYFP emission channel, a special filter set
was used that clearly separates the two fluorochromes. A third
fluorochrome, the far red/infrared fluorescent cell-permeant DNA
probe, DRAQ5, was employed to perform automated segmenta-
tion of cell nuclei. An image algorithm was applied to segment the
cell nucleus based on local thresholds. The ratios of the cyan and
yellow fluorescence signals were determined by dividing the
number of ECFP positive cells by the number of EYFP positive
cells in each well.
As a proof of principle, we sought to determine how a panel of
commercially available agents of known mechanism of action
would behave in the BaFiso screen. The test compounds included:
the DNA-damaging chemotherapeutic compound cisplatin; the
modulator of membrane lipid structure Minerval; the Akt inhibitor
10-(49-(N-diethylamino)butyl)-2-chlorophenoxazine (Akt Inhibitor
X); the protein tyrosine kinase inhibitor Genistein; the inhibitor of
nuclear export Leptomycin B; the broad protein kinase inhibitor
Staurosporine; the PDK1 inhibitor UCN-01; the Raf1 Kinase
Inhibitor; the PI3K inhibitor LY294002; the topoisomerase II
inhibitor Etoposide; and Lithium chloride, a GSK-3 inhibitor.
A robotic workstation was used to prepare mother plates
containing three different concentrations of these compounds. Co-
cultured BaFiso BYA/BCS cells were exposed to equal volumes of
the test compounds, resulting in a final concentration range
greater than two orders of magnitude around the IC50 value for
each compound. The final concentration of dimethyl sulfoxide was
kept at 1% after addition of the compounds. Each plate contained
several internal controls, including untreated wells and wells
treated with different concentrations of DMSO or ethanol alone.
The performance of the BaFiso system upon exposure to the panel
of test compounds was measured in terms of the ECFP/EYFP
ratio. The majority of the test compounds reduced the number of
DRAQ5 positive cells (Fig. 5A) without affecting the ratio of cyan
and yellow fluorescent signals (Fig. 5B), suggesting a non-selective
cytotoxic effect on both BaFiso cell lines independent of the gene
that has been engineered to sustain interleukin-3 independent
survival of the cells. In contrast exposure to Minerval or LiCl did
not affect the viability of the BaFiso cell lines (Fig. 5A) nor did it
alter the ratio of the fluorescent signals (Fig. 5B). Most importantly,
two compounds that are known to inhibit the kinase activity of
Akt, UCN-01 and Akt Inhibitor X, [16,17] selectively compro-
mised the viability of the yellow tagged BYA cells thereby
increasing the ratio of cyan to yellow fluorescent cells (Fig. 5B, C
and D). In contrast, the broad spectrum PI3K isoform inhibitor
LY294002 failed to affect the proportion of the fluorescent signals,
indicating that the myristoylated form of Akt bypasses the
requirement of PIP3-mediated membrane recruitment for its
activity. Taken together, these data demonstrate that we have
developed an image-based screening system that is capable of
identifying specific inhibitors of the Akt pathway.
Discussion
The most frequently used anti-cancer therapies were discovered
on the basis of their anti-proliferative activity in functional cell
assays but with no pre-existing knowledge of the mechanism of
action. As a result none of the current drugs directly targets the
molecular lesions responsible for malignant transformation and
they are not selective. Indeed this lack of selectivity between cancer
cells and normal cells is currently one of the main reasons for the
failure of conventional chemotherapy. In recent years, our
understanding of the genetics of human cancer has increased
rapidly, enabling more rational approaches to drug discovery for
anti-cancer therapies to be adopted. Accordingly, the present
study set out to develop a rational cell-based drug discovery
strategy, an approach that has historically been compromised by
the lack of appropriate control cells [18].
Figure 4. The analysis of Akt phosphorylation in BaFiso cell
lines. Immunoblot analysis of total lysates from the Ba/F3 derived cell
lines BY, BC, BYA and BCS. Cells were seeded, grown to 80% confluence
and starved for 12 h in IL-3 free medium (2IL-3) or maintained in
medium containing 3 ng/ml of the recombinant cytokine (+IL-3).
Relevant proteins are indicated by arrows in the blot from a
representative experiment.
doi:10.1371/journal.pone.0001823.g004
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With the objective of identifying lead compounds that
specifically kill cells with activated Akt signaling and that spare
control cells, we have combined the use of co-cultured isogenic cell
lines with fluorescent technology. We introduced a myristoylated
form of Akt which constitutively localizes to the plasma
membrane, bypassing the requirement for PIP3 in Akt activation.
This myr-Akt has been shown to constitutively inactivate pro-
apoptotic downstream targets [14]. In order to generate Ba/F3
cells that survive in the absence of IL-3 independent of activated
PI3K/Akt signaling, we transduced Ba/F3 cells with a retrovirus
encoding STAT5A1*6, an activated mutant of STAT5.
STAT5A1*6 has two amino acid substitutions and it is
constitutively phosphorylated, localized in the cell nucleus and
transcriptionally active in the absence of IL-3 [11]. In the BaFiso
system presented here, the protective potential of myr-Akt is
slightly greater than that provided by STAT5A1*6, which may be
explained by the greater expression of myr-Akt. The design of the
screen relies on the lack of relevant crosstalk between the pathways
engineered to support IL-3 independent survival. Previous work
has shown that the induced expression of bcl-xL and pim-1
promotes the IL-3-independent survival of Ba/F3 cells upon
activation of STAT5 [13]. In contrast, studies in multiple cell lines
suggest that Akt phosphorylates and inactivates proapoptotic
proteins such as GSK-3b, Foxo3a and Bad in response to IL-3
[8,19,20]. We confirmed that the activation of Stat5 signaling in
BCS cells did not increase Akt activity either in the presence or
absence of IL-3.
Another common source of interference to be mitigated in
multiplexed screening procedures is the bleed-through of fluores-
cence from one channel to the other. BaFiso allows simultaneous
viewing of three different fluorescent signals and sharp separation
of the emission signals from the cyan and yellow protein is
achieved using a special filter set. We implemented BaFiso as an
automated live-cell assay using a multidrop dispenser, a robotic
workstation and a robotic cell imaging platform. We assessed the
properties of this HTS co-culture assay using a panel of test
compounds of known activity. The cytotoxicity of the test
compounds was monitored by quantifying the DRAQ5 labelled
cells and all compounds tested except LiCl and Minerval reduced
the viability of Ba/F3 cells. The fact that only two compounds
known to selectively interfere with Akt signaling, Akt inhibitor X
and UCN-01, reduced the number of yellow tagged BYA cells
demonstrates the specificity of the BaFiso system. The Akt
inhibitor X is a N-substituted phenoxazine that inhibits the
activity of Akt even in the absence of its pleckstrin homology
domain and it has been suggested that it may bind in the ATP
binding site [17]. In contrast, UCN-01 has been reported to inhibit
several kinases including PDK1, a key regulator of Akt activity
[16]. Interestingly, staurosporine that differs from UCN-01 only
by the absence of a hydroxy group on the lactam ring failed to
change the ratio of the BaFiso cell lines. A specificity analysis
against a kinase panel revealed different patterns of inhibition for
UCN-01 with respect to staurosporine [16]. It remains to be
determined if these differences in specificity could account for the
different behaviour observed for these two compounds in the
BaFiso assay.
The BaFiso screening design presented here offers some major
advantages over traditional in vitro biochemical assays or more
classical cellular assays. Co-culture and simultaneous testing of the
paired isogenic cell lines in this assay provides an internal control
and eliminates errors resulting from separate assessments. BaFiso
is an image based high throughput assay that enables compound
that produce artefacts and cytotoxicity to be identified on a single
cell basis. Live cell imaging of the BaFiso cell lines permits the
Figure 5. Validation of BaFiso assay using a panel of test
compounds. (A) Analysis of the general toxicity of compound
treatment. The total cell numbers in each well were determined by
nuclear counterstain with the far-red fluorescent DNA probe DRAQ5.
The number of DRAQ5-stained nuclei was determined after exposure to
30 mM Cisplatin (Cis), 100 mM Minerval (Min), 500 nM Akt Inhibitor X
(AIX), 20 mM Genistein (Gen), 1 nM Leptomycin B (LMB), 20 nM
Staurosporine (Stau), 1 mM UCN-01, 20 nM Raf1 Kinase Inhibitor (RKI),
20 mM LY294002 (LY), 10 mM Etoposide (Eto) and 1 mM lithium chloride
(LiCl) for 12 hours and compared to vehicle treatment. (B) Equal
numbers of BCS and BYA cells were co-cultured in IL-3-free medium. We
exposed the paired BaFiso cell lines to 3 mM, 30 mM and 300 mM
Cisplatin (Cis), 25 mM, 100 mM, 200 mM Minerval (Min), 50 nM, 500 nM,
5 mM Akt Inhibitor X (AIX), 200 nM, 20 mM, 50 mM Genistein (Gen),
0.5 nM, 1 nM, 4 nM Leptomycin B (LMB), 2 nM, 20 nM, 10 mM
Staurosporine (Stau), 200 nM, 1 mM, 10 mM UCN-01; 5 nM, 20 nM,
200 nM Raf1 Kinase Inhibitor (RKI), 1 mM, 20 mM, 50 mM LY294002 (LY),
100 nM, 10 mM, 100 mM Etoposide (Eto) and 100 mM, 1 mM, 10 mM
lithium chloride (LiCl), and Dimethyl sulfoxide (DMSO) as a negative
control (striped bar). Three images specific for ECFP, EYFP or DRAQ5
from each well were acquired using BD Pathway Bioimager. The ECFP/
EYFP ratio was determined by dividing the number of ECFP positive
cells by the number of EYFP positive cells. Light, dark grey and black
bars represent low, medium and high concentrations of the corre-
sponding compounds, respectively. The data shown here represents
three independent experiments. The average Z’ value for BaFiso was
0.53. (C) Untreated, co-cultured BaFiso cells imaged before exposure to
Akt Inhibitor X and (D) 12 h after treatment with 5 mM AIX.
doi:10.1371/journal.pone.0001823.g005
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repeated monitoring of the same cells over the timecourse of an
experiment, leading to a more accurate assessment that minimizes
the variability in cell numbers between wells. Finally, the dual
fluorescence co-culture system used in BaFiso is adaptable to any
gene or pathway that can support IL-3 independent survival of
Ba/F3 cells.
Methods
Expression Vectors and Reagents
The enhanced fluorescent protein vectors (pECFP-C1 and
pEYFP-C1) were purchased from Clontech. The cDNAs encoding
ECFP and EYFP were subcloned into the SnaBI sites of the pBABE-
puro retroviral vector. The myr-Akt was kindly provided by Dr.
Philip Tsichlis and we PCR amplified myr-Akt-HA using forward
59–CGCGGATCCATGGGGAGCAGCAAGAGCAAGC–39 and
reverse 59–ACGCGTCGACTCATCTAGAAGCGTAATCTG-
GAACC–39 primers, before subcloning the BamHI and SalI
digested PCR product into the corresponding restriction site of the
retroviral vector pWZL-Blast. The Stat5A1*6-Flag construct was a
kind gift from T. Nosaka (University of Tokyo). The nature of all
constructs was confirmed by DNA sequencing.
All chemicals were purchased from commercial sources except
UCN-01 which was kindly provided by NCI, Cisplatin which was
provided by C. Navarro (Universidad Auto´noma de Madrid,
Spain), and Minerval which was generously provided by P. Escriba
(University of the Balearic Islands, Palma de Mallorca, Spain).
The Akt Inhibitor X, LY294002 and Raf1 Kinase Inhibitor were
purchased from Calbiochem (San Diego, CA), Leptomycin B and
Genistein were purchased from LC Laboratories (Woburn, MA,
USA), Lithium chloride (LiCl), Etoposide and Staurosporine ware
all purchased from Sigma-Aldrich (St. Louis, USA).
Cell Culture
Murine pro-B Ba/F3 cells were obtained from the American
Type Culture Collection (ATCC) and maintained in RPMI 1640
containing: 10% fetal calf serum; 2 mM L-glutamine; 50 mM 2-
mercaptoethanol (Sigma); antibiotics and antimycotics (Gibco);
and 3 ng/ml of recombinant murine IL-3 (R&D Systems,
Minneapolis, MN, USA). LinXE ecotropic retrovirus producing
cells [21] were grown in Dulbecco’s modified Eagle’s medium with
glutamax supplemented with 10% fetal bovine serum (FBS),
penicillin, streptomycin and fungizone (Gibco). Cell cultures were
maintained in a humified incubator at 37uC with 5% CO2. To
remove IL-3, the cells were washed twice in PBS at room
temperature. Retroviral constructs were introduced into packaging
cells by standard calcium phosphate transfection and retroviral-
mediated gene transfer was performed as described previously
[22]. After infection of Ba/F3 cells with retroviral supernatants
containing either EYFP or ECFP, stable cell lines were selected in
medium containing 2 mg/ml of puromycin for one week. In order
to establish Ba/F3 cell lines homogeneously expressing EYFP or
ECFP, we performed clonal propagation in Clona-cell TCS semi-
solid culture medium (Stem Cell Technologies, Vancouver,
Canada) containing 2 mg/ml puromycin according to the
manufacturer’s protocol. Ba/F3 cell clones stably expressing
EYFP (BY cells) or ECFP (BC cells) were used as parental cells
for the secondary stable infection with retroviral supernatants
containing either myr-Akt or Stat5A1*6-Flag, respectively. Stable
Ba/F3 cells co-expressing EYFP and myr-Akt (BYA cells) were
selected with 0.8 mg/ml Neomycin and 1 mg/ml puromycin for
2 weeks. Stable Ba/F3 cells co-expressing ECFP and Stat5A1*6-
Flag (BCS cells) were selected with 15 mg/ml Blasticidine and
1 mg/ml puromycin for 2 weeks. The generation of cell clones was
performed as described above. Fluorescence-activated cell sorting
(FACS) of EYFP or ECFP expressing cells was performed on a
FACSAria (BD Biosciences, San Jose, CA, USA).
Western Blot Analysis
Cells incubated under different conditions were washed twice
with TBS prior to lysis in buffer containing: 50 mM Tris HCl,
150 mM NaCl, 1% NP-40, 2 mM Na3VO4, 100 mM NaF,
20 mM Na4P2O7, and protease inhibitor cocktail (Roche Molec-
ular Biochemicals, Indianapolis, IN). Proteins were resolved on
10% SDS-PAGE, and transferred to PVDF membranes (Im-
mobilon-P, Millipore). The membranes were incubated with the
first antibody overnight at 4uC, washed and incubated with anti-
mouse (1:10000) or anti-rabbit (1:5000) horseradish peroxidase
conjugated antibodies. Immunoreactive proteins were visualized
using the enhanced chemiluminescence (ECL) Western blotting
detection system (Amersham Pharmacia Biotech) and Kodak-X-
Omat LS film (Kodak). Antibodies against phospho-AKT (Ser473)
and AKT were purchased from Cell Signaling (Beverly, MA),
those against STAT-5 from (R&D Systems, Minneapolis, MN,
USA), and the antibodies against a-tubulin and Flag were obtained
from Sigma (St Louis, MO).
Survival assay
Each cell line was individually seeded at 104 cells per well in a
96 well plate, in the presence or absence of IL-3. AlamarBlueTM
(Serotec, Oxford, UK) was added to the culture medium at a final
concentration of 10% (v-v) and after 24 hours, absorbance was
measured at the two different wavelengths of maximal absorbance
of the reduced and oxidized forms of AlamarBlueTM, 570 and
600 nm using Victor 1420 Multilabel Counter (Perkin-Elmer,
Wellesley, USA). The percentage cell survival was calculated
according to the manufacturers’ instructions. Time course
experiments of cell viability post IL-3 withdrawal were performed
using trypan blue exclusion.
BaFiso assay
Equal numbers of parental BC/BY cells or activated test cells
BCS/BYA were mixed in culture medium deprived of IL-3 and
seeded in 96-well black clear bottom microplates coated with Poly-
D-Lysine (Becton Dickinson Biosciences, San Jose, California,
USA) at a density of 20,000 cells per well using Titan Multidrop
384 automatic dispenser (Titertek Instruments, Inc., Huntsville,
AL). The final volume of the cell suspension was 200 ml in each
well. After incubation at 37uC with 5% CO2 for 1 hour the far-red
fluorescent cell-permeable DNA probe, DRAQ5TM (Biostatus Ltd,
Leicestershire, UK) was added at a final concentration of 5 mM to
all wells 15 minutes prior to obtaining the first images. Then, 2 ml
of each test compound or vehicle was transferred from the mother
plates to the assay plates using a robotic workstation (BiomekR FX
Beckman). Cells were incubated in the presence of the test
compounds for 12 hours.
Image acquisition and processing
Assay plates were read on the BD PathwayTM 855 Bioimager
(Becton Dickinson Biosciences, San Jose, California, USA)
equipped with a 430/25 nm/470/30 nm ECFP excitation/
emission filter, 500/20 nm/535/30 nm EYFP excitation/emis-
sion filter and 635/20 nm/695/55 nm DRAQ5 excitation/
emission filter. Images for each well were acquired in the three
different channels for ECFP, EYFP and DRAQ5 using a 206dry
objective. The plates were exposed for 0.55 ms (Gain 14) to
acquire ECFP images, 0.68 ms (Gain 32) for EYFP images and
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0.47 ms (Gain 5) to acquire DRAQ5 images. The far red
fluorescence intensity of DRAQ5 was used to perform automated
segmentation of the cell nuclei and in turn to quantify the total cell
number.
Data analysis
The data output of the BD Pathway Bioimager is as standard
text files. These files contained the raw fluorescence data for each
cells population. Data were imported into the data analysis
software, BD Image Data Explorer, and the ratios of the ECFP
positive cells to EYFP positive cells were determined by dividing
the number of cyan fluorescence-emitting single cells by the
number of yellow fluorescence-emitting single cells in each well.
This procedure was repeated for each well. By measuring changes
in the ratio between the cyan and yellow signal, the possible
pathway-specific cytotoxicity of each compound could be
determined. In order to estimate the quality of the HCS assay,
the Z’ factor was calculated by the equation: Z’ = 1 – [(36std. dev.
of positive controls)+(36std. dev. of negative controls)/(mean of
positive controls) - (mean of negative controls)] as described
previously [23].
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Results 
3.2 Identification of Novel Targets implicated in FOXO regulation by High 
Content-High Throughput screenings 
 
3.2.1 Fourth Project: A chemical genetics screening for compounds able to 
induce FOXO nuclear translocation 
 
Summary 
In this project a HCS system generated with U2-OS human osteosarcoma cells 
stably transfected with a GFP-FOXO3A fusion protein was used. Automated image 
analysis allows for the quantification of nuclear/cytoplasmic ratios of the reporter signal 
as a readout for FOXO activation. This system allowed us to perform a chemical 
genetic analysis of 73 compounds. Some of them, previously related to PI3K/Akt 
inhibition scored positive in our study, as well as the small tubuline-binding molecule 
Vimblastine, previously reported to activate the JNK pathway. Moreover, the effect of 
Calmodulin inhibition on FOXO translocation was detected and further analyzed. This 
system was also used for the validation of the hits obtained in our RNAi screening. 
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Introduction
Mammalian FOXO proteins are the orthologues of Candida ele-
gans DAF16, and they pertain to the O class of forkhead tran-
scription factors that have a characteristic forkhead box DNA
binding domain. FOXO proteins function as transcriptional reg-
ulators in the cell nucleus and they bind as monomers to their
consensus DNA binding sites. They are components of highly
conserved signal-transduction pathways that link growth and
stress signals to the control of gene expression. The ever-grow-
ing list of target genes for these factors contains many ele-
ments that function in metabolism, apoptosis, resistance to ox-
idative stress, and cell-cycle inhibition, and includes glucose-6-
phosphatase, phosphoenolpyruvate carboxykinase,[1] FasL,
Bim,[2,3] MnSOD, catalase, p27KIP1, p130, and cyclin G2.
[4–6] FOXO
factors are inactivated in a variety of cancers and indeed,
FOXO3a was found mainly in the cytoplasm in human primary
breast cancer where nuclear exclusion was closely correlated
with poor survival.[7] Moreover, the expression of a constitutive-
ly active form of FOXO1 diminished tumorigenesis in cells with
aberrant PI3K/Akt activity in nude mice.[8] In fact, the simulta-
neous disruption of the three principal FOXO genes leads to
thymic lymphoma and haemangiomas, indicative that FOXO
factors are bona fide tumor suppressors.[9]
Despite these consequences of their inactivation and some-
what surprisingly, no inactivating mutations in the FOXO genes
have yet been reported. Hence, inactivation of FOXO proteins
in human cancer seems to be mainly due to aberrant upstream
signaling. Subcellular localization of FOXO proteins plays a
major role in the regulation of their activity. Nuclear–cytoplas-
mic shuttling of FOXO factors is controlled by a sophisticated
signaling network that integrates information from PI3K/Akt
and stress-induced signaling pathways via the Jun N-terminal
kinase (JNK), the mammalian sterile 20-like kinase MSTI, and
the NAD-dependent deacetylase SIRT1.[10] In the absence of
growth factor signaling, FOXO factors are localized in the nu-
cleus and are transcriptionally active. By contrast, FOXO tran-
scription factors are phosphorylated by several kinases in re-
sponse to growth and survival factors, including AKT, SGK, and
CK1,[11] and phosphorylation by DYRK1A and IKKb has been
shown to drive FOXO factors out of the nucleus.[7, 11] Akt nega-
tively regulates FOXO proteins through the phosphorylation of
residues at three highly conserved RXRXXS/T consensus sites;
this leads to conformational changes that facilitate 14-3-3
binding and that activate CRM-1-mediated nuclear export.
Stress signals have been shown to antagonize Akt signaling by
preventing the binding of FOXO to 14-3-3 by phosphorylation
of FOXO at S207 by MST1 and the phosphorylation of 14-3-3
FOXO proteins are direct targets of PI3K/Akt signaling and they
integrate the signals of several other transduction pathways at
the transcriptional level. FOXO transcription factors are involved
in normal cell homeostasis and neoplasia, and they are regulated
by multiple post-transcriptional modifications. In cancer research,
the regulation of the FOXO factors is receiving increasing atten-
tion as their activation has been linked to cell-cycle arrest and
apoptosis. Hence, FOXO proteins have been proposed to act as
tumor suppressors. Here, we applied a chemical biology ap-
proach to study the mechanisms that influence the intracellular
localization of the FOXO family member FOXO3a. We established
a high-throughput cellular-imaging assay that monitors the nu-
clear–cytoplasmic translocation of a GFP–FOXO3a fusion protein
in tumor cells. Nuclear accumulation of fluorescent signals upon
treatment with the known PI3K inhibitors LY294002, wortmannin,
PIK-75, and PI-103 was dose dependent and agreed well with the
IC50 values reported for PI3Ka inhibition in vitro. Additionally, we
identified 17 compounds from a panel of 73 low-molecular-
weight compounds capable of inducing the nuclear accumula-
tion of GFP–FOXO. These compounds include chemicals known
to interfere with components of the PI3K/Akt signaling pathway,
as well as with nuclear export and Ca2+/calmodulin (CaM)-depen-
dent signaling events. Interestingly, the therapeutic agent vinblas-
tine induced efficient nuclear translocation of the FOXO reporter
protein. Our data illustrate the potential of chemical genetics
when combined with robust and sensitive high-content-screening
technology.
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by JNK.[12, 13] Furthermore, oxidative stress promotes Ral-medi-
ated, JNK-dependent phosphorylation of FOXO4.[14] Additional-
ly, monoubiqutination and SIRT-dependent deacetylation of
FOXO proteins in response to increased cellular oxidative
stress is thought to induce their nuclear translocation.[15,16] De-
spite considerable efforts, our understanding of how non-Akt-
mediated regulation of FOXO factors affects their subcellular
localization is very limited. To define the circuit that regulates
the subcellular transport of FOXO proteins, we performed
chemical genetic studies to interrogate the FOXO shuttling
system.
Results
U2foxRELOC cells respond to inhibition of the PI3K/Akt
pathway
To generate a system suitable to monitor nuclear–cytoplasmic
shuttling of FOXO protein in a high-throughput-screening
(HTS) format, we stably transfected a GFP–FOXO3a reporter
plasmid into U2OS cells and prepared cell clones. As a proof of
principle, we treated U2foxRELOC cells with LY294002, a broad
spectrum PI3K inhibitor widely used to suppress the activation
of PI3K/Akt signaling. Whereas the GFP fusion protein was
present in both the cytoplasm and nucleus in U2foxRELOC
cells, with significantly more GFP in the cytoplasm than in the
nucleus, when exposed to LY294002 for 1 h almost all the
GFP–FOXO3a translocated to the nucleus of these cells
(Figure 1). To analyze whether treatment with LY294002 com-
promised the integrity of the cell cytoplasm, we used cell-
tracker orange as a vital cytoplasmic counterstain. The overall
morphology of U2foxRELOC cells remained unaffected by ex-
posure to LY294002 (Figure 1F), indicating that the kinetics of
the assay allowed us to reduce the incubation time necessary
to attain unambiguous responses when cells were exposed to
different compounds. This is an important factor to minimize
the possible toxic effects that might interfere with the analysis,
as well as other indirect effects.
Dose-response analysis of PI3K inhibitors with different IC50
values by using automated U2foxRELOC
We next explored the feasibility of extracting quantitative data
from the U2foxRELOC system by analyzing the effects of PI3K
Figure 1. Translocation of GFP–FOXO following PI3K inhibition. U2foxRELOC cells stably expressing GFP–FOXO fusion protein were seeded in 96-well plates,
incubated for 12 h, preincubated with cell-tracker orange dye, and treated with DMSO (A–C) or 20 mm LY294002 (D–F). After 1 h at 37 8C, the cells were
washed, fixed, and stained with DAPI in a fully automated manner by using a robotic workstation. The cells were photographed by using a BD Pathway HT
cell-imaging platform. A) and D) GFP; B) and E) GFP and DAPI merged images; C) and F) cell-tracker orange. G) a close-up view of the region in (A) outlined
by the square. I) Close-up view of the region in (D) outlined by the square. H) and J) Corresponding cell-tracker orange images.
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inhibitors that act on the recombinant p110a protein with dif-
ferent IC50 values. The IC50 in vitro value of the competitive,
pan-PI3K inhibitor LY294002 is 500 nm and hence, it is about
60-fold less potent than the imidazopyridine inhibitor PIK-75
(7.8 nm), about 135-fold less potent than the synthetic selec-
tive class I PI3K inhibitor PI-103 (IC50=3.7 nm) and about 900-
fold less potent than the fungal metabolite wortmannin (IC50=
0.57 nm).[17] U2foxRELOC cells were exposed to eleven different
concentrations of the PI3K inhibitors for 1 h in culture, the final
concentrations of the inhibitors ranging from 50 mm to 1.6 nm.
The morphological integrity of the assayed cells was confirmed
by cell-tracker orange fluorescence of cytoplasm of viable cells
(data not shown). The data obtained from these experiments
agree well with the IC50 values for the corresponding com-
pounds in biochemical assays (Figure 2). Thus, LY294002 in-
duced nuclear translocation of the FOXO reporter protein at
50 mm, and 33.3 mm, and was slightly less efficient at 11.1 mm.
However, exposure of U2foxRELOC cells to 3.7 mm LY294002
failed to affect the intracellular localization of the fluorescent
signal. By contrast, wortmannin triggered nuclear shuttling of
GFP–FOXO even at low nanomolar concentrations. PI-103 pro-
duced fluorescent precipitates at 50 mm and 33.3 mm, visible in
both the DAPI and the GFP channel, although nuclear accumu-
lation of GFP–FOXO was also evident under these conditions.
Importantly, exposure of U2foxRELOC cells to concentrations
as low as 46 nm of PI-103 or 15 nm of wortmannin was suffi-
cient to induce the nuclear translocation of the FOXO reporter
protein. The slightly greater potency of PI-103 in comparison
with PIK-75 on the recombinant p110a protein was reflected
by the small difference in the minimal effective concentration
at which accumulation of the fluorescent signal could be de-
tected in the U2foxRELOC system. In contrast to PI-103, PIK-75
was unable to induce significant translocation of the reporter
protein at 46 nm. Hence, the U2foxRELOC appeared to be a
very sensitive system to detect inhibitors of the PI3K/Akt path-
way with different potencies.
Chemical interrogation of nuclear–cytoplasmic shuttling of
FOXO by using the U2foxRELOC-based assay
We applied a chemical biology approach to study the signaling
network that regulates the intracellular localization of FOXO
transcription factors. Accordingly, we screened a panel of com-
pounds with known biological activity in the U2foxRELOC cell
system (see Table S1 in the Supporting Information for the
complete list of compounds studied). The initial test panel con-
sisted of 73 compounds known to interfere with the major
signal transduction pathways. A major concern when using
small molecules for pathway analysis is their specificity for
their corresponding target. To draw useful conclusions, it is rec-
ommended to use two structurally unrelated compounds for
each target[18] and therefore, we included several independent
small-molecule inhibitors for the same molecular target wher-
ever possible. Likewise, to distinguish on target and off target
effects, different concentrations of the compounds were as-
sessed in the primary screen. We exposed U2foxRELOC cells to
equal volumes of test compounds at final concentrations in a
range of two orders of magnitude around their IC50 value. As
reference compounds we used LY294002 and the nuclear
export inhibitor leptomycin B. To determine the cutoff thresh-
old for primary hits, the nuclear accumulation of fluorescence
triggered by LY294002 in the U2foxRELOC assay was defined
as 100% activity. Primary hits were defined as those samples
that have an activity above 60% and several test compounds
fulfilled these criteria (Figure 3A).
Ras farnesyltransferase inhibitor, manumycin A was shown to
be capable of inducing FOXO translocation into the nucleus.
Several small molecule compounds known to interfere with
the PI3K/Akt pathway, one of the major signaling branches
downstream of Ras, also induced nuclear FOXO translocation.
Namely, the Akt inhibitors, Akt inhibitor VIII, Akt inhibitor X, PI-
103, wortmannin, D000, and UCN01, were active in this assay
at concentrations previously reported to affect targets related
to PI3K/Akt signaling, demonstrating the capacity of the
U2foxRELOC system to identify inhibitors of the PI3K/Akt path-
way. In contrast, known activators of the PI3K/Akt pathway in-
cluding EGFP, IGF, PDGF, and insulin produced little nuclear lo-
calization of GFP–FOXO. However, insulin was the only factor
that decreased the number of cells with nuclear fluorescent
signal below the level of vehicle-treated cells. Rapamycin, is a
widely used inhibitor of mTOR that has no effect on GFP–
FOXO localization; this indicates that the rapamycin-sensitive
mTOR complex acts downstream of the PI3K/Akt-associated
signaling events relevant for the regulation of FOXO activity.
To analyze the involvement of alternative downstream Ras
signaling pathways in FOXO translocation, we tested several
compounds previously shown to interfere with different ele-
ments in the MAPK cascade. Inhibition of Raf1, Mek1/2, JNK, or
p38a MAP kinase upon treatment with GW5074, arctigenin,
U0126, PD98059, SP600125, JNK inhibitor VIII, or SB202190, did
not induce nuclear translocation of GFP–FOXO. Conversely, the
p38 MAP kinase inhibitor SB203580 triggered the accumulation
of nuclear fluorescence, although at a concentration that has
been shown to decrease Akt activity in several cell lines.[19,20]
As anticipated, staurosporine, a relatively nonselective protein
kinase inhibitor that blocks many kinases to a differing extent
was capable of inducing the nuclear accumulation of the
FOXO reporter protein. We analyzed the effect of six different
tyrosine kinase inhibitors on translocation in the U2foxRELOC
assay, including tyrphostatin SU1498, tyrphostin AG 82, tyr-
phostin AG 1478, tyrphostin AG 1433, tyrphostatin SU 1498,
genistein, and PP1 analogue. Only the broad tyrosine kinase
specific inhibitor genistein induced GFP–FOXO nuclear translo-
cation.
From a subgroup of drugs currently used in anticancer che-
motherapy and known to act through different molecular
mechanisms, including etoposide, camptothecin, cisplatin, oxa-
liplatin, flavopiridol, gemcitabine, paclitaxel, and vinblastine,
only the latter drug displayed activity in the U2foxRELOC
assay. Vinblastine has been shown to activate the JNK path-
way.[21] Whether FOXO translocation mediated by these drugs
is due to the activation of JNK and in turn, the phosphoryla-
tion of 14-3-3 protein, or the direct inactivating phosphoryla-
tion of FOXO3a remains to be determined. Roscovitine is a
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Figure 2. Dose-response relationship of the nuclear–cytoplasmic shuttling of FOXO following PI3K inhibition. A) We used LY294002, wortmannin, PIK-75, and
PI-103, four structurally unrelated PI3K inhibitors that inhibit the recombinant p110a protein with IC50 values of 500, 7.8, 3.7, and 0.57 nm, respectively.
[17]
U2foxRELOC cells were seeded in 96-well plates, incubated for 12 h, and treated with eleven different concentrations of LY294002, PIK-75, PI-103, or wortman-
nin ranging from 50 mm to 1.6 nm. After 1 h at 37 8C in medium containing one of each of the compounds, the cells were washed, fixed, and stained with
DAPI and photographed by using automated microscopy. The minimal effective concentration (MEC) is the lowest dose of each corresponding compound
that induced GFP–FOXO translocation, as determined by assessing 11 different concentrations. B) The graph shows the proportion of cells exhibiting nuclear/
cytoplasmic (Nuc/Cyt) ratios of fluorescence intensity greater than 1.8 for each treatment.
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potent pan-CDK inhibitor currently undergoing phase II clinical
testing that failed to induce FOXO protein translocation into
the nucleus. Hence, despite promoting a cytoplasmic localiza-
tion of FOXO1,[22] CDK-mediated phosphorylation is not in-
volved in the nuclear–cytoplasmic shuttling of the FOXO3a-re-
porter protein. Likewise, other CDK inhibitors, such as kenpaul-
lone, alsterpaullone, and purvalanol A, had no effect in this
assay.
As expected, exposure of U2foxRELOC cells to the nuclear
export inhibitor ratjadone A resulted in the nuclear accumula-
tion of fluorescent signal. In agreement with previous data,[23]
the calmodulin antagonists W-7, W-13, and calmidazolium
chloride (CDZ) also produced a positive result in the U2fox-
RELOC assay. The nuclear accumulation of fluorescent signal
was not attributable to shrinkage of the cell cytoplasm, as wit-
nessed by vital staining when using cell-tracker orange fluores-
cent dye (Figure 3B and data not shown).
Further analysis of the compounds that produce FOXO
ACHTUNGTRENNUNGrelocation
After screening the initial panel of compounds, we validated
the compounds of interest to identify those whose activity was
not specific for FOXO3a nuclear translocation using independ-
ent image-based translocation assays. To rule out general per-
turbations affecting the fluorophore, we tested the hit com-
pounds using a U2gfpRELOC assay based on U2OS cells stably
expressing GFP alone. GFP localization was unaffected upon
exposure to the compounds identified in the U2foxRELOC
assay (data not shown). Likewise, when analyzed in the U2nes-
RELOC assay, a cell-based system to detect inhibition of the
general export machinery, only the two known nuclear export
inhibitors, ratjadone A and leptomycin B, were shown to
induce nuclear trapping of the reporter protein (ref. [24] and
data not shown).
As specificity is closely correlated with the concentrations
used, we determined the minimal dose necessary to induce
the nuclear accumulation of GFP–FOXO for each hit compound
(Table 1). We performed dose-response experiments at eleven
different concentrations and ratjadone A, leptomycin B, PI-103,
wortmannin, and vinblastine were identified as the most
potent activators of GFP–FOXO nuclear translocation, acting in
the low nanomolar range. Submicromolar concentrations of
D000 were sufficient to induce nuclear shuttling of the report-
Figure 3. Nuclear accumulation of the GFP–FOXO reporter protein induced
by the test compounds. A) We exposed U2foxRELOC cells to three different
concentrations of the 73 compounds for 1 h. Bar graphs show the percent-
age of the cells in each well exhibiting nuclear/cytoplasmic (Nuc/Cyt) ratios
of fluorescence intensity greater than 1.8. Low, medium, and high concen-
trations are indicated by light gray, gray, and dark gray bars, respectively.
Untreated wells are indicated by U, control wells containing dimethyl sulfox-
ide, ethanol, LY294002, or leptomycin B are indicated by D, E, Ly, and L, re-
spectively. The data shown represent three independent experiments. B) The
morphology of U2foxRELOC cells remained unaffected by exposure to Akt
inhibitor X (AIX), vinblastine, or W13. U2foxRELOC cells were preincubated
with cell-tracker orange dye and exposed to the Akt inhibitor X (AIX, 5 mm),
vinblastine (100 nm), or W13 (20 mm). After 1 h at 37 8C, the cells were pro-
cessed as described in Figure 1.
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er protein whereas micromolar concentrations of manumycin
A, LY294002, Akt inhibitor, Akt inhibitor VIII, Akt inhibitor X,
staurosporine, genistein, CDZ, W-7, and W-13 were required to
obtain the same result.
Analysis of calcium signaling
We investigated whether the nuclear accumulation of the
FOXO-reporter protein upon exposure to the calmodulin (CaM)
inhibitors W-7, W-13, and CDZ was mediated by specific inhibi-
tion of CaM. We took advantage of a closely related naphtha-
lene-sulfonamide analogue that displays a very different inhibi-
tory profile on CaM. W-7 and W-13 inhibit the CaM regulated
activity of Ca2+-modulin-dependent phosphodiesterase at IC50
values of 28 mm and 68 mm, respectively.[25] The related W-12, a
compound that lacks chlorine, is a much less effective CaM
ACHTUNGTRENNUNGinhibitor[25] than W-7 or W-13, and it was used to distinguish
CaM-specific inhibitory effects from nonspecific drug effects.
Indeed, W-12 failed to produce nuclear translocation of the
FOXO reporter protein even at 50 mm (Figure 4B). Conversely,
the minimal effective concentrations of W-7 or W-13 necessary
to induce nuclear localization of GFP–FOXO were in good
agreement with the IC50 values reported previously for CaM
ACHTUNGTRENNUNGinhibition by these two naphthalene-sulfonamide analogues.
Taken together these data indicate that CaM is involved in reg-
ulating FOXO translocation.
To further study the implication of Ca2+ signaling in FOXO
shuttling, we used different chemical probes capable of alter-
ing the cellular Ca2+ homeostasis. When the reporter cells were
loaded with the intracellular Ca2+-chelator, BAPTA-AM, we con-
firmed the nuclear accumulation of the fluorescent signal, in
agreement with a role for Ca2+ signaling in mediating the nu-
clear translocation of FOXO3a. In addition, the extracellular
Ca2+-chelator EGTA also produced the nuclear accumulation of
the FOXO reporter protein, providing further evidence that in-
tracellular and extracellular Ca2+ regulates the subcellular local-
ization of FOXO proteins. In contrast, the increase in cytosolic
Ca2+ induced by caffeine, thapsigargin, or ionomycin did not
promote the nuclear retention of GFP–FOXO, nor did they re-
store its cytoplasmic localization when applied together with
W-7, W-13, and CDZ (Figure 4 and data not shown).
The molecular mechanisms by which the CaM antagonists
exert their effect on FOXO translocation were further explored
by examining the impact of inhibiting of multifunctional calci-
um/CaM-dependent protein kinases. KN-62 and K-93 inhibit
CaMKI, CaMKII, and CaMKIV, yet they had no effect on the sub-
cellular localization of FOXO. Likewise, when using ML-7 to in-
hibit the calcium/CaM-dependent protein kinase, myosin light-
chain kinase (MLCK), failed to induce nuclear accumulation of
the fluorescent reporter. Furthermore, inhibiting the CaM-
kinase-kinases (CaMKK), upstream activators of the calcium/
CaM-dependent protein kinases, CaMKI and CaMKIV, did not
reproduce the effect of CaM inhibition on FOXO translocation.
To explore the effect on Akt/PI3K signaling of the chemical
probes that interfere with Ca2+ signaling and that induce nu-
clear FOXO localization, we monitored the phosphorylation of
Akt. In Western blots probed with a specific antibody against
Akt Ser473, a dramatic decrease in Akt phosphoylation on
Ser473 was evident upon treatment with W-7, W-13, Bapta AM,
or EGTA. These data indicate a direct relationship between
blocking CaM activity and decreased Akt phosphorylation.
Discussion
Chemical genetics has emerged as an exciting new research
field that explores the interface between chemistry and biol-
ogy. In this study, we demonstrate the potential of chemical
genetics combined with high-content screening to dissect out
the complex regulation of the subcellular localization of FOXO
transcription factors. We established U2foxRELOC, a quantita-
tive cell-based high-content screening assay that monitors the
nuclear–cytoplasmic translocation of a GFP–FOXO3a fusion
protein. Herein, U2foxRELOC was used to obtain quantitative
information about the impact of different PI3K inhibitors on
downstream signaling, to perform a large-scale chemical ge-
netic study with a panel of test compounds. We also used this
system to analyze the effect of chemical probes that modulate
Ca2+ signaling on the nuclear–cytoplasmic shuttling of a FOXO
reporter protein. High-throughput cellular imaging has ena-
bled us to measure the minimal effective concentration of dif-
ferent PI3K inhibitors necessary to induce nuclear shuttling of
a FOXO reporter protein. Using this approach we screened a
panel of 73 compounds with a known mechanism of action
and we identified 17 compounds that induced the nuclear ac-
cumulation of the fluorescent reporter. The majority of these
small molecules are known inhibitors of the PI3K/Akt pathway
confirming the essential role of signaling through PI3K, PDK1,
and Akt in regulating the subcellular localization of FOXO pro-
teins. Interestingly, D000 a compound claimed to specifically
Table 1. The compounds capable of inducing the nuclear accumulation
of GFP–FOXO and their main molecular targets.
COMPOUND TARGET MEC [mm][a]
manumycin A Ras-farnesyltransferase 11.1
LY294002 PI3K 11.1
wortmannin PI3K 0.015
PI-103 PI3K 0.046
PIK-75 PI3K 0.41
D000 PI3Kd 11.1
Akt inhibitor Akt 11.1
Akt inhibitor VIII Akt 3.7
Akt inhibitor X Akt 3.7
UCN01 PDK1, other protein kinases 0.045
staurosporine protein kinases 11.1
leptomycin B CRM1 0.045
ratjadone A CRM1 0.045
genistein tyrosine protein kinases 11.1
vinblastine tubulin 0.045
W7 CaM 11.1
W13 CaM 11.1
calmidazolium chloride CaM 11.1
[a] The minimal effective concentration (MEC) is the lowest dose of each
corresponding compound that induced GFP–FOXO translocation, as de-
termined by assessing 11 different concentrations.
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inhibit p110d,[26] was capable of inducing the translocation of
the GFP–FOXO reporter. These data are in agreement with our
previous observation that a constitutively active form of p110d
efficiently induced the activation of Akt in Rat1 fibroblasts.[27]
However, whether the nuclear shuttling of the FOXO reporter
protein on exposure to D000 is due to the specific inhibition
of the delta isoform of PI3K remains to be determined.
We tested an extensive panel of chemotherapeutic agents
reported to target a variety of cellular macromolecules includ-
ing topoisomerase I, topoisomerase II, thymidylate synthetase,
DNA, tubulin, and cyclin-dependent kinases. However, the ma-
jority of these drugs failed to produce nuclear trapping of
GFP–FOXO. Although the tubulin-targeting agent paclitaxel
has been shown to induce nuclear translocation in MCF7
cells,[28] it had no impact on the subcellular translocation of
GFP–FOXO in the U2foxRELOC assay. These differences might
be due to the experimental setting or the different cell lines
used in these experiments. Indeed, FOXO translocation in
MCF7 cells was identified after 16 h in the presence of paclitax-
el, whereas U2foxRELOC were exposed to paclitaxel for only
1 h.[28] Conversely, we identified the vinca alkaloid vinblastine
as a very potent FOXO translocating agent, active in the low-
nanomolar range. Vinblastine is a microtubule-depolymerizing
drug whose mode of action has been characterized.[29] Our
data suggest that the molecular mechanisms employed for the
nuclear translocation of FOXO factors following exposure to
the small tubulin-binding molecules paclitaxel and vinblastine
differ. Paclitaxel and vinblastine bind to different sites in tubu-
lin and they promote microtubule bundling or microtubule
disassembly in vitro, respectively. Whether these contrasting
ACHTUNGTRENNUNGeffects on microtubule dynamics account for the different be-
havior observed in the U2foxRELOC assay remains to be deter-
mined.
Figure 4. A) Nuclear accumulation of the GFP–FOXO reporter protein following treatment with chemical probes that interfere with Ca2+ signaling. Bar graphs
show the percentage of cells in each well exhibiting nuclear/cytoplasmic (Nuc/Cyt) ratios of fluorescence intensity greater than 1.8. Untreated wells are indi-
cated by U, control wells containing dimethyl sulfoxide, ethanol, LY294002, or leptomycin B are indicated by D, E, LY, and LMB, respectively. We exposed U2-
ACHTUNGTRENNUNGfoxRELOC cells to W7 (20 mm), W13 (20 mm), calmidazolium chloride (CDZ, 20 mm), W12 (50 mm), KN62 (30 mm), KN93 (30 mm), ML-7 (30 mm), STO-609
(1 mgmL1), Bapta AM (100 mm), EGTA (5 mm), caffeine (4 mm), thapsigargin (200 nm), ionomycin (200 nm), and to thapsigargin (200 nm) in the presence of
W7 (20 mm), W13 (20 mm), or CDZ (20 mm). The data shown represent three independent experiments. B) Representative images of treated cells by using the
high-throughput format of the U2foxRELOC system. Images of fixed and DAPI-stained cells were taken by automated microscopy 1 h after drug exposure.
Images corresponding to U2foxRELOC cells exposed to W7 (20 mm), W12 (200 mm), Bapta AM (100 mm), EGTA (5 mm), KN62 (30 mm), STO-609 (1 mgmL1), ML-7
(30 mm), or W7 (20 mm) in the presence of thapsigargin (200 nm) are shown. C) Immunoblot analysis of total lysates from U2foxRELOC cells exposed to DMSO
(1%), W7 (20 mm), Bapta AM (100 mm), EGTA (5 mm), W12 (50 mm), thapsigargin (200 nm), or LY294002 (20 mm) for 1 h. A representative experiment is shown
and the relevant proteins are indicated by arrows.
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The inhibition of the Ca2+-binding protein CaM produces the
nuclear accumulation of FOXO proteins in cell assays based on
the immunodetection of transiently expressed reporter pro-
tein.[23] We confirmed this observation using U2foxRELOC, a
technology based on the stable expression of a genetically
tagged FOXO reporter protein. Importantly, we extended previ-
ous data regarding the implication of Ca2+-signaling in the reg-
ulation of FOXO transcription factors by analyzing the effect of
several chemical probes in the U2foxRELOC assay and on Akt
phosphorylation.
Chemical genetic analysis of the Ca2+-dependent regulation
of FOXO localization revealed the important role of intra- and
extracellular calcium concentrations. Calcium/calmodulin-regu-
lated FOXO-translocation is not directly mediated either by
multifunctional or dedicated calcium/CaM-dependent protein
kinases, or by upstream CaM-kinase-kinases. This is consistent
with a model in which low calcium concentrations decrease
the activity of CaM, in turn inhibiting Akt and the translocation
of FOXO proteins into the cell nucleus. Akt associates with
CaM in mouse mammary carcinoma cells and has been pro-
posed as a CaM-binding protein.[30] However, whether a de-
crease in CaM-binding induces the nuclear translocation of
FOXO proteins by directly affecting Akt activity remains to be
explored. CaM expression is altered in several cancers and its
inhibition might be a strategy to restore the tumor suppressor
activity of the FOXO factors.
In summary, our data demonstrate that U2foxRELOC is a
sensitive and robust assay system suitable for identifying
small-molecule inhibitors of signaling events that regulate the
subcellular localization of FOXO proteins. The signaling events
identified here include PI3K/Akt signaling, nuclear export, and
calcium/CaM-dependent signaling. This work illustrates the
power of chemical genetics combined with image-based cellu-
lar screening to analyze signaling pathways. Moreover, our
data raise expectations that a more extensive chemical inter-
rogation of the nuclear–cytoplasmic shuttling of FOXO could
lead to the identification of new molecular targets and small
molecules that might aid the development of more potent
therapeutic agents to treat tumors.
Experimental Section
Compound supply and recombinant proteins : A complete list of
compounds used in the present study is given in Table 1 of the
Supporting Information. The PI3K inhibitors PIK-75 and PI-103 were
synthesized according to published patent specifications. UCN01
and flavopiridol were kindly provided by the NCI, National Insti-
tutes of Health, cisplatin was provided by C. Navarro, minerval was
generously provided by P. Escriba, and gemcitabine was a gift from
Eli Lilly Pharmaceuticals (Indianapolis, IN). All other chemicals were
purchased from commercial sources. Akt inhibitor, Akt inhibitor VIII,
Akt inhibitor X, alsterpaullone, Bapta-AM, Bay11–7082, ionomycin,
JAK3 inhibitor VI, JNK inhibitor VIII, kenpaullone, KN62, KN93,
LY294002, MG132, ML-7, NL71–101, PD98059, PP1, purvalanol A,
ratjadone A, SB202190, SB203580, W-13 HCl, W-7 HCL, W-12 HCL,
and wortmannin were purchased from Calbiochem (San Diego, CA,
USA). Brefeldin, cyclosporin A, forskolin, genistein, H89, leptomy-
cin B, rapamycin, roscovitine, thapsigargin, tyrphostatin AG 1478,
tyrphostatin SU1498, and U0126 were purchased from LC Labora-
tories. (Woburn, MA, USA); D-609, LY83583, manumycin A, pifithrin-
a cyclic, rifampicin, tyrphostin AG 82, and tyrphostin AG 1433 were
purchased from Alexis Biochemicals (San Diego, CA, USA); Caffeine,
calmidazolium chloride, EGTA, etoposide, GW5074, hydrocortisone,
nicotinamid, oxaliplatin, paclitaxel, staurosporine, STO-609, 12-O-
tetradecanoylphorbol-13-acetate (TPA), trichostatin A, and vinblas-
tine were purchased from Sigma–Aldrich.
Arctigenin, SL327 and SP6000125 were purchased from Biaffin
(Kassel, Germany); lithium chloride (LiCl) was purchased from
Merck; D000 was purchased from Labotest (Niederschoena, Germa-
ny); epidermal growth factor (EGF), and platelet-derived growth
factor (PDGF) were purchased from RELIATech A.S. (Braunschweig,
Germany) and human insulin-like growth factor-I (IGF-I) and human
insulin were purchased from Roche Diagnostics. Stock solutions of
the test compounds were deposited in three different concentra-
tions onto 96-well mother plates, transferred to multiple replica
plates, and frozen at 80 8C.
Generation and maintenance of U2foxRELOC and U2gfpRELOC
cells : U2-OS cells obtained from the ATCC were cultivated as indi-
cated. These cells were transfected at confluence with the plasmid
containing the GFP–FOXO3a fusion protein (a gift from T. Finkel) as
described by Zanella et al,[24] or that containing EGFP alone, by
using the effectene transfection reagent (Qiagen). Selection was
performed with G418 (1 mgmL1, Calbiochem) for one week and
the resistant colonies were then cultured selecting those that best
expressed the reporter by FACS, as well as the most homogeneous
population. The selected clones, designated as U2foxRELOC or
U2gfpRELOC, were then cultured in Dulbecco’s modified Eagle’s
medium (DMEM; Sigma) supplemented with 10% FBS (Sigma),
ACHTUNGTRENNUNGantibiotics (penicillin, streptomycin), antimycoplasm (plasmocin),
and G418 at 100 mgmL1.
Compound administration and relocalization assay : The U2fox-
RELOC-based assay was formatted in 96-well plates and workflow
has been automated. All liquid handling for compound treatment,
washing, fixing, and staining steps was performed by a robotic
workstation.[31] Clonal U2foxRELOC cells were seeded at a density
of 1.0Q105 cellsmL1, in black-walled clear-bottomed 96-well mi-
croplates (BD Biosciences), in a final volume of 200 mL per well
ACHTUNGTRENNUNGdistributed by using a multidrop automatic dispenser. Cells were
allowed to attach for 12 h at 37 8C in an atmosphere of 5% CO2,
and each test compound was then automatically administered to
the assay plates in 2 mL by using a robotic workstation (Biomek
1000, Beckman). Treated cells were then incubated for 1 h before
the culture medium was aspired, the cells were washed with PBS
twice, and they were fixed in paraformaldehyde (100 mL, 6%) for
30 min at RT. The fixed cells were then washed twice with PBS and
stained with DAPI (Invitrogen) for 20 min at RT to define the nu-
cleus. The DAPI solution was removed by aspiration and finally, the
plates were washed with PBS twice and stored in the dark at 4 8C
before analysis. Vital staining with the cell-tracker orange (CMTMR)
fluorescent dye (Invitrogen) was performed following the manufac-
turer’s guidelines. As such, cell-tracker orange working solution
(5 mm) was added to the assay plates and incubated at 37 8C. After
30 min the dye solution was replaced with fresh medium, and the
cells were incubated for another 30 min. Cells were then fixed and
processed as described above.
Assay readout : Assay plates were read on the BD PathwayR 415
Bioimager equipped with a 488/10 nm EGFP excitation filter, a 380/
10 nm DAPI excitation filter, a 515 LP nm EGFP emission filter, and
a 435 LP nm DAPI emission filter. Images were acquired in the
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DAPI and GFP channels of each well by using 20Q dry objective.
The plates were exposed for 0.066 ms (Gain 31) to acquire DAPI
images and 0.55 ms (Gain 30) for GFP images.
Data analysis : Data was exported from the BD Pathway Bioimager
as text files and imported into the data analysis software BD Image
Data Explorer for processing. The nuclear/cytoplasmic (Nuc/Cyt)
ratios of fluorescence intensity were determined by dividing the in-
tensity of the GFP fluorescence from the nucleus by that in the cy-
toplasm. We applied a threshold ratio of greater than 1.8 to define
nuclear accumulation of fluorescent signal for each cell. Based on
this procedure we calculated the percentage of cells per well ex-
hibiting nuclear translocation. Compounds that induced nuclear
accumulation of the fluorescent reporter above 60% of the signal
obtained from wells treated with 20 mm LY294002 were considered
as hits.
Western blot analysis : Subconfluent cells were incubated under
different conditions and washed twice with TBS prior to lysis. Lysis
buffer was added containing 50 mm Tris HCl, 150 mm NaCl, 1%
NP40, 2 mm Na3VO4, 100 mm NaF, 20 mm Na4P2O7, and protease in-
hibitor cocktail (Roche Molecular Biochemicals). The proteins were
resolved on 10% SDS-PAGE and transferred to nitrocellulose mem-
brane (Schleicher & Schuell, Dassel, Germany). The membranes
were incubated overnight at 4 8C with antibodies specific for Akt,
phospho-Ser-473-Akt (Cell Signaling Technology), phospho-Thr32-
FOXO3a (Upstate), and a-tubulin (Sigma), they were washed and
then incubated with IRDye800 conjugated anti-mouse and Alexa
Fluor 680 goat anti-rabbit IgG secondary antibodies. The bands
were visualized by using an Odyssey infrared imaging system (Li-
Cor Biosciences).
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3.2.2 Fifth Project: A large scale RNAi screening for novel genes implicated in 
FOXO regulation. 
 
Summary 
Luciferase-based reporter assays have been widely used for a transcriptional readout 
of interference with pathways that culminate in the activation or repression of 
transcription factors. Taking advantage of that technology we generated the 
293foxREP system, in which firefly luciferase transcription occurs upon FOXO 
activation and binding to its recognition sequence, DBE. The assay was adapted to a 
high throughput fashion to perform a large scale RNAi screening in which genes 
previously implicated in PI3K/Akt signaling events known to be important for FOXO 
function appeared as positive hits. This screening also confirmed our chemical genetics 
results, as calmodulin was obtained as a positive hit. shRNA targeting calmodulin also 
triggered FOXO3A transcriptional activity, strengthening the notion that inhibition of 
Calmodulin plays an important role in FOXO activation. Most importantly, we revealed 
a previously unrecognized FOXO-repressor function of the pseudokinase TRIB2, the 
mammalian homolog of the drosophila gene tribbles. TRIB2 expression was found to 
be elevated in malignant melanoma and our functional studies suggested that TRIB2 
plays a fundamental role in those skin neoplasias by maintaining the tumorigenic 
potential of those cells. 
 
Personal contribution 
I generated the 293foxREP cell-based system and performed the experiments 
required for its validation and adaptation to the high-throughput format. Once 
established, I performed the complete screening of the NKI shRNA library, confirmed 
and validated the hits obtained. The further experiments referring to TRIB2 
characterization in the melanoma system were carried out by me with punctual 
assistance of Beatriz García and Sergio Callejas. All the data analysis and 
interpretation were carried by me. 
 
Publication: 
 
Zanella F, Renner O, García B, Callejas S, Dopazo A, Carnero A and Link W. Human 
TRIB2 is a repressor of FOXO-function required for the maintenance of the 
malignant phenotype of melanoma cells. Manuscript currently in preparation.
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FOXO transcription factors are evolutionarily conserved proteins that 
orchestrate programs of gene expression known to control a variety of 
cellular processes such as cell cycle, apoptosis, DNA repair and 
protection from oxidative stress. Since the abrogation of FOXO function is 
a key feature of many tumor cells, regulation of the FOXO factors is 
receiving increasing attention in cancer research. In order to discover 
genes involved in the regulation of FOXO activity, we performed a large-
scale RNAi screen using cell based reporter systems that monitor 
transcriptional activity and subcellular localization of FOXO. We identified 
genes previously implicated in PI3K/Akt signaling events which are known 
to be important for FOXO function. In addition, we discovered a previously 
unrecognized FOXO-repressor function of TRIB2, the mammalian 
homolog of the drosophila gene tribbles. A cancer profiling array revealed 
specific overexpression of TRIB2 in malignant melanoma, but not in other 
types of skin cancer. We provide experimental evidence that the TRIB2 
transcript levels correlate with the degree of the cytoplasmic localization 
of FOXO3a. Moreover we show that TRIB2 is important in the maintenance 
of the oncogenic properties of melanoma cells since its silencing reduces 
cell proliferation, colony formation and wound healing. Tumor growth  
was also substantially reduced upon RNAi-mediated TRIB2 knockdown in 
an in vivo melanoma xenograft model. Our studies suggest that TRIB2 
provides the melanoma cells with growth and survival advantages 
through the abrogation of FOXO function. Altogether, our results 
demonstrate the potential of large scale cell-based RNAi screens to 
identify promising diagnostic markers and therapeutic targets. 
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Introduction 
FOXO transcription factors are bona fide tumor suppressors that are inactivated 
in the majority of human cancers, due to the overactivation of the PI3K/Akt 
pathway (1). The four members of mammalian FOXO proteins - FOXO1, 
FOXO3a, FOXO4 and FOXO6 - belong to the class O of the forkhead/winged 
helix transcription factors (Fox). FOXO proteins can regulate a variety of genes 
that influence cell proliferation, survival, metabolism and responses to stress 
(2). The FOXOs are regulated via synthesis, phosphorylation, acetylation and 
ubiquitination at three different levels: subcellular localization, stability and 
transcriptional activity (3). Upon the activation of PI3K/Akt, signaling FOXOs 
undergo Akt-mediated phosphorylation, which promotes binding to 14-3-3, 
nuclear export via CRM1 and cytoplasmic sequestration. In stress conditions or 
in the absence of growth or survival factors when the PI3K/Akt pathway is 
inhibited, FOXO proteins translocate to the cell nucleus, where their 
transcriptional functions can be executed (4).  
Triple knockout mouse models proved the tumor suppressor properties of 
FOXOs, as mice lacking the principal members of the mammalian FoxO 
subfamily FoxO1, FoxO3a and FoxO4 simultaneously are prone to develop 
hemangiomas and lymphoproliferative diseases (5). Conversely, the individual 
or paired inactivation of FoxO1, FoxO3a or FoxO4 resulted in a less severe 
phonotype supporting the idea of functional redundancy of these FOXO factors 
(5). Furthermore, forced expression of FOXO has been shown to curb 
tumorigenesis in xenograft experiments using human tumor-cell-lines grown in 
nude mice (6, 7). Therefore, reactivation of FOXO based on its tumor 
suppressor properties is considered as a very attractive anti-cancer strategy. 
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Contrary to other tumor suppressors like p53 or PTEN whose functions are 
abrogated via genetic or epigenetic changes, inactivation of FOXO occurs 
mostly due to the overactivation of their inhibitory inputs (1). That offers a wide 
range of possibilities for restoring FOXO activity with small molecule inhibitors 
targeting up-regulated FOXO repressors. Nevertheless, since FOXO also 
induces genes involved in resistance to cellular stress, including the multidrug 
resistance gene ABCB1 (8, 9) such a strategy has to be carefully evaluated and 
the most suitable points of intervention must be identified. The transcriptional 
program finally executed by FOXO is thought to be dependent on the pattern of 
its post-transcriptional modifications (10). Hence, the characterization of the 
components that participate in the signaling network that controls the activity of 
FOXO is essential to reveal possible therapeutic targets for future anticancer 
therapies. In order to identify endogenous suppressors of FOXO which could be 
exploited pharmacologically to restore FOXO function in human tumors we 
conducted a systematic large-scale loss-of-function screening. Among the 
genes identified and validated as negative FOXO regulators we found the 
pseudokinase TRIB2. In vitro and in vivo results reported here indicate that 
TRIB2 can facilitate the growth and survival of melanomas by downregulating 
FOXO activity 
 
Results 
 
Generation of the assay cell line 293foxREP 
FOXO proteins bind to TTGTTTAC FOXO responsive enhancer element, 
generally referred to as daf-16 family protein-binding element, DBE (11) and 
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drive transcription of downstream genes. In order to establish a cell line capable 
of measuring the transcriptional activity of FOXO and suitable for a transfection-
based RNAi screening we introduced the reporter construct pGLpuro-3xDBE 
(Zanella et al, in press) into HEK293T cells. pGLpuro-3xDBE contains three 
copies of the DBE consensus cassette in front of a SV40 minimal viral promoter 
linked to a luciferase reporter gene and a puromycin-resistance cassette (Fig 
S1A). Stable 293foxREP cells displayed a strong responsiveness to the 
inhibition of the PI3K/Akt pathway (Fig. S1B) and hence proved to be suitable 
tools to screen for the interference with FOXO regulation. 
 
Screening of a RNAi library against 7914 human genes 
The identification of components implicated in the regulatory network that 
determines the activity of FOXO proteins is an essential step to develop 
targeted therapies that reactivate specific FOXO functions in human tumors. 
Hence we performed a large scale loss of function screen aimed at the 
identification of genes that suppress transcriptional activity and the nuclear 
localization of FOXO transcription factors (Fig. S2). We employed a vector-
based RNAi library with 23742 shRNAs against 7914 genes that has been 
widely used for target discovery efforts (12, 13). We introduced these shRNA 
constructs in pools of three RNAi per gene into 293foxREP cells and monitored 
the activation of firefly luciferase, normalizing these values against the 
luminescence that resulted from Renilla luciferase. Those pools of shRNAs that 
caused activation of normalized luciferase activity greater than three fold when 
compared with the control shRNA vector were analyzed for its capacity to 
induce nuclear translocation of FOXO in the U2foxRELOC system that has 
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been described previously (14). Briefly, U2foxRELOC cells stably express a 
GFP-tagged version of FOXO3a to monitor the subcellular localization of FOXO 
proteins. We prioritized those hits scoring positive in both 293foxREP and 
U2foxRELOC cells (Table 1). Among these dual hits were several genes known 
to be part of the PI3K/Akt signalling cascade, including PIK3CA and Akt-3, 
indicating the specificity of our screening strategy. Importantly, several genes 
previously not associated with the regulation of FOXO activity were identified. 
 
Validation of TRIB2 silencing 
The RNAi mediated silencing of TRIB2, the human homolog of the Drosophila 
gene tribbles, resulted in the induction of FOXO-dependent transcription in 
293foxREP cells and the nuclear translocation of GFP-FOXO in U2foxRELOC 
cells. We isolated and verified the sequences of the corresponding shRNA pool. 
qPCR analysis revealed that two of the three shRNAs of the silencing pool were 
capable of reducing TRIB2 transcript levels. In order to validate our findings with 
independent RNAi agents against TRIB2, we analyzed different siRNA 
oligonucleotides as well as vector based shRNA constructs for their efficiency to 
silence the expression of TRIB2. These shRNAs and siRNAs were chosen to 
contain different sequences 5´-portion of the guide strand which has been 
implicated in unintended transcript silencing (15) Several RNAi-based agents 
effectively reduced the expression of TRIB2 (Table S1). Two different vector 
based shRNA constructs - TRIB2NKI shRNA and TRIB2ORI shRNA - proved to be 
the most efficient tools to silence TRIB2 and were used for further analysis. 
Figure 1A shows the reduction of TRIB2 mRNA upon the transfection of 
HEK293T cells with TRIB2NKI shRNA as compared with cells transfected with 
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the corresponding control vector. Importantly, the transient expression of 
TRIB2NKI shRNA resulted in increased FOXO-driven luciferase activity (Fig. 1B). 
and the nuclear localization of GFP-FOXO (Fig.1C and D). In contrast, 
unrelated shRNA sequences failed to produce similar effects on FOXO (data 
not shown). On the other hand, the overexpression of a V5-tagged versions of 
TRIB2 which was detected by western blot analysis using a V5-specific 
antibody (Fig 2A) markedly decreased FOXO-driven luciferase activity in 
293foxREP cells (Fig. 2B). These results suggest that TRIB2 act as a repressor 
of FOXO promoting its cytoplasmatic sequestration and impairing its 
transcriptional functions. 
 
TRIB2 transcript levels are elevated in malignant melanoma 
The implication of TRIB2 in the regulation of the tumor suppressor FOXO 
prompted us to analyze its expression levels in human tumors. To that end, we 
used a cancer profiling array containing samples from 154 patients with different 
tumors including breast, ovary, colon, stomach, lung, kidney, bladder, vulva, 
prostate, uterus, cervix, rectum, thyroid, testis, skin, small intestine and 
pancreas. For this array, cDNAs generated from matched normal and tumor 
tissue samples from individual patients had been spotted side by side on a 
nylon membrane. In addition cDNAs from nine different cancer cell lines have 
been included (Figure S3). Interestingly, elevated levels of TRIB2 mRNA were 
observed in seven out of ten skin cancer samples (Fig. 3A and B). Moreover, 
the seven samples that showed high TRIB2 expression correspond to malignant 
melanoma lesions (Fig. 3A: P1-P5, P9; P10) while the remaining three samples 
(Fig. 3A: P5, P6 and P7) that did not display a significant increase of TRIB2 
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transcripts refer to squamous-cell carcinomas (Table S2). Consistently, we 
detected the highest levels of TRIB2 transcripts in G-361 melanoma cells when 
compared to eight other non-melanoma cells represented on the same 
membrane (Fig. 3C and D). In order to confirm this observation we analyzed an 
independent arrayed panel of 43 prenormalized cDNAs selected from normal 
and melanoma tissues and from mixed ages and genders (Table S3). qRT-PCR 
analysis of these samples revealed a significantly increased level of TRIB2 
expression in malignant melanoma diagnosed at stage III or IV when compared 
with normal skin tissues (Figure S2C). The same pattern was reproduced when 
the mRNA level of TRIB2 was analyzed in a panel of melanoma cell lines 
versus non-melanoma cell lines by qRT-PCR. We detected an abundance of 
TRIB2 transcripts between three and 23 times greater in cell lines derived from 
melanoma biopsies than in non-melanoma cells including keratinocytes and 
fibroblasts (Fig. 4A). Interestingly, human epidermal melanocytes also displayed 
high levels of TRIB2 transcripts. The levels of Bim, a pro-apoptotic molecule 
transcriptionally regulated by FOXO were also assessed. We observed a direct 
inverse correlation between the transcript levels of TRIB2 and Bim (Fig. 4B). In 
human epidermal melanocytes and melanoma cells high expression of TRIB2 
coincides with very low levels of Bim transcripts. In contrast, non-melanoma cell 
lines with low level of TRIB2 transcription displayed increased abundance of 
Bim transcripts.  Taken together these data suggest that the overexpression of 
TRIB2 leads to the reduction of FOXO-dependent transcriptional activity in 
melanocyte- derived cells. 
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TRIB2 is regulated by calcium signalling in melanoma 
TRIB2 has been previously reported to be a highly inducible gene under specific 
cellular conditions (16, 17). To investigate the mechanisms and signalling 
events that are implicated in TRIB2 activation in melanoma we treated G-361 
cells with a panel of inhibitors or activators of known signalling cascades for 6 
hours and total mRNA has been extracted for qRT-PCR analysis. Interestingly, 
the treatment of G-361 melanoma cells with thapsigargin and caffeine, two 
agents that have been shown to initiate a rise in intracellular Ca2+ significantly 
increased in the levels of TRIB2 transcripts (Fig 5). The results obtained here 
suggest that calcium signalling might be responsible for the elevated level of 
TRIB2 transcripts in melanocyte-derived cells. 
 
TRIB2 knockdown increases the activity of FOXO in melanoma 
To assess the influence of TRIB2 on FOXO functions in melanoma, G-361 
human melanoma cells were adopted as a model, as they display increased 
levels of TRIB2 mRNA (see above). G-361 cells stably expressing a GFP-
FOXO3a fusion protein and the FOXO-driven luciferase reporter construct 
pGL3puro-3xDBE, hereafter designated as G-361FireFox, were transiently 
transfected with shRNA agents against TRIB2, PIK3CA, Akt or their respective 
empty control plasmids. A significant increase in luciferase-produced 
luminescense was detected upon silencing of TRIB2, coincident with the 
nuclear relocalization of the GFP-FOXO fusion protein. The effect obtained was 
comparable to FOXO stimulation via the knockdown of PI3K or Akt (Fig 6). 
These data support the hypothesis that TRIB2 may function as a FOXO 
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repressor and proves this model to be suitable to analyze the role of TRIB2 in 
malignant melanoma.  
 
TRIB2 facilitates the growth and survival of melanoma cells 
In order to investigate the importance of TRIB2 for melanoma cells, we 
developed a stable knockdown system for TRIB2.  G-361 melanoma cells were 
transfected either with a control vector or with a shRNA against TRIB2. Stable 
cells were isolated via puromycin selection resulting in the cell lines 361C and 
361shTRIB, respectively. TRIB2 mRNA levels in these cell lines were monitored 
by qRT-PCR.  Figure 7A shows that continuous silencing of TRIB2 in 
361shTRIB cells led to a tenfold decrease of TRIB2 mRNA compared to the 
transcript level in 361C cells.  
In order to explore the role of TRIB2-mediated FOXO inactivation in melanoma 
we assessed the tumorigenic properties of the generated melanoma knockdown 
system. 361C and 361shTRIB cells were seeded in triplicates in 6-well plates, 
maintained in standard growth factor conditions and cell growth was monitored 
every other day by crystal violet staining. At day 10 cells were lyzed and the 
measured absorbance of the lysis products was taken as an indirect 
measurement of the cell growth at each day. 361shTRIB cells showed a 
significantly decreased proliferation rate when compared to 361C cells (Fig. 
7B), indicating that TRIB2 expression confers growth advantage to those 
melanoma cells. To determine whether TRIB2 influences the ability of 
melanoma cells to overcome apoptosis in the absence of cell contact, 104 361C 
or 361shTRIB cells were seeded at low density in 10 cm plates in triplicates and 
allowed to grow over a period of 10 days when cells were fixed, stained and the 
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number of colonies was quantified. 361C cells were considerably more efficient 
in bypassing the barriers of low density seeding than 361shTRIB cells, as the 
latter generated a significantly reduced number of colonies in this assay (Fig. 
7C). 
The ability of these cells to grow in anchorage-independent conditions was 
analyzed by seeding 105 cells from both cell lines in soft agar and allowing them 
to grow for one month. Importantly, 361C cells produced a significantly greater 
number of foci than 361shTRIB cells (Fig. 7D). Furthermore, the foci formed by 
361shTRIB cells displayed increased size and pigmentation (Fig 7E). 
To investigate the influence of TRIB2 in the migration properties of melanoma 
cells, both cell lines were seeded in 24 well plates and allowed to reach 
confluence. At that point, a wound was produced in the central vertical axis of 
each well, the growth medium was replaced and a fixed point of reference for 
microscopic photography was set. Pictures taken every 24 hours indicated a 
greater efficiency of 361C cells in refilling the wounded area, closing of the 
wound over a period of 72 hours, while 361shTRIB cells were unable to refill the 
wounded area even 96 hours after the wound had been created. (Fig. 7F). 
Furthermore, 361shTRIB cells showed contact inhibition upon reaching 
confluence, while 361C cells piled up and formed colonies beyond the cell 
monolayer, a feature of transformed cells. Taken together, these results support 
the hypothesis that TRIB2 is necessary for the maintenance of the tumorigenic 
properties of melanoma cells. 
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TRIB2 knockdown impairs melanoma growth in vivo 
To investigate the possible effects of TRIB2 knockdown in a tumorigenic 
process in vivo, 7 x 105 361C or 361shTRIB cells respectively were xenografted 
subcutaneously in ZSCID mice, and their respective tumor growth was followed 
over a period of 10 weeks. Once a week, tumors were measured and their 
volumes calculated as described in Material & Methods. Tumor development 
occurred significantly faster in those mice injected with control cells (361C) 
when compared with animals in which TRIB2 knockdown cells (361shTRIB) 
have been implanted (Fig 8A). Except for time point day 34, the comparison of 
the tumor volumes of the two mouse cohorts was statistical significant. The p-
values for the time points day 41 to day 69 were 0.0075, 0.0024, 0.0082, 
0.0149, and 0.0080, respectively. On day 69 pictures taken from the animals 
before sacrifice and after tumor resection show a clear difference in the in vivo 
growth potential of the cell populations implanted (Fig 8B). While 361C cells 
produced larger, spherical tumors 361shTRIB cells could rarely grew beyond a 
few mm3. 
 
Discussion 
The advent of RNA-mediated interference (RNAi)-based functional genomics in 
mammals paved the way for unbiased screens in human cell systems. In the 
present work we report a large scale loss of function screen aimed at the 
identification and validation of gene targets involved in the framework of 
signalling events that control the activity of FOXO transcription factors. 
Based on two independent cell-based systems which were shown to effectively 
report FOXO-dependent transcriptional activity and the subcellular localization 
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of GFP-FOXO fusion protein, we screened a vector-based RNAi expression 
library that direct the synthesis of short hairpin RNAs targeting 7,914 different 
human genes for suppression. Those genes whose silencing produced positive 
hits in both screening systems were included in the high confident list of FOXO 
suppressors. PIK3CA and Akt-3, both components of the canonical PI3K/Akt 
pathway were among these selected genes. Interestingly, silencing of the Ca2+-
binding protein Calmodulin 2 increased FOXO driven luciferase activity and 
induced nuclear translocation of FOXO reporter protein. These data are in 
agreement with the previous observation that inhibition of Calmodulin by its 
specific small molecule inhibitors W7, W13 and Calmidazol led to the nuclear 
accumulation of FOXO (14) and strengthens the notion that calcium signaling is 
an important factor influencing the subcellular localization of FOXO. The 
presence of genes within our priority list that are known to be involved in the 
regulation of FOXO validated the specificity of our screening systems. Among 
the genes that have not been associated previously with FOXO functions we 
identified TRIB2, the human homolog of the Drosophila gene tribbles. Tribbles 
has been reported to regulate ventral furrow formation in Drosophila through 
binding to String/CDC25 (2). The three human orthologs of tribbles, namely 
TRIB1, TRIB2 and TRIB3 share a strong similarity in their peptide sequence, 
consisting essentially of their pseudokinase domain (16, 18).  
We found TRIB2 highly expressed specifically in melanoma malignancies, 
melanocyte-derived cells and melanoma cell lines. Interestingly, overexpression 
was not observed in samples from other tumor sources, including non-basal 
skin carcinoma. Our data suggest a potential use of TRIB2 as a diagnostic 
marker for detection of malignant melanoma, although more studies are needed 
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to confirm its utility as a tool in a diagnostic setting. Further experiments 
including a larger patient cohort with survival information also must elucidate its 
clinical significance. 
The regulatory mechanisms that maintain high TRIB2 expression in 
melanocyte-derived cells remain unknown at present. TRIB2 expression might 
be regulated by lineage-specific signaling events such as the signal 
transduction cascade initiated by c-kit shown to modulate the activity and 
stability of the tissue-restricted dimeric transcription factor MITF (19). 
We identified several features within the TRIB2 gene including an ATTTA 
potential mRNA destabilizing element in the 3'-untranslated region (20) and 
several conserved binding sites for inducible transcription factors in the 
promoter region that suggest its regulation at the transcript level .  
The fact that the TRIB2 mRNA expression is increased upon the treatment with 
compounds which increase the intracellular concentration of calcium, namely 
thapsigargin and caffeine suggests that calcium signaling might be involved in 
the molecular events that lead to the high expression level of TRIB2 in 
melanocyte-derived cells. Interestingly, recent studies reported the 
overexpression of  Ca2+ channels and elevated intracellular Ca2+ influx in 
human melanoma cell lines  (21, 22). Our data presented here, together with 
our previous findings on the implication of calcium in the regulation of FOXO 
(14) support the hypothesis that high level of intracellular calcium leads to the 
inactivation of FOXO proteins through the activation of the FOXO repressors 
calmodulin and TRIB2. 
Malignant melanoma is one of the most aggressive human tumors that arise 
from the malignant transformation of melanocytes, the pigment-producing cells 
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that reside in the basal epidermal layer in human skin. Several signaling 
pathways are thought to exert key functions in melanoma development and 
progression, including Ras-Raf-MEK-ERK (MAPK) and the PI3K/Akt signaling 
pathways (23). A recent study reported the upregulation miR-182 in melanoma 
cell lines and tissue samples promoting the repression of FOXO3a (24). 
Interestingly, ectopic expression of a non-phosphorylable, constitutively nuclear 
form of FOXO has been shown to induce apoptosis in A375 melanoma cells 
(25).  
In the present study we provide strong evidence for an alternative mode of 
FOXO inactivation in melanocyte-derived and melanoma cells through 
overexpression of TRIB2. One appealing possibility is that downregulation of 
FOXO activity through TRIB2 is one of the elusive intrinsic survival features of 
paternal melanocytes that determines the aggressive and highly resistant 
behavior of melanocyte-derived malignancies nourished by additional 
alterations acquired during tumor progression (26). 
In functional assays we could show that suppression of TRIB2 protein in 
melanoma cells resulted in a significant decrease in cell proliferation, cell 
migration and anchorage-independent growth. Thus, high TRIB2 expression 
could contribute to the formation and progression of melanoma lesions. 
Consistently, retroviral expression of TRIB2 has been shown to immortalize 
hematopoietic progenitors and TRIB2-reconstituted mice uniformly developed 
fatal transplantable acute myelogenous leukemia (27). Our study further reveals 
that in vivo tumor formation of G361 cells in immunocompromised mice was 
impaired upon silencing of TRIB2. Taken together, our data lead to the 
conclusion that TRIB2 can promote the growth of melanoma cells and support 
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in vivo tumorigenesis of those cells. Future experiments should determine 
whether TRIB2 is part of the differentiation program of normal melanocytes 
which predisposes their transformed derivatives to forming aggressive tumors 
(28). 
In summary, sophisticated cell based screening systems allowed us to 
systematically interrogate the signaling network that controls the activity of 
FOXO proteins and to identify possible targets for the restoration of FOXO 
functions independent of preconceived notions of mechanistic relationships. Our 
work identifies TRIB2 as a suppressor of FOXO activity overexpressed in 
malignant melanoma and provides evidence that TRIB2 contributes to the 
maintenance of the malignant phenotype of melanoma cells. Thus, further 
investigation on the role of TRIB2 in the pathogenesis of melanoma lesions may 
provide new therapeutic insights into this most aggressive form of skin cancer 
resistant to all standard anticancer therapies. 
 
 
Materials and Methods 
 
Reagents and plasmids 
The PI3K inhibitor PI-103 was synthesized following published patent 
specifications. All other chemicals were purchased from commercial sources. 
Akt Inhibitor X, Bapta-AM, JNK Inhibitor V, LY294002, PD98059, SB203580, 
were purchased from Calbiochem (San Diego, CA). Forskolin, Thapsigargin and 
U0126 were purchased from LC Laboratories. (Woburn, MA, U.S .A.); Caffeine, 
and GW5074 were purchased from Sigma-Aldrich (St. Louis, USA). SP6000125 
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were purchased from Biaffin (Kassel, Germany); human insulin was purchased 
from (Roche Diagnostics, Mannheim, Germany). The NKI shRNA libray was 
provided by R. Bernards. The RNAi agents to validate TRIB2 silencing were 
purchased from Applied Biosystems, Thermo Fisher Scientific and OriGene. 
The sequences of the shRNAs and siRNAs are shown in table S1. The RNAi 
constructs targeting PIK3CA or Akt  carried the small hairpin RNAs 5´-AAAAA 
GACCATCATCAGGTGAACTTCTCTTGAAAGTTCACCTGATGATGGTCGG-3´ 
or 5´-AAAAAGGAGATCATGCAGCATCGCTCTCTTGAAGCGATGCTGCATGA 
TCTCCGGG-3´ respectively, in the pRS vector backbone (Berns et al) 
The wild type form of FOXO3a cloned into a pCL-neo vector as well as a 
constitutively active construct FOXO3a-A3, in which three PI3K-dependent 
phosphorylation sites have been mutated to alanine was kindly provided by Dr. 
M. Hu (University of Texas M. D. Anderson Cancer Center, Houston). 
TRIB2 cDNA was amplified from HEK293T cells by PCR with primers 5’- 
CACCATGAACATACACAGGTCTACCCCCATC-3’ and 5’- GTTAAAGAAAGG 
GTCCAAGTTCTCTTCC-3’ to be cloned into a pCDNA/V5/GW/D-TOPO vector. 
Subsequently, PCR was used to amplify TRIB2-V5 with primers 5’-
AGCGGCTAGCACCATGAACATACACAGGTCTACCCCCATC-3’ and 5’-ACG 
CGGATCCCTAACCGGTACGCGTAGAATCGAGACC-3’, and the resulting 
fragment was cloned into a pIRESpuro2 vector. 
 
Cell culture 
U2-OS, HEK293T, A375, Hs895T, Sk-Mel-94, Sk-Mel-19, UACC-257, Hs 895 T, 
Sk-Mel-147, VA-13 and HACAT cells were obtained from the American Type 
Culture Collection (ATCC) and cultivated in Dulbecco’s Modified Eagle’s 
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medium (DMEM) (Sigma), supplied with 10% Fetal Bovine Serum (FBS). Sk-
mel-5, Sk-mel-28, UACC62 and M14 cells were obtained from ATCC and 
cultivated in RPMI supplemented with 10%FBS (Sigma). G-361 cells obtained 
from the ATCC were maintained in Mc Coy’s 5A medium complemented with 
10% FBS. Previously described U2foxRELOC cells (29) stably expressing a 
plasmid containing a FOXO3a-GFP fusion protein were cultivated in 10% FBS 
DMEM with 100ug/ml G-418 (Gibco). Human epidermal melanocytes were 
obtained from Cascade Biologics and maintained in medium 254 (Cascade 
Biologics) supplemented with HMGS (Cascade Biologics). Cell cultures were 
maintained in a humified incubator at 37ºC with 5% CO2. 
 
Generation of 293lucRep Cells 
HEK293T (human embryonic kidney) cells were cultivated to appropriate 
confluence and transfected with a plasmid containing 3 copies of the DBE 
sequence cloned upstream of firefly luciferase cDNA, as well as puromycin 
resistance cassette (pGL3-DBE3X-Luc-Puro) (Zanella et al,,in press). After 
selection with puromycin, resistant clones were sub-cultivated in order to be 
assayed for luciferase expression. The cell clones were assayed for luciferase 
activity and responsiveness to the inhibition of PI3K/Akt signaling. The most 
suitable clone was selected as the assay cell line and designated 293foxREP. 
 
Preparation of the shRNA library 
Prior to its transfection the bacteria cultures of the arrayed shRNA library were 
replicated and purified. The replication was carried out using a Biomek FX liquid 
handler (Beckman-Coulther). The plasmids contained in the bacterial cultures 
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were purified using the Montage plasmid extraction kit of Millipore adapted to a 
vacuum manifold preceded by a preclearing with the Wizard SV96 lysate 
clearing plates of Promega. 
 
Western Blot analysis 
Cells were grown in a 10 cm plate until confluence and washed twice with cold 
TBS and lysed with 1 ml of a solution containing 50mM Tris-Cl, 150mM NaCl, 
1% Igpal, 10 ug of Aprotinin and 10 ug of Leupeptin. A pan proteases inhibitor 
(Roche) and a pan phosphatase inhibitor (Roche) were also used, according to 
manufacturers instructions. Protein amounts were quantified using the Bio Rad 
Protein Assay, absorbance at 590 nm was measured in a Victor3a (Perkin 
Elmer) plate reader. 100ug of total protein were loaded in a 7,5% SDS-PAGE 
and ran for 1 h at 150 V, in a Bio Rad system. Transference to a nitrocellulose 
membrane was carried in a Bio Rad System, at 200 mA, for 2 hours. After 
transference, nitrocellulose membranes were blocked in a infra-red specific 
solution (Li-Cor) for a minimum of 4 hours, at 4ºC. Incubation with the primary 
antibodies was carried for 4-12 hours, at 4ºC with constant shaking.  
TRIB2 levels were probed using an anti-V5 antibody (Invitrogen) and α-tubulin 
levels were probed as a loading control with a commercially available antibody 
(Sigma). All the dilutions used were indicated in the manufacturers instructions. 
 
Luciferase Assays 
2 X 105 293foxREP cells were seeded per well in transparent round-bottom 96-
well plates (Nunc), and allowed to attach for at least 6 hours at 37°C with 5% 
CO2, before transfection. Once attached, cells were co-transfected with 25ng of 
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the pCDNA3 vector containing cDNA for FOXO3a, 50 ng of the commercially 
available pRG-TK vector (Promega), containing Renilla Luciferase cDNA  for 
normalization of results, and 25 ng of the empty pSuperRetro vector (in the 
case of controls and wells to be treated with LY294002), or pSuperRetro 
containing shRNAs against PI3K and Akt, or each shRNA pool contained in the 
library plate. All transfection experiments were performed in triplicates, with 
Effectene transfection reagent (Qiagen) following the manufacturers’ 
instructions. All liquid handlings were performed automatically in a Biomek 2000 
station (Beckman & Coulter). After transfection cells were incubated for 48 
hours prior to LY294002 administration, when mentioned. Following incubation 
automated luciferase assays were carried out using the Dual-Luciferase 
Reporter Assay System (Promega), according the manufacturer's instructions 
on a multilabel plate reader (Wallac Victor, Perkin-Elmer), and the ratio of firefly- 
to Renilla-luciferase activities was calculated. For triplicate experiments the 
average value has been calculated to be presented as the final result. 
 
HCS Assays 
U2foxReloc cells were seeded at a density of 105 cells/ml into black-wall clear-
bottom 96-well microplates (BD Biosciences) with a multidrop automatic 
dispenser, to a final volume of 200μl per well. Cells were then allowed to attach 
for 12 h at 37°C with 5% CO2, and transfected as mentioned above. The cells 
were then incubated for 48 hours prior to aspiration of culture medium, washing 
with 1X PBS twice and fixation in 100μl of 6% paraformaldehyde for 30 min at 
room temperature (RT). After aspiration of the paraformaldehyde, fixed cells 
were washed twice with 1X PBS and stained with DAPI (Invitrogen) for 20 min 
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at RT for cell nucleus definition. DAPI solution was removed by aspiration, and 
finally the plates were washed with 1X PBS twice and stored at 4ºC before 
analysis. 
Assay plates were read on the BD Pathway™ 855 Bioimager as previously 
reported (29, 30). Images were acquired in the DAPI and GFP channels of each 
well using 10X dry objective. The nuclear/cytoplasmic (Nuc/Cyt) ratios of 
fluorescence intensity were determined by dividing the intenstity of the GFP 
fluorescence of the nucleus by the cytoplasmic. We applied a threshold ratio of 
greater than 1.8 to define nuclear accumulation of fluorescent signal for each 
cell. Based on this procedure we calculated the percentage of cells per well 
displaying nuclear translocation. 
 
Cancer profiling Array 
TRIB2 cDNA was PCR-amplified with primers 5´-AGCGAAGCTTACCATGAAC-
ATACACAGGTCTACCCCCATC-3´ and 5’-ACGCGGATCCCTGTTAAAGAAA-
GGGTCCAAGTTCTCTTCC-3’, resulting in a 950 bp fragment which was 
purified with Phenol/Chloroform. 25 ng of this probe were radioactively labeled 
in a mix of  10ul of labeling buffer (Promega), 2 ul of 10mg/ul BSA, 2ul of a 
solution containing 5mM of dATP, dGTP and  dTTP nucleotides, 5ul of 32P-
labelled dCTP-Nucleotides (Amersham), and 30 units of the Klenow polymerase 
(Promega) for 2 hours at 37ºC. After purification of the radiolabeled probe in a 
NICK column (Amersham) following the manufacturers’ instructions, the probe 
was boiled for 3 min at 100ºC, transferred to ice and hybridized overnight to the 
Cancer Profiling Array II membrane (BD biosciences) previously incubated with 
10 ml of a solution containing 5X SSPE, 2,5X Denhardts solution, 0,25% SDS 
 - 135 -
Results 
and 0,15 mg/ml salmon sperm DNA. The membrane was then washed for 20 
min 2 times with 2XSSPE, 0,1% SDS, once with 1XSSPE, 0,1% SDS and finally 
with 0,1XSSPE, 0,1% SDS, at 65ºC. Following the washing steps the 
membrane was exposed to an Amersham Phosohor Screen overnight and 
scanned in a Typhoon 9400 Variable Mode Imager (Amersham). After stripping 
off the probe specific for TRIB2, the membrane was re-hybridized with a probe 
specific for the housekeeping gene Ubiquitin. Quantification of TRIB2 levels was 
carried in the Quantity One software version 4.5.2 (BioRad), using the signal 
obtained for ubiquitin for normalization. For each patient, samples were 
normalized against their respective ubiquitin signal and the tumoral samples 
were normalized against their corresponding normal tissue samples. 
 
Quantitative RT-PCR 
Total RNA was extracted using TRI-Reagent (Sigma), according to the 
manufacturers’ indications. After RNA isolation DNAse I (Roche) treatment was 
performed using 40 units of enzyme in the presence of 40 units of RNAse 
inhibitor (Roche) per sample, at 37ºC, for 1h. Following Phenol-Chloroform 
purification RNAs were quantified in a NanoDrop® 1000 spectophotometer 
quality-checked in a MOPS-1,2% Agarose gel and cDNA synthesis was carried 
out using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems) using 1 ug of total RNA as starting material for each sample. PCR 
reactions were set up in 96-well optical plates (Applied Biosystems) and run in a 
ABI PRISM® 7900HT sequence detection system (Applied Biosystems). 
Reaction mix was prepared as using 1x SYBRGreen Master Mix (Applied 
Biosystems), 50nM of each primer [TRIB2: 5’-GCCAGACTGTTCTACCAGATT-
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GC-3’ (forward) and 5’- GCTTGACCCGAGT-CCTCTCTT-3’ (reverse). GAPDH: 
5’-ATCACCATCTTCCAGGAGCG-3’   (forward) and 5’- CCTGCAAATGAGCC-
CCAG-3’ (reverse) Bim: 5’-CACAAAA-CCCCAAGTCCTCCTT-3’ (forward) and 
(5’-TTCAGCCTGCCTCATGGAA-3’ reverse)] and 100ng of cDNA in a final 
volume of 50ul. Cycling conditions were set to 10 min at 95ºC followed by 40 
cycles of 15 sec at 95ºC and 1min at 60ºC. Identical PCR conditions were used 
with the human melanoma TissueScan™ Tissue qPCR Array (OriGene). 
Finally, a dissociation curve was carried out to check specificity of amplification. 
 Results were analyzed and the relative mRNA quantity calculated using the 
qBasePlus software (31). TRIB2 levels were quantified using GAPDH or 18S 
RNA expression levels for normalization.  
 
Generation of 361C and 361shTRIB cells 
G-361 cells were transfected at 70-80% confluency using the Effectene 
(QIAGEN) reagent, according to the manufacturers indications either with an 
empty pSuperRetro vector (361C) or with the validated TRIB2NKI shRNA 
(361shTRIB). After selection with Puromycin, both cell populations were 
maintained in Mc Coy’s 5A Medium supplemented with 10% FBS and 0,5 ug/ml 
puromycin. 
 
Proliferation and Doubling time Assay 
361C and 361shTRIB cells were seeded in triplicates at a density of 104 
cell/well in 6-well plates. After 24 hours growth medium was changed (day 0) 
and a point of the curve was taken every second day. For each point of the 
curve, cells were fixed with 0,5% glutaraldehyde for 30 min and stained with 1% 
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crystal violet. After washing for removal of excess of dye cells were lysed with 
15% acetic acid and the lysis products were transferred to clear bottom 96-well 
plates, (Nunc) and the absorbance at 590 nm wavelength was measured in a 
Victor3 (Perkin Elmer) plate reader. The relative number of cells was 
determined as a direct measurement of the absorbance obtained in each well. 
Doubling time has been calculated at exponential growth. 
 
Clonogenic Assay 
361C and 361shTRIB cells were seeded in triplicates at a density of 104 
cells/well in 10 cm plates. Growth medium was changed every second day and 
cells were allowed to grow for a period of 10 days. At day 10 cells were fixed 
with 0,5% glutaraldehyde for 30 min and stained with 1% crystal violet. After 
washing for removal of excess of dye, colonies were counted. 
 
Growth in Soft Agar 
The anchorage-independent growth of 361C and 361shTRIB cells was 
analyzed by seeding triplicates of 4 x  105 cells/well of each population in 1.4% 
agarose D-1 Low EEO (Pronadisa) growth medium containing 10% FBS, 
disposed onto previously solidified base of growth medium containing 2.8% 
agar (agarose D-1 Low EEO, Pronadisa) in a 6-well plate. Once the soft agar 
had been solidified 1 ml of growth medium was added. After 24 hours, media 
containing 10% FBS was added to each well and renewed twice weekly. 
Colonies were scored after one month of growth.  Photographs were taken in a 
Olympus CK40 microscope equipped with a Olympus DP12 camera at 40X 
magnification. 
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Wound Healing Assays 
361C and 361shTRIB cells were seeded in triplicates at a density of 5 x 105 
cells/well in 24-well plates and allowed to attach overnight. Following 
attachment a wound was produced in the cell monolayer with a 10ul pipette tip, 
growth medium was replaced and a picture was taken (Day 0) in a Olympus 
CK40 microscope equipped with a Olympus DP12 camera at 40X magnification. 
Pictures were taken every 24 hours in the same fields, until the time point in 
which the wound from a given group was totally closed. 
 
Xenografts 
ZSCID mice were injected with 7 x 105 361C and 361shTRIB cells and the 
growth of the resulting tumours was followed by direct measurement of tumour 
volume every 7 days over a total period of 69 days. The smallest and the 
largest diameter of tumors were mearsured with a digital caliper, and tumor 
volumes were calculated using the following formula: volume (mm3) = [(smallest 
diameter) 2 x (lagest diameter)] / 2. All values were presented as means ± SE. 
The unpaired t-test (two-tailed) was performed for statistical analysis using the 
GraphPad PRISM® Version 4.0 program. The photos of the animals and their 
respective tumors were taken at day 69, before animal sacrifice and after tumor 
dissesection. All animal procedures were conducted according to the 
experimental protocol approved by the Institutional Committee for Care and Use 
of Animals of the Spanish National Cancer Research Centre which complies 
with European legislation on the care and use of animals, NIH guidelines for the 
use of laboratory animals, and related codes of ethic practice. 
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Figure Legends 
 
Table 1  
List of gene targets of sequence-verified shRNAs identified in two independent 
cell-based systems. For candidate validation, multiple RNAi agents directed 
against independent sequences within a gene target were tested for 
modification of luciferase activity. Gene targeting region for the silencing pools 
are shown. ORF, open reading frame; 5'UTR and 3'UTR, five-prime and three-
prime untranslated regions, respectively. 
 
Fig. 1. Silencing of TRIB2 induces FOXO driven luciferase activity and nuclear 
translocation of GFP-FOXO. A. Relative TRIB2/GAPDH mRNA levels after 
transfection of HEK293T cells with the shRNA construct TRIB2_NKI. Cells were 
harvested 48 hours after transfection and processed for qPCR using methods 
described above. B. Transcriptional activity of FOXO upon silencing of TRIB2 
with shRNA construct TRIB2_NKI as measured by FOXO-driven expression of 
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luciferase in co-transfection experiments. Each construct was transiently co-
transfected with plasmids encoding FOXO3a and Renilla luciferase into 
293foxREP cells, and the luciferase activities were determined as described in 
the “Materials and Methods” section. The data were normalized to the Renilla 
luciferase (phRG-TK vector) reporter construct. The results are given as the 
mean ± SEM of three independent experiments performed in triplicate. C and D. 
Subcellular localization of fluorescent FOXO reporter protein after transfection 
of U2foxRELOC cells with control vector (C) or shRNA construct TRIB2_NKI 
(D). 
 
Fig. 2. Ectopic expression of TRIB2 increased FOXO-driven luciferase 
expression. A. TRIB2 cDNA was tagged with a V5 epitope and expressed in 
HEK293T cells. Overexpression was detected by western blot analysis using a 
specific antibody against the V5 tag. Equal loading was confirmed by the 
specific detection of α-tubulin expression. Relevant proteins are indicated by 
arrows in the blot from a representative experiment. B. Luciferase expression 
from a FOXO driven promoter was monitored upon expression of control 
plasmid or V5 tagged TRIB2 cDNA. Each construct was transiently co-
transfected with plasmids encoding FOXO3a and Renilla luciferase into 
293foxREP cells, and the luciferase activities were determined as described 
above. The data were normalized to the Renilla luciferase (phRG-TK vector) 
reporter construct. The results are given as the mean ± SEM of three 
independent experiments performed in triplicate. 
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Fig. 3. TRIB2 is overexpressed in malignant melanoma. A cancer profiling array 
was hybridized separately with a radiolabeled probe for the housekeeping gene 
ubiquitin and a radiolabeled probe for TRIB2. Hybridization signals were 
detected by phosphoimaging. A. Samples from ten patients (P1 – P10) with skin 
cancer and matched normal tissue are shown. N = normal; T = tumor. B. 
Quantification of TRIB2 levels was performed using Quantity One software. The 
hybridization signals for TRIB2 were normalized against signals obtained for 
ubiquitin. Then, the ratio between normalized values from normal tissue to 
those from tumors was calculated for each patient (P1 – P10). Black bars 
represent malignant melanoma, white bars indicate non-melanoma skin cancer. 
C. Hybridization signals from nine different cancer cell lines were shown. D. 
Quantification of TRIB2 levels was performed as described above. Black bars 
represent melanoma cells, dashed bars indicate non-melanoma cancer cell 
lines. 
 
Fig. 4. TRIB2 expression negatively correlates with Bim expression. qRT-PCR 
analysis of TRIB2 (A) and BIM (B) mRNA levels in a panel of cell lines. Black 
bars refer to melanocyte-derived cells while white bars correspond to non-
melanocyte derived cells. Error bars refer to standard error. Normalization of the 
results was performed taking 18S mRNA levels as reference. 
 
Fig. 5. Calcium signalling regulates the abundance of TRIB2 mRNA. G361 cells 
were treated with several compounds for a period of 6 hours, followed by RNA 
extraction for qRT-PCR quantification of TRIB2 mRNA levels.  Error bars refer 
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to standard error. Normalization of the results was performed taking 18S mRNA 
levels as reference. 
 
Fig. 6. Silencing of TRIB2 in melanoma cells activates FOXO dependent 
transcription. G-361FireFOX cells were transiently transfected with 2 different 
shRNAs against TRIB2 respectively or with shRNAs against PI3K or Akt, using 
Renilla luciferase as a transfection control. After 48 hours, firefly luciferase 
activity was measured and normalized against Renilla luciferase activity. The 
results refer to the average obtained in triplicate experiments and the error bars 
are representative of the standard deviation obtained in each triplicate. 
 
Fig. 7. Silencing of TRIB2 decreases the malignant phenotype of melanoma 
cells. A. qRT-PCR analysis of TRIB2 mRNA levels in 361C and 361shTRIB 
cells. Error bars refer to standard error. Normalization of the results was 
performed taking 18S mRNA levels as reference. B. 361C and 361shTRIB cells 
were grown in standard culture conditions over a period of 10 days and cell 
density was measured every second day. The relative number of cells was 
estimated by crystal violet staining.as described above. C. In order to 
investigate their clonagenic potential 361C and 361shTRIB cells were seeded at 
low density and allowed to grow for 10 days prior to fixation, crystal violet 
staining and quantification of the number of colonies formed. D. 361C and 
361shTRIB cells were seeded in soft agar and maintained for one month for 
anchorage-independent growth analysis. Bars refer to the average number of 
colonies obtained from triplicates of each cell line with their respective standard 
deviation. E- Microscopic detail of the colonies formed by 361C and 361shTRIB 
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cells in soft agar after one month of culture. F- 361C and 361shTRIB cells were 
grown until confluence and their migratory capabilities were analyzed in a 
wound healing assay. 
 
Fig. 8. Silencing of TRIB2 reduces tumor growth in vivo. 7x105  361shTRIB or 
361C cells were xenografted in ZSCID mice and the growth of the tumors 
formed by each cell population was followed. The statistical significance for 
each time point was determined by unpaired t-test. Except for the first depicted 
time point, the differences of all time points were significant. B and C, At day 69, 
both groups of animals were photographed, euthanized, and tumors were 
dissected and photographed. Mice (B) and dissected tumors (C) representative 
for the both groups are depicted. The rulers at the bottoms of the photographs 
(C) are scaled in mm. 
 
Table S1  
RNAi agents used for the validation of TRIB2 silencing. In order to rule out off-
target effects several independent TRIB2 interfering agents from different 
sources were tested and their respective induced knockdown over TRIB2 
mRNA was analyzed by qRT-PCR. 1- Both shRNAs obtained from the NKI 
library initially included in the same pool. For further characterization both oligos 
were isolated and characterized independently. 2- This pool contains four 
different siRNAs. ORF, open reading frame; 5'UTR, five-prime untranslated 
regions. 
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Table S2 
Description of samples included in the cancer profiling array. Information about 
the cDNAs and controls immobilized on the cancer profiling array and the 
corresponding hybridization signals specific for TRIB2. Normalization was 
performed against signals obtained using the ubiquitin control probe. 
 
Table S3 
Description of samples included in the Tissue qPCR Arrays. qRT-PCR was 
performed using TissueScan Melanoma Tissue qPCR Array I containing 43 
tissues (OriGene Technologies, Rockville, MD). Quantification of TRIB2 mRNA 
levels was performed using qPCR. qRT-PCR amplification signals specific for 
TRIB2 were normalized against GAPDH expression. 
 
Fig. S1.  
A. General structure of the construct used to generate the 293foxREP cells. B. 
Validation of the 293foxREP system. FOXO-driven expression of luciferase was 
determined upon activation or inhibition of the PI3K/Akt pathway. Each 
construct was transiently co-transfected with plasmids encoding FOXO3a or 
constitutively active A3 FOXO3a mutant and Renilla luciferase into 293foxREP 
cells, and the luciferase activities were measured as described above. The data 
were normalized to the Renilla luciferase (phRG-TK vector) reporter construct. 
The results are given as the mean ± SEM of three independent experiments 
performed in triplicate. 
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Fig. S2. 
Schematics of the strategy used to screen the NKI library of shRNAs for novel 
modulators of FOXO activity. The shRNA library was introduced in pools of 
three RNAi per gene into 293foxREP cells. Those pools of shRNAs that caused 
activation of FOXO driven luciferase activity were analyzed for its capacity to 
induce nuclear translocation of FOXO in the U2foxRELOC system.  
 
Fig. S3.  
A and B. The Cancer Profiling Array II membrane after hybridization with the 
TRIB2 and ubiquitin probes. Tissue sources are listed above each sample 
group. C. Relative abundance of TRIB2 as compared with GAPDH expression 
as determined by comparison of TRIB2 and GAPDH qRT-PCR amplification 
signals. cDNAs studied were normal skin tissues (n=3), malignant melanoma 
diagnosed at stage III (n = 21) or IV (n = 19). The P-values were calculated 
using unpaired t test with Welch's correction for comparisons of normal skin 
versus melanoma stage III (P = 0.0421) and for normal skin versus melanoma 
stage IV (P = 0.0288) 
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 Table 1. Suppressors of FOXO Function 
 
Gene  Full Name       Previously Known Function  Targeting region 
Akt-3  v-Akt murine thyoma viral oncogene homolog 3   Protein Kinase    ORF 
PIK3CA Phosphatidylinositol 3- kinase catalytic, alpha polypeptide  Lipid kinase    ORF 
TRIB2  Tribbles homolog 2      Kinase-like protein    5´UTR / ORF 
CALM2  Calmodulin 2       Ca2+-binding protein    5´UTR / ORF 
DCLK1  Doublecortin-like 1 kinase     Protein Kinase    ORF / 3´UTR 
ZNF281 Zink finger protein 281      Transcription factor   5´UTR / ORF 
 
Table 1. List of gene targets of sequence-verified shRNAs identified in two independent cell-based systems. For candidate validation, multiple RNAi agents directed against 
independent sequences within a gene target were tested for modification of luciferase activity. Gene targeting region for the silencing pools are shown. ORF, open reading 
frame; 5'UTR and 3'UTR, five-prime and three-prime untranslated regions, respectively. 
 
 
 
 
 
 
- 149 - 
ts 
 
R
esul
Fig. 1
C D
A B
0
500
1000
1500
2000
2500
3000
3500
Control TRIB2shRNA
R
el
at
iv
e 
Lu
ci
fe
ra
se
 
A
ct
iv
ity
0
0.2
0.4
0.6
0.8
1.0
1.2
TRIB2shRNA
R
el
at
iv
e 
TR
IB
2 
m
R
N
A
 le
ve
ls
Control
- 150 -
Results
Fig. 1. Silencing of TRIB2 induces FOXO driven luciferase activity and nuclear translocation of GFP-FOXO. A. 
Relative TRIB2/GAPDH mRNA levels after transfection of HEK293T cells with the shRNA construct TRIB2_NKI. Cells 
were harvested 48 hours after transfection and processed for qPCR using methods described above. B. Transcriptional 
activity of FOXO upon silencing of TRIB2 with shRNA construct TRIB2_NKI as measured by FOXO-driven expression of 
luciferase in co-transfection experiments. Each construct was transiently co-transfected with plasmids encoding 
FOXO3a and Renilla luciferase into 293foxREP cells, and the luciferase activities were determined as described in the 
“Materials and Methods” section. The data were normalized to the Renilla luciferase (phRG-TK vector) reporter 
construct. The results are given as the mean ± SEM of three independent experiments performed in triplicate. C and D. 
Subcellular localization of fluorescent FOXO reporter protein after transfection of U2foxRELOC cells with control vector 
(C) or shRNA construct TRIB2_NKI (D).
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Fig. 2. Ectopic expression of TRIB2 increased FOXO-driven luciferase expression. A. TRIB2 cDNA was tagged with a 
V5 epitope and expressed in HEK293T cells. Overexpression was detected by western blot analysis using a specific 
antibody against the V5 tag. Equal loading was confirmed by the specific detection of α-tubulin expression. Relevant proteins 
are indicated by arrows in the blot from a representative experiment. B. Luciferase expression from a FOXO driven promoter 
was monitored upon expression of control plasmid or V5 tagged TRIB2 cDNA. Each construct was transiently co-transfected
with plasmids encoding FOXO3a and Renilla luciferase into 293foxREP cells, and the luciferase activities were determined 
as described above. The data were normalized to the Renilla luciferase (phRG-TK vector) reporter construct. The results are 
given as the mean ± SEM of three independent experiments performed in triplicate.
Fig. 3
N T
P1
P2
P3
P5
P6
P7
P8
P9
P10
P4
HeLa
Daudi
K562
HL-60
G-361
A549
MOLT4
SW480
Raji
TRIB2 Ubiquitin
TRIB2 Ubiquitin
A B
C
D
0
1
2
3
4
5
6
7
8
9
P1 P2 P3 P4 P5 P6 P7 P8 P9 P10
R
el
at
iv
e
 
TR
IB
2 
m
R
N
A
 
le
ve
ls
0
2
4
6
8
10
12
14
HeLa
Daudi
K562
HL-60
G-361
A549
MOLT4
SW
480
RajiR
el
at
iv
e
 
TR
IB
2 
m
R
N
A
 
le
ve
ls
- 152 -
Results
Fig. 3. TRIB2 is overexpressed in malignant melanoma. A cancer profiling array was hybridized separately with a 
radiolabeled probe for the housekeeping gene ubiquitin and a radiolabeled probe for TRIB2. Hybridization signals 
were detected by phosphoimaging. A. Samples from ten patients (P1 – P10) with skin cancer and matched normal tissue 
are shown. N = normal; T = tumor. B. Quantification of TRIB2 levels was performed using Quantity One software. The 
hybridization signals for TRIB2 were normalized against signals obtained for ubiquitin. Then, the ratio between normalized 
values from normal tissue to those from tumors was calculated for each patient (P1 – P10). Black bars represent malignant 
melanoma, white bars indicate non-melanoma skin cancer. C. Hybridization signals from nine different cancer cell lines were
shown. D. Quantification of TRIB2 levels was performed as described above. Black bars represent melanoma cells, dashed 
bars indicate non-melanoma cancer cell lines.
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Fig. 4. TRIB2 expression negatively correlates with Bim expression. qRT-PCR analysis of TRIB2 (A) and BIM (B) mRNA 
levels in a panel of cell lines. Black bars refer to melanocyte-derived cells while white bars correspond to non-melanocyte
derived cells. Error bars refer to standard error. Normalization of the results was performed taking 18S mRNA levels as 
reference.
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Fig. 5. Calcium signalling regulates the abundance of TRIB2 mRNA. G361 cells were treated with several 
compounds for a period of 6 hours, followed by RNA extraction for qRT-PCR quantification of TRIB2 mRNA 
levels.  Error bars refer to standard error. Normalization of the results was performed taking 18S mRNA levels 
as reference.
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Fig. 6. Silencing of TRIB2 in melanoma cells activates FOXO dependent transcription. G-
361FireFOX cells were transiently transfected with 2 different shRNAs against TRIB2 respectively or with 
shRNAs against PI3K or Akt, using Renilla luciferase as a transfection control. After 48 hours, firefly 
luciferase activity was measured and normalized against Renilla luciferase activity. The results refer to the 
average obtained in triplicate experiments and the error bars are representative of the standard deviation 
obtained in each triplicate.
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Fig. 7. Silencing of TRIB2 
decreases the malignant 
phenotype of melanoma cells. 
A. qRT-PCR analysis of TRIB2 
mRNA levels in 361C and 
361shTRIB cells. Error bars refer 
to standard error. Normalization 
of the results was performed 
taking 18S mRNA levels as 
reference. B. 361C and 
361shTRIB cells were grown in 
standard culture conditions over 
a period of 10 days and cell 
density was measured every 
second day. The relative number 
of cells was estimated by crystal 
violet staining.as described 
above. C. In order to investigate 
their clonagenic potential 361C 
and 361shTRIB cells were 
seeded at low density and 
allowed to grow for 10 days prior 
to fixation, crystal violet staining 
and quantification of the number 
of colonies formed. 
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Fig. 7. Silencing of TRIB2 decreases the malignant phenotype of melanoma cells. D. 361C and 361shTRIB cells were seeded in soft agar and 
maintained for one month for anchorage-independent growth analysis. Bars refer to the average number of
 
colonies obtained from triplicates of each cell 
line with their respective standard deviation. E-
 
Microscopic detail of the colonies formed by 361C and 361shTRIB
 
cells in soft agar after one month of 
culture. F-
 
361C and 361shTRIB cells were grown until confluence and their migratory capabilities were analyzed in a wound healing assay.
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Fig. 8. Silencing of TRIB2 reduces 
tumor growth in vivo. A. 7x105
361shTRIB or 361C cells were 
xenografted in ZSCID mice and the 
growth of the tumors formed by 
each cell population was followed. 
The statistical significance for each 
time point was determined by 
unpaired t-test. Except for the first 
depicted time point, the differences 
of all time points were significant. B
and C, At day 69, both groups of 
animals were photographed, 
euthanized, and tumors were 
dissected and photographed. Mice 
(B) and dissected tumors (C) 
representative for the both groups 
are depicted. The rulers at the 
bottoms of the photographs (C) are 
scaled in mm.
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Fig. S1. A. General structure of the construct used to generate the 293foxREP cells. B. Validation of the 
293foxREP system. FOXO-driven expression of luciferase was determined upon activation or inhibition of the 
PI3K/Akt pathway. Each construct was transiently co-transfected with plasmids encoding FOXO3a or 
constitutively active A3 FOXO3a mutant and Renilla luciferase into 293foxREP cells, and the luciferase
activities were measured as described above. The data were normalized to the Renilla luciferase (phRG-TK 
vector) reporter construct. The results are given as the mean ± SEM of three independent experiments 
performed in triplicate.
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Fig. S2. Schematics of the strategy used to screen the NKI library of shRNAs
 
for novel modulators of FOXO activity. The shRNA
 
library was introduced in pools of 
three RNAi
 
per gene into 293foxREP cells. Those pools of shRNAs
 
that caused activation of FOXO driven luciferase
 
activity were analyzed for its capacity to induce 
nuclear translocation of FOXO in the U2foxRELOC system.
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Fig. S3.
 
A
 
and B. The Cancer Profiling Array II membrane after hybridization with the TRIB2 and ubiquitin
 
probes. Tissue sources are listed above each 
sample group. C. Relative abundance of TRIB2 as compared with GAPDH
 
expression as determined by comparison of TRIB2 and GAPDH
 
qRT-PCR 
amplification signals. cDNAs
 
studied were normal skin tissues (n=3), malignant melanoma diagnosed at stage III (n = 21) or IV
 
(n
 
= 19). The P-values 
were
 
calculated using unpaired t test
 
with Welch's correction
 
for comparisons of normal skin versus melanoma stage III (P = 0.0421) and for normal skin 
versus melanoma stage IV (P =
 
0.0288)
 Table S1. RNAi agents used to validate TRIB2 silencing 
 
Provider Presentation  Reference  Sequence      Targeting region Knockdown effciency 
NKI   shRNA Pool1  102911  5’-GCTATTAGGAAGTCAAACG-3’   5’UTR   30% 
NKI   shRNA Pool1  102911  5’-GAAAGACACACTCTTAAGT-3’   ORF   80% 
Origene shRNA Single  TI200873  5’-CCAGGACGAGATCCAGTTCTC-3   5’UTR   30% 
Origene shRNA Single   TI200874 5’-CCTGCCGACCGAGGACCCCCG-3   5’UTR   10% 
Origene shRNA Single  TI200875 5’-TAAAATCAGTGGCACCGAGGC-3’   5’UTR   20% 
Origene shRNA Single   TI200876 5’-CTCCCTCTTCAGCAAGATCCG-3’    ORF   90% 
Origene shRNA Single   TI200877 5’-CCCAGGAGTGAGCGAGGGCAG-3’   ORF   0% 
Origene shRNA Single   TI200878 5’-AGCGAGATATGGGAGATCGCG-3’    ORF   40% 
Dharmacon siRNA Pool2   D-005391-01  5’-GAAGAGUUGUCGUCUAUAA-3’   5’UTR    
D-005391-02  5’-GAGAGGAGCUGGUGUGCAA-3’    ORF   80%  
D-005391-03  5’-CCAAAUCACUGAAAUUAUC-3’    ORF  
D-005391-05  5’-UCGAAGAGUUGUCGUCUAU-3’   5’UTR 
 
 
 
Table S1. RNAi agents used for the validation of TRIB2 silencing. In order to rule out off-target effects several independent TRIB2 interfering agents from different sources were 
tested and their respective induced knockdown over TRIB2 mRNA was analyzed by qRT-PCR. 1- Both shRNAs obtained from the NKI library initially included in the same pool. 
For further characterization both oligos were isolated and characterized independently. 2- This pool contains four different siRNAs. ORF, open reading frame; 5'UTR, five-prime 
untranslated regions. 
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 Table S2A Description of samples from skin cancer patients included in the cancer profiling array 
 
Patient  Tissue Source      Stage  Normalized TRIB2 levels   Gender   Age 
P1  Malignant melanoma NOS    I; T2N0M0  7.94     Female   49 
P2  Malignant melanoma NOS    III;T4N0M0  5.64     Female   45 
P3  Malignant melanoma NOS    III;T4N0M0 4.89     Male    73 
P4  Malignant melanoma NOS    IV; N/A  3.49     Male    58 
P5  Malignant melanoma NOS    III;T4N0M0 6.37     Female   74 
P6  Unknown      N/A; N/A 1.06     Male   64 
P7  Squamous cell carcinoma     II; T2N0M0 0.46     Female   70 
P8  Squamous cell carcinoma, keratinizing type NOS  II; T2N0M0 0.74     Male   68 
P9  Malignant melanoma NOS    III;T4N0M0 2.45     Female   40 
P10  Malignant melanoma NOS    I; T2N0M0 1.77     Female   43 
 
 
Table S2B Description of samples from cancer cell lines included in the cancer profiling array 
 
Cell line Organ / Cell type  Disease    Normalized TRIB2 levels   Gender   Age 
HeLa  Cervix     Adenocarcinoma    2.48     Female   31 
Daudi   Peripheral blood   Burkitt's lymphoma   2.60     Male   16 
K562  Bone marrow   Chronic myelogenous leukemia  8.18      Female   53 
HL60  Peripheral blood   Acute promyelocytic leukemia  8.43      Female   36 
G361  Skin    Malignant melanoma   12.61      Male   31 
A549  Lung     Carcinoma    2.70      Male   58 
MOLT4  T lymphoblast   Acute lymphoblastic leukemia  1.52      Male   19 
SW480  Colon    Colorectal adenocarcinoma  1.81      Male   50 
Raji  B lymphocyte   Burkitt's lymphoma   3.06      N/A    N/A 
 
Table S2. Description of samples included in the cancer profiling array. Information about the cDNAs and controls immobilized on the cancer profiling array and the 
corresponding hybridization signals specific for TRIB2. Normalization was performed against signals obtained using the ubiquitin control probe. 
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 Table S3 Description of samples included in the Tissue qPCR Array 
 
Patient  Tissue Source   Diagnosis    Stage  Normalized TRIB2 levels  Gender  Age 
1  Normal skin   Normal     0  2.44    Male  36 
2  Normal skin   Normal, Merkel cell carcinoma  0  10.30    Not Sp  69 
3  Normal skin   Normal     0  5.04    Male  51 
4  Skin / Lymph node  Malignant melanoma, metastatic III  8.84    Female  42 
5  Skin / Lymph node  Malignant melanoma, metastatic III  2.90    Female  59 
6   Skin / Lymph node: sentinel Malignant melanoma, metastatic III  35.62    Female  66 
7  Skin / Lymph node  Malignant melanoma, metastatic III  7.18    Male  56 
8  Skin / Lymph node  Malignant melanoma, metastatic III  3.26    Male  46 
9  Skin / Lymph node  Malignant melanoma, metastatic III  2.01    Female  66 
10  Skin / Lymph node  Malignant melanoma, metastatic III  13.50     Female  34 
11  Skin / Lymph node  Malignant melanoma, metastatic III  6.70    Female  56 
12  Skin / Lymph node  Malignant melanoma, metastatic III   2.17    Male  59 
13  Skin / Lymph node  Malignant melanoma, metastatic III   4.81    Female  49 
14  Skin / Lymph node  Malignant melanoma, metastatic IIIA  77.42    Female  67 
15  Skin / Lymph node  Malignant melanoma, metastatic IIIB   1.02    Male  61 
16  Skin / Lymph node  Malignant melanoma, metastatic IIIB   12.00    Male  43 
17  Skin / Lymph node  Malignant melanoma, metastatic IIIB   6.17    Male  42 
18  Skin / Lymph node  Malignant melanoma, metastatic IIIB   12.42    Female  49 
19  Skin / Lymph node  Malignant melanoma, metastatic IIIB   35.87    Female  72 
20  Skin / Groin   Malignant melanoma, metastatic IIIB  12.77    Male  50 
21  Skin / Lymph node  Malignant melanoma, metastatic IIIC   12.08    Male  56 
22  Skin / Lymph node  Malignant melanoma, metastatic IIIC   26.81    Male  81 
23  Skin / Lymph node  Malignant melanoma, metastatic IIIC   7.97    Male  66 
24  Skin / Lymph node  Malignant melanoma, metastatic IIIC   6.38    Female  52 
25  Skin / Lymph node  Malignant melanoma, metastatic IV   15.29    Male  66 
26  Skin / Lung   Malignant melanoma, metastatic IV   8.42    Female  42 
27  Skin / Lymph node  Malignant melanoma, metastatic IV   5.44    Female  45 
 
Table S3. Description of samples included in the Tissue qPCR Arrays. qRT-PCR was performed using TissueScan Melanoma Tissue qPCR Array I containing 43 tissues 
(OriGene Technologies, Rockville, MD). Quantification of TRIB2 mRNA levels was performed using qPCR. qRT-PCR amplification signals specific for TRIB2 were normalized 
against GAPDH expression.
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Table S3 Description of samples included in the Tissue qPCR Array 
 
Patient  Tissue Source   Diagnosis    Stage  Normalized TRIB2 levels  Gender  Age 
28  Skin / Lung   Malignant melanoma, metastatic IV   5.41    Female  74 
29  Skin / Lymph node  Malignant melanoma, metastatic IV   5.37    Male  54 
30  Skin / Mesentery  Malignant melanoma, metastatic IV   27.95    Male  48 
31   Skin / Jejunum    Malignant melanoma, metastatic  IV   25.19    Male  60 
32  Skin / Lung   Malignant melanoma, metastatic IV   21.48    Male  58 
33  Skin / Lung   Malignant melanoma, metastatic IV   193.29    Male  45 
34  Skin / Small intestine  Malignant melanoma, metastatic IV   27.75    Male  75 
35  Skin / Liver   Malignant melanoma, metastatic IV   14.77    Male  56 
36  Skin / Jejunum   Malignant melanoma, metastatic IV   32.78    Male  46 
37  Skin / Lung   Malignant melanoma, metastatic IV   16.85    Male  56 
38  Skin / Omentum  Malignant melanoma, metastatic IV   57.47    Female  66 
39  Skin / Small intestine  Malignant melanoma, metastatic IV   7.33    Male  56 
40  Skin / Lymph node  Malignant melanoma, metastatic IV   9.22    Male  81 
41  Skin / Lung   Malignant melanoma, metastatic IV   14.37    Male  56 
42  Skin / Lung   Malignant melanoma, metastatic IV   7.54    Male  73 
43  Skin / Skin   Malignant melanoma, metastatic IV   2.06    Female  42 
 
Table S3. Description of samples included in the Tissue qPCR Arrays. qRT-PCR was performed using TissueScan Melanoma Tissue qPCR Array I containing 43 tissues 
(OriGene Technologies, Rockville, MD). Quantification of TRIB2 mRNA levels was performed using qPCR. qRT-PCR amplification signals specific for TRIB2 were normalized 
against GAPDH expression. 
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4.1 High Content Screening: Applications and limitations. 
 
In the present work we presented novel cell–based platforms that enable the 
identification of molecules that influence FOXO activity. We established previously 
undescribed molecular factors that repress the activity of FOXO, including  Calmodulin 
and TRIB2. 
The core technology used, high content screening (HCS), has emerged as a powerful 
technology which as been increasingly and successfully implemented both in the 
academic research and pharmaceutical industry for the discovery of novel targets and 
potential interfering small molecules. The concept of HCS per se consists in obtaining 
the most information possible in a single cell-based assay and it is well suited to 
monitor the phenotype of cells in systematic loss-of-function studies. 
The sequencing of the human genome provided many potential therapeutic targets 
for developing new drugs. However, the lack of knowledge concerning the function of 
the gene products has limited the success of target-based drug discovery (132). 
HCS has filled an important technological gap in the post-genomic era with a 
breakthrough: The possibility to analyze gene function through genetic-like studies. 
In this post-genomic era, the perceived pitfalls of target-based drug discovery has 
recently led to the renaissance of a more holistic approach that involves the screening 
of test compounds to determine whether they elicit any phenotypic changes in 
organism model systems, such as worm, fly, and zebrafish but at present it is mainly 
mammalian cells in culture that are compatible with high-throughput screening (HTS) 
with a phenotypic read-out. Hence, our choice to use high content cell basaed assays 
to search for novel molecules implicated the modulation of FOXO activity. 
Our strategy consisted in the combination of phenotypic and target-based 
approaches to monitor a specific molecular event, taking the benefits of both 
methodologies. This approach, which goes beyond individual genes and proteins as it 
involves the investigation of signaling pathways in a systems-based manner,  
constitutes an unbiased approach for the identification of novel targets implicated in a 
given event (17). A wide range of different technologies can be used to identify 
molecular targets that underlie the phenotypic effects elicited by small organic 
molecules or RNAi in complex biological assay systems (145). For our FOXO-related 
assays the phenotypical changes to be monitored were cytoplasmic/nuclear shuttling 
and transcriptional activity. As for the BaFiso system, cell viability and integrity are the 
main parameters evaluated. In addition, taking advantage of our image-based readouts 
morphological changes associated with toxicity, namely cell shrinkage, can be further 
detected and analyzed. 
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We designed our assays aiming for a restricted target space. However, it is not 
always possible to isolate the particular molecular target responsible for the 
phenotypes observed, and hence the need for target deconvolution. 
Target deconvolution is the retrospective identification of the molecular targets that 
underlie the observed phenotypic responses. Deconvolution is not only important for 
elucidating the biological mechanisms of disease, aspects that are related to target-
specific toxicity and side effects can be addressed. Hence, target deconvolution is an 
important aspect of current target discovery. The final aim of all strategies and methods 
for target deconvolution is not only the identification of biological targets that are 
directly affected by a given agent, but also the confirmation that modulation of the 
identified target is associated with functional effects that are detectable in the 
phenotypic assay that was originally used for the identification of the interfering agent. 
Our strategy consisted in developing independent cell-based assays in which the hits 
could be re-screened for deconvolution, so that the information obtained in each 
system can complement the previous data, allowing us to cut-off less interesting 
candidates early in the screening process, prior to a deeper analysis with small-scale 
molecular biology techniques. 
All cell-based platforms presented here can function as primary screening systems, 
but particularly the U2nesRELOC and the BaFiso systems have been proven extremely 
useful for deconvolution. With the U2nesRELOC system, it was possible to specifically 
detect inhibitors of the nuclear export machinery from a panel of compounds (165). 
Hence, this system constitutes a valuable tool for dissecting the mode of action of a 
agents scored as FOXO activators in the U2foxRELOC or in U2transLuc system, but 
which inhibit the general nuclear export machinery. 
All screening procedures have to account for the risk of obtaining “off-target effects” 
and hence the need for appropriate validation steps. RNAi off target effects are mainly 
a consequence of a shared similarity between the sequence designed to target the 
transcripts of a given gene and similarity to other gene transcripts. It has been shown 
that a perfect complementarity between the 5’ end of the siRNA sequence and the 
seed region of the 3’ UTR of a transcript is enough to trigger the knockdown of its 
respective gene, by the same mechanism of action reported for miRNAs (9). 
Conversely, small molecules can elicit off target effects due to high structural similarity 
between the target and another protein, resulting in unspecific binding and unspecific 
activity. Off target effects can induce phenotypical changes that resemble the effects of 
the silencing of the initial target, masking the undesired and unspecific inhibition of 
another protein (57). The hits obtained in our chemical genetic analysis and in our 
RNAi screening were subjected to a thorough validation process in which off-target 
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effects could be successfully detected and discarded. For both screens we tried 
redundancy strategies which involved the use of several independent inhibitors  of the 
same target (small molecules with different chemical structures) and several 
independent siRNA agents (vector-based shRNAs and siRNAs with different 3’ 
sequence ends).  
The principles applied in the generation of the assays described here can be 
extrapolated to other signaling pathways, maintaining the general characteristics of the 
assays. In fact, over the last years other assays have been published based on the 
translocation properties of molecules like NF-kB, p38 and c-JUN (7). 
In order to establish robust and reproducible reporter systems we engineered stable 
and clonal cell lines. Those characteristics are fundamental since the generation of 
quantitative data requires homogeneous cell populations that provide consistent 
readouts. 
In the U2foxRELOC cells, a reduction on the intensity of the GFP signal can be 
observed after long periods of culture. This issue can be overcome by re-sorting the 
cultured cells, discarding the population with lower signal intensity or simply by 
replacing the assay cells with a freshly thawed vial from a backup stock, highlighting 
another fundamental step of assay development: the generation of a large stock of 
frozen vials shortly after the assay cell line has been established and purified. 
The final parameter we used in the U2foxRELOC system to determine the impact of 
the interfering agents over FOXO translocation was the percentage of cells displaying a 
nuclear/cytoplasmic ratio of the intensity of the GFP signal superior to 1,8. This was 
shown to accurately link the phenotypical changes observed in the assays with their 
respective quantitative data. The establishment of this parameter was based on several 
observations and optimization experiments. In control conditions we could still observe 
some nuclear localization of the GFP signal, suggesting that FOXO translocation does 
not occur as an “all-or-nothing” event, but as a shift in the cytoplasmatic/nuclear ratio 
instead. Interestingly, the kinetics of FOXO translocation is still to be determined. To 
clarify how the spatial distribution of FOXO is altered upon stimulation it would be 
interesting to analyze the patterns of migration of florescent-labeled FOXO proteins 
through live-video high resolution microscopy. Of note, the basal levels of the nuclear 
localization of our reporter protein did not interfere with the quantitative data obtained 
using our defined parameters. 
The definition of our measurement parameter allowed us to tackle another challenge 
of high content analysis: The generation of an assay robust enough to provide 
quantitative data. Using the U2foxRELOC system we demonstrated that the IC50 
values of the well characterized PI3K inhibitors LY294002, PIK-75, PI-103 and 
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Wortmannin were in agreement with previously established data obtained from 
classical in vitro biochemical assays. The U2foxRELOC is, therefore, a very sensitive 
system capable of providing quantitative data upon inhibition of the PI3K/Akt pathway. 
Due to the intrinsic characteristics of the parental cell line (U2-OS osteosarcoma 
cells), we observed that the U2foxRELOC cells and the U2transLuc cells display a 
lower transfection efficiency than the HEK293T-derived 293foxREP cells. Thus, 
although both cells are appropriate for high throughput experiments, we decided to use 
the 293foxREP system for our transfection-based screening, to assure that the results 
were not limited by transfection issues. Conversely, compound screenings were shown 
more feasible with the U2foxRELOC and U2transLuc cells. We determined that one 
hour of incubation is sufficient for a robust readout of FOXO translocation in those 
cells. This short incubation time constitutes an advantage, as it minimizes the risk of 
unspecific toxicity. On the other hand, either FOXO, our luciferase reporter or both are 
already stably expressed in those cells, while 293foxREP cells need to be transfected 
with FOXO and a transfection control (e .g. Renilla luciferase) 48hs before treatment 
with the compounds. Furthermore, U2-OS are bigger, attach strongly to the plates and 
tend to grow stretched and exclusively in monolayer, all features very desirable for 
image analysis. Contrarily, HEK293T cells detach easily, complicating the washing 
steps which are required for automated fixing and staining. Also, they have a reduced 
size, making it harder to define the nuclei/cytoplasm transition and they may grow 
irregularly and eventually form foci, generating different focal planes which complicate 
image analysis. 
For the U2foxRELOC, U2transLUC and U2nesRELOC systems we took advantage 
of the benefits of fixation to establish our screening workflows. The use of fixed cells 
avoids the need to use live stains which lead to cytotoxicity after extended periods of 
exposure. Furthermore, fixation allowed us to perform DAPI staining for nuclei 
definition. DAPI was shown to be a robust nuclear stain with minimal signal loss for 
periods of up to one month which enables a flexible scheduling of the analysis and also 
permits the re-analysis of the plates. 
On the other hand, the use of live cells enables a kinetic analysis and toxicology 
studies in a ‘real-time’ manner (87).  
The live cell assay BaFiso was shown to accurately discriminate dependency on 
activated Akt or STAT5 for survival. The versatility of this system allows for its 
adaptation to any signaling pathways or genes which confer IL3-independent survival 
to BaF/3 cells. Therefore, this system possesses an immense potential for target and 
drug discovery, offering a wide array of options for dissecting the signaling pathways 
downstream of the engineered gene activations. 
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We challenged this system with a panel of test compounds of known activity and the 
only two compounds known to selectively interfere with Akt signaling, Akt inhibitor X 
and UCN-01, reduced the number of yellow tagged BYA cells demonstrating the 
specificity of the BaFiso system. The Akt inhibitor X is a N-substituted compound 
reported to inhibit Akt activity even in the absence of its pleckstrin homology domain 
and it has been suggested that it may bind in the ATP binding site (147). In contrast, 
UCN-01 has been reported to inhibit several kinases including PDK1, an upstream 
activator of Akt (82). Interestingly, staurosporine which shares a high structural 
similarity with UCN-01, differing only by the absence of a hydroxy group on the lactam 
ring, failed to change the ratio of the BaFiso cell lines. A specificity analysis against a 
kinase panel revealed different patterns of inhibition for UCN-01 with respect to 
staurosporine (82). It remains to be determined if these differences in specificity could 
account for the different behavior observed for these two compounds in the BaFiso 
assay. 
The BaFiso screening design offers some major advantages over traditional in vitro 
biochemical assays or more classical cellular assays. Co-culture and simultaneous 
testing of the paired isogenic cell lines in this assay provides an internal control and 
eliminates errors resulting from separate assessments. BaFiso is an image based high 
throughput assay that enables the identification of compounds that produce artifacts 
and cytotoxicity on a single cell basis. Live cell imaging of the BaFiso cell lines permits 
the constant monitoring of the same cells over the time course of an experiment, 
leading to a more accurate analysis that minimizes the variability in cell numbers 
between wells.  
One of the major challenges of BaFiso and live cell assays in general is the 
cytotoxicity of the nuclear stain required for image segmentation. At the moment, there 
is no availability of non-toxic nuclear dyes although the staining finally adopted for this 
system – DRAQ5 – was shown to be less toxic, but only if a long exposure is avoided. 
An alternative approach would involve the stable expression of an exclusively nuclear 
RFP-tagged construction that would allow object definition needless of other reagents. 
The assay design of BaFiso also has to cope with the fact that the cells are not 
adherent, which requires special attention for automatic image capture. 
 
4.2 Multiplexed Assays: Adding more content to screening 
 
Several studies have been carried out over the last years, aiming for the identification 
of new genes and molecules implicated in FOXO regulation in a mono-parametric 
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fashion, measuring either FOXO translocation or FOXO transcriptional activity 
separately as readouts (73, 98). 
With the U2transLuc system, both translocation and transactivation can be resolved 
in a single assay, while cell viability can be monitored needless of additional reagents. 
The multiplexing of fluorescent and luciferase-based readouts is a new concept and 
constitutes a breakthrough in the screening field, as the amount of information 
gathered in a single assay is importantly increased. The same cell plate is initially used 
for an in vivo translocation assay and the scores on nuclear trapping are re-checked for 
transcriptional activity immediately afterwards in a luciferase assay. 
Importantly, different effects of a given agent in FOXO translocation, transcriptional 
activity and proliferation can be analyzed side by side in the same experiment allowing 
for the construction of the activity profiles. 
This system allows the investigation of one of the most intriguing issues of FOXO 
regulation, which is the interdependency between translocation and transactivation. 
There is some evidence pointing that transcription and subcellular localization are 
events that can be regulated independently. It has been documented that a mutation 
within the NES of FOXO1 that lead to its permanent nuclear localization did not 
override the influence of Akt signaling over FOXO transcriptional activity (149), showing 
that nuclear sequestration per se, at least in the experimental setting used, does not 
implicate transactivation. 
This system adds to the above mentioned technological platforms developed in the 
course of this work. The integration of these systems allows for the realization of 
multiplexed screens which, opposite to classical candidate gene approaches, provide 
unbiased data for novel interactions that translate to target discovery. 
 
4.3 Chemical Genetics: New Insights on FOXO 
 
Chemical genetics is gaining relevance as a promising research field that explores 
the interface between chemistry and biology. In the course of this work we 
demonstrated the potential of chemical genetics combined with high-content screening 
to dissect the complex regulation of the subcellular localization of FOXO transcription 
factors. 
In our chemical genetics analysis of a panel of 73 compounds with known 
mechanism of action, the majority of the drugs tested failed to produce nuclear trapping 
of GFP–FOXO. However, we identified 17 compounds that induced the nuclear 
accumulation of the fluorescent reporter. Most of these small molecules were described 
as inhibitors of the PI3K/Akt pathway, in agreement with the essential role of signaling 
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through PI3K, PDK1, and Akt in the regulation of the subcellular localization of FOXO 
proteins. 
The vinca alkaloid vinblastine scored as a very potent FOXO translocating agent, 
active in the low nanomolar range. Vinblastine is a microtubule-depolymerizing drug 
whose mode of action has been characterized (45). Currently vinblastine is a 
component of a number of chemotherapy regimens, including ABVD (adriamycin, 
bleomycin, vimblastine and dacarbazine), which was shown specially effective in 
Hodgkin Lymphoma (156). Recent data suggest that many classical chemotherapeutic 
agents are able to activate FOXO (47). However, it remains to be determined if the 
functions of FOXO are required for the therapeutic effect of vinblastine. 
It has been reported that the inhibition of the Ca2+-binding protein CaM produces the 
nuclear accumulation of FOXO proteins in cell assays based on the immunodetection 
of transiently expressed reporter protein (73). With the U2foxRELOC system we were 
able to reproduce this observation and we extended previous data regarding the 
implication of Ca2+-signaling in the regulation of FOXO transcription factors by 
analyzing the effect of several chemical probes in the U2foxRELOC assay and on Akt 
phosphorylation. Chemical genetic analysis of the Ca2+-dependent regulation of FOXO 
localization revealed the important role of intra- and extracellular calcium. 
Calcium/calmodulin-regulated FOXO translocation is not directly mediated either by 
multifunctional or dedicated calcium/CaM-dependent protein kinases, or by upstream 
CaM-kinase-kinases. This is consistent with a model in which low calcium 
concentrations decrease the activity of CaM, in turn inhibiting Akt and facilitating the 
translocation of FOXO proteins to the cell nucleus. Akt associates with CaM in mouse 
mammary carcinoma cells and has been proposed as a CaM-binding protein (28). 
However, whether a decrease in CaM-binding induces the nuclear translocation of 
FOXO proteins by directly affecting Akt activity remains to be explored. CaM 
expression is altered in several cancers and its inhibition might be a strategy to restore 
the tumor suppressor activity of the FOXO factors. 
 
4.4 The novel association of TRIB2 with FOXO repression in melanoma 
 
The technological platforms which have been generated in the scope of this work 
allowed us to perform a large-scale RNAi screening leading to the identification of 
several FOXO repressors including TRIB2, a homolog of Drosophila tribbles. Our 
findings suggest that TRIB2 is an essential gene in melanoma malignancies, correlated 
with low levels of pro-apoptotic transcripts via the inhibition of FOXO.  
Melanoma commonly arises within the epidermis from melanocytes, which are cells 
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of neuroectodermal origin that provide pigmentation to the skin in the form of melanin 
(24). Of the three most common skin cancers, malignant melanoma is the rarest but by 
far the most deadly because metastatic malignant melanoma is highly resistant to 
treatment (77, 131). 
Our findings that TRIB2 are elevated in malignant melanomas and in melanocytes 
are in accordance with the melanocytic origin of melanoma.  
Since Akt activity is one of the principal mechanisms of FOXO inactivation, a possible 
influence of TRIB2 on Akt signaling could explain its effects seen on FOXO 
translocation and transcriptional activity. However, western blot analysis did not reveal 
any changes in Akt or FOXO phosphorylation upon TRIB2 overexpression or 
knockdown, suggesting that the effect on FOXO subcellular localization and 
transcriptional activity mediated by TRIB2 occurs independently of Akt signaling.  
TRIB2 has been reported to bind to C/EBPα and C/EBPβ  and to promote their 
degradation in a proteasome-dependent manner, causing acute myelogenous 
leukemia (74) and suppressing adipocyte differentiation (106), respectively. Those 
observations prompted us to analyze whether TRIB2 could exert the same effect over 
FOXO, however a direct binding association between the two proteins could not be 
demonstrated in co-immunoprecipitation assays. 
TRIB2 has been reported to be a highly inducible gene (60, 80, 94) and our 
investigations support this idea.  Sequence analysis of the promoter of the TRIB2 gene 
revealed several binding sites for inducible transcription factors and a conserved 
mRNA instability motif in the 3’UTR of the transcribed sequence. TRIB2 protein has 
also been reported to be highly unstable (61), suggesting that TRIB2 is rapidly induced 
upon designated stimuli and its expression is shut down shortly after the cessation of 
the triggering stimuli and the protein levels are brought to basal levels. 
Our findings suggest that TRIB2 is highly inducible upon intracellular Calcium 
release, as seen by the increase in TRIB2 transcript levels upon stimulation of G-361 
cells with Caffeine and Thapsighargin, both agents shown to trigger the release of 
intracellular Ca2+ (37, 146). Interestingly, some reports associate high levels of 
intracellular Ca2+ in melanoma cells with resistance to apoptosis (40). As TRIB2 was 
seen to be induced by intracellular Ca2+, the elevated levels of intracellular Ca2+ 
observed in some melanoma cells could constitute the a mechanism by which TRIB2 is 
elevated in those cells.  
Previous reports from our lab showed that FOXO translocates to the cell nucleus 
when intracellular calcium is chelated. In agreement with this observation, CaM was 
obtained in our RNAi screening as a FOXO repressor. Thus, enhanced CaM activity 
and increased TRIB2 expression might constitute parallel means to repress FOXO 
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function in response to Ca2+ signaling events. In summary, through a large-scale RNAi 
screen we identified two novel molecular associations that were shown to influence 
FOXO subcellular localization and transcriptional activity: Calmodulin and TRIB2. 
Interestingly, both associations are linked to the intracellular calcium homeostasis, 
reinforcing the importance of calcium signaling in the modulation of FOXO activity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 177 -
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 178 -
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 Conclusions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 179 -
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 180 -
Conclusions 
1. We developed, characterized, and validated an image-based system suitable for 
monitoring of FOXO cytoplasmic/nuclear translocation in a high throughput 
manner. 
 
2.  We developed, characterized, and validated a transcription-based assay 
suitable to monitor the recovery of FOXO transcriptional activity in a high 
throughput manner. 
 
3. We developed, characterized and validated a multiplexed system that combines 
luminescent and fluorescent readouts to monitor simultaneously subcellular 
localization of FOXO and FOXO-driven transcription in a single cell line and in a 
in a single high throughput assay. 
 
4. We developed, characterized, and validated a cell-based system suitable for 
high throuput detection of nuclear export inhibitors. This system can be used 
either as a primary screening or as a deconvolution system to further investigate 
the candidates obtained in our FOXO-based systems. 
 
5. We developed, characterized, and validated a live cell-based system suitable for 
high throuput analysis of signaling events downstream of engineerd genetic 
modifications. This system was shown accurate for the detection of Akt inhibitors 
and can also be used as a deconvolution system to further investigate the 
dependency on different signaling pathways for BaF/3 cells survival. 
 
6. Through a large-scale RNAi screening we identified an undescribed FOXO 
repressor function of TRIB2. 
 
7. TRIB2 is highly expressed in melanocyte-derived cells, which correlates with 
diminished FOXO-driven transcription of the pro-apoptotic gene Bim. In 
functional studies, TRIB2 knockdown diminished the tumorigenicity of melanoma 
cells in vitro and in a in vivo xenograft model, suggesting that the maintenance of 
high levels of TRIB2 is a pre-requisite for melanomas to keep their malignancy.  
 
8. Through Chemical Genetics and RNAi studies we came to the conclusion that 
intracellular calcium regulation is crucial in the modulation of FOXO activity. 
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Conclusiones 
1. Hemos desarrollado, caracterizado, y validado un sistema basado en imágenes 
adecuado al análisis de la translocación de FOXO entre el citoplasma y el 
núcleo adaptado para HTS. 
 
2. Hemos desarrollado, caracterizado y validado un sistema basado en 
transcripción adecuado para avaliar la recuperación de la actividad 
transcripcional de FOXO adaptado para HTS. 
 
3. Hemos desarrollado, caracterizado, validado y adaptado para HTS un sistema 
multiparamétrico que combina datos de fluorescencia y de luminiscencia, 
proprcionando informaciones a cerca de la translocación y de la actividad 
transcripcional de FOXO en un único ensayo. 
 
4. Hemos desarrollado, caracterizado, validado y adaptado para HTS un sistema 
adecuado a la detección de inibidores del exporte nuclear, que puede funcionar 
bien como un sistema de rastreo primário  o como unb sistema de 
deconvolución para una investigación más detallada de las dianas obtenidas a 
través de los sistemas basados en FOXO. 
 
5. Hemos desarrollado, caracterizado, y validado un sistema adecuado al análisis 
de la señalización dependente  de modificaciones genéticas previamente 
diseñadas, adaptado para HTS. Este sistema se ha mostrado fiable para 
detectar inhibidores de Akt y puede tambien ser usado para una investigación 
más detallada de la dependencia de células BaF/3 a diferentes vías de 
señalización para supervivencia. 
 
6. A través de nuestro rastreo por RNA de interferencia hemos identificado TRIB2 
como un nuevo represor de FOXO. 
 
7. TRIB2 tiene un alto nivel de expresión en melanocitos normales  y en 
melanomas malignos, lo que se correlaciona con una baja expresión de la 
transcripción mediada por FOXO del gen pro-apoptótico Bim. A través de 
estudios funcionales hemos verificado que la reducción de los niveles de TRIB2 
disminuye las capacidades tumorigénicas de células de melanoma en cultivo y 
en un modelo de xenograft, lo que sugiere que la manutención de altos niveles 
de TRIB2 es un pre-requisito de los melanomas para que puedan mantener su 
malignidad.  
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8. A través de estudios de genética química e RNA de interferencia hemos podido 
concluir que la regulación del calcio intracelular tiene un papel fundamental en 
la modulación de la actividad de FOXO. 
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